



SCM09

NATIONAL KIDNEY FOUNDATION
SPRING CLINICAL MEETINGS
NASHVILLE, TN/MARCH 25-29, 2009

PROGRAM



Patrick B.

CKD Stage 5 on dialysis:

iPTH = 496 pg/mL

Ca = 9.9 mg/dL

P = 6.1 mg/dL

What is his outcome?


IN SECONDARY HPT, IT CAN BE EASY TO OVERLOOK THE WARNING SIGNS



► MORTALITY

Patients' mortality risk is 51% greater over the next 3 months when all secondary HPT lab parameters are out of range.¹

- The attributable risk of mortality associated with elevations in all secondary HPT lab parameters was 17.5%, higher than inefficient dialysis (5.1%) or anemia (11.3%)²
- Mortality risk increases 12% and 40%, respectively, when PTH or phosphorus are out of range for only 3 months. If PTH, calcium, or phosphorus are out of range for 1 year, the corresponding mortality risks increase further to 33%, 16%, and 61%, respectively¹



► CALCIFICATION

Just a 1-mg/dL increase in phosphorus carries the same risk of vascular calcification as nearly 2.5 years of dialysis treatment. With a 1-mg/dL calcium increase, the risk is similar to > 5 years of dialysis treatment.³

► FRACTURE

With iPTH in the range of 300-800 pg/mL, every 100 pg/mL increase raises patient rate of hip fracture by 15% and vertebral fracture by 33%.⁴

References: 1. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. [published online ahead of print July 2, 2008]. *Clin J Am Soc Nephrol*. doi:10.2215/CJN.01060308. 2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*. 2004;15:2208-2218. 3. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol*. 2002;39:695-701. 4. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. *Am J Kidney Dis*. 2006;47:149-156.

HPT = hyperparathyroidism;
 CKD = chronic kidney disease;
 iPTH = intact parathyroid hormone; Ca = calcium;
 P = phosphorus.

Be aggressive—patients like Patrick deserve a closer look.



NATIONAL KIDNEY FOUNDATION KIDNEY EARLY EVALUATION PROGRAM (KEEP)

KEEP IS THE LARGEST KIDNEY HEALTH DETECTION PROGRAM IN THE U.S.,
WITH MORE THAN 125,000 PARTICIPANTS TO DATE



Join Us for This Important Breakfast Symposium!

Kidney and Vascular Risk Factor Control in **KEEP**

6:00AM – 7:45AM, MARCH 26, 2009

What You'll Learn

- How does CKD impact measured blood pressure in the KEEP population?
- How are blood pressure targets and management different in patients with CKD?
- How do diabetes, obesity and dyslipidemia interact to predict CKD outcomes?
- Understand the impact of CKD stages 1 and 2 on blood pressure awareness, treatment and control.
- Understand the impact of CKD stages 1 and 2 on diabetes awareness, treatment and control.

PRESENTERS:

**Peter A. McCullough, MD
MPH, FACC, FACP, FAHA, FCCP – Chair**

Vice Chair, NKF KEEP Steering Committee
Consulting Cardiologist and Chief
Division of Nutrition and Preventive Medicine
William Beaumont Hospital Health Center
Royal Oak, MI

Blood Pressure Targets

George Bakris, MD

Chair, NKF KEEP Steering Committee
Professor of Medicine
Director, Hypertensive Diseases Unit
Section of Endocrinology, Diabetes & Metabolism
University of Chicago – Pritzker School of Medicine
Chicago, IL

**Optimizing Cardiometabolic Risk:
Impact on Kidney Outcomes**

Adam Whaley-Connell, DO, MSPH

Assistant Professor of Internal Medicine,
Division of Nephrology
University of Missouri -Columbia School of Medicine

Relevance of CKD Stages 1 and 2

Allan J. Collins, MD, FACP

Past President, National Kidney Foundation
Professor of Medicine, University of Minnesota
Minneapolis, MN

ACCREDITATION:

ACCREDITATION STATEMENT: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The NATIONAL KIDNEY FOUNDATION gratefully acknowledges the support of our KEEP sponsors:



ADDITIONAL SUPPORT PROVIDED BY Lifescan, Inc., Suplena, OceanSpray Cranberries, Inc.

SPONSORED BY



WWW.KEEPONLINE.ORG

Shaping the future of kidney care.

DaVita® has superior clinical outcomes for dialysis modalities and offers value-added services for your patients.

Dialysis options

In-center hemodialysis
Nocturnal hemodialysis*
Self Care hemodialysis*
Home hemodialysis*
Peritoneal dialysis

Value-added services

EMPOWER™
DaVita RxSM
DaVita Clinical Research®
Lifeline Vascular AccessSM
DaVita Diet Helper™ at DaVita.com



* Available in select locations nationwide.

www.davita.com | 1-800-400-8331





AMGEN NEPHROLOGY.

WHERE THE MIND OF A SCIENTIST MEETS THE HEART OF AN EXPLORER.

At Amgen Nephrology, we believe making a difference requires taking a different approach. Your patients deserve it. The fight against kidney disease demands it. So we see ourselves as bio-explorers—continually searching to understand the underlying mechanisms of kidney disease and the challenges your patients face. This discovery-based approach has enabled us to create a wide range of treatments. But we're still looking to take understanding of this disease to new heights.

Explore booth #1105 to learn more

AMGEN®

Nephrology

A HISTORY OF DISCOVERY. A FUTURE OF POSSIBILITIES.

Impact of Special Populations and Vitamin D Therapy in Chronic Kidney Disease Outcomes

National Kidney Foundation 2009 Spring Clinical Meetings

Wednesday, March 25, 2009

7:30 PM – 9:30 PM

Gaylord Opryland Resort & Convention Center
Nashville, Tennessee
Delta Ballroom B



PROGRAM OVERVIEW

The symposium will provide information on differences in cardiovascular risk factors and therapies that impact survival outcomes for CKD patients. Both cardiovascular and noncardiovascular mortality rates are persistently higher for African-American compared with white patients. Recent studies suggest that African-American and Hispanic patients have a higher mortality in earlier CKD stages when compared to white patients. In addition, a recent study indicates that the greater use of activated vitamin D analogs contribute to the survival advantage observed in African-American and Hispanic dialysis patients compared with white patients. The data from recent studies examining special populations' issues and associated cardiovascular risk and therapy options in management of CKD provide insight into managing CKD patients. The discussions will examine the influence of early identification and treatment in an effort to reduce cardiovascular risk and attenuate the progression of renal function in CKD patients.

LEARNING OBJECTIVES

- Evaluate the incidence and differences in cardiovascular risk factors that contribute to increased mortality among special populations of CKD patients.
- Recognize how special population differences contribute to disparities in survival outcomes for CKD and dialysis patients and integrate appropriate changes into clinical practice.
- Manage active vitamin D therapy in CKD patients and monitor effect on survival outcomes for special populations.

AGENDA

Wednesday, March 25, 2009

- | | |
|---------|---|
| 7:30 PM | Registration |
| 8:00 PM | Welcome and Introduction
Keith Norris, MD |
| 8:05 PM | Special Population Differences in CKD and Dialysis Patients: Impact on Survival
Keith Norris, MD |
| 8:30 PM | The Relationship of Special Populations and Cardiovascular Outcomes in CKD Patients
Janice P. Lea, MD, MSc, FASN |
| 8:55 PM | Special Populations Differences in CKD: the Impact of Vitamin D Therapy
Rajnish Mehrotra, MD |
| 9:20 PM | Q&A/Discussion |

FACULTY

Janice P. Lea, MD, MSc, FASN

Associate Professor of Medicine, Renal Division, Emory University
Atlanta, Georgia

Rajnish Mehrotra, MD

Associate Chief, Division of Nephrology and Hypertension
Harbor-UCLA Medical Center, Torrance, California

Keith C. Norris, MD

Professor of Medicine and Executive Vice President of Research & Health Affairs
Charles Drew University of Medicine and Science
Los Angeles, California

TARGET AUDIENCE: This CME-certified symposium is directed towards nephrologists and clinicians who treat patients with chronic kidney disease.

HOW YOU WILL LEARN: This CME activity will be a live symposium consisting of lectures with audience participation.

ACCREDITATION STATEMENT: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT: The National Kidney Foundation designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

DECLARATION OF DISCLOSURE: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

UNLABELED / INVESTIGATIONAL USE DECLARATION: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

DISCLAIMER: The faculty, National Kidney Foundation, and Abbott do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

REGISTRATION

Complete instructions and the online registration form are available at: www.theCKD.org/NKF-SpecialPopulations. You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit. For questions or to request additional information, please call 1-888-731-7322, extension 122.



Abbott
A Promise for Life

Sponsored by an
educational grant
from Abbott.

A CME-CERTIFIED SYMPOSIUM

Sponsored by the
National Kidney
Foundation





THURSDAY, MARCH 26, 2009

6:00 AM – 6:15 AM

Registration and Breakfast

6:15 AM – 7:45 AM

Symposium

Gaylord Opryland Resort and Convention Center
Delta Ballroom B
Nashville, Tennessee

Preventing and Managing Acute Kidney Injury in Patients With Tumor Lysis Syndrome: A TEAM APPROACH

Activity Purpose

The purpose of this symposium is to educate nephrologists, fellows, residents, physician assistants, nurse practitioners, nephrology nurses and technicians, and renal and clinical dietitians interested in learning about the prevention and management of acute kidney injury in patients with tumor lysis syndrome.

Target Audience

This activity is designed to meet the educational needs of nephrologists and other health care professionals of the nephrology community who are involved in the prevention and treatment of acute kidney injury associated with TLS.

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statements

The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-O6. This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Declaration of Disclosure

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, and sanofi aventis do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

National Kidney Foundation (NKF) 2009 Spring Clinical Meetings

Educational Objectives

Upon completion of this symposium, participants will be able to:

- Describe the pathophysiology and clinical presentation of tumor lysis syndrome (TLS)
- Evaluate kidney injury, both as a risk factor for developing TLS, and as a complication of TLS
- Assess the impact of kidney injury on patient outcome
- Discuss the role of uric acid elevation in acute kidney injury (AKI) and current clinical data on the treatment of hyperuricemia
- Formulate a treatment plan for the prevention and management of AKI in TLS based on patient risk stratification

Program Agenda

6:00 AM Registration and Breakfast

6:15 AM Welcome and Introduction
A. Ahsan Ejaz, MD, FACP, FASN

6:20 AM TLS: An Oncologic and Nephrologic Emergency
Ching-Hon Pui, MD

6:35 AM Acute Kidney Injury and TLS
A. Ahsan Ejaz, MD, FACP, FASN

6:55 AM Prevention and Treatment of Acute Kidney Injury
Aldo J. Peixoto, MD

7:15 AM A Case-Based Interactive Debate
Faculty Panel

7:35 AM Q&A Session
Faculty panel

7:45 AM Adjourn

Moderator and Program Chair

A. Ahsan Ejaz, MD, FACP, FASN
Associate Professor of Medicine
University of Florida
Director, Nephrology Hospital
Clinical Services
Shands Hospital at the University
of Florida
Gainesville, Florida

Faculty Speakers

Aldo J. Peixoto, MD
Associate Professor of Medicine,
Nephrology Division
Yale University School of Medicine
New Haven, Connecticut
Associate Chief of Medical Service
VA Connecticut Healthcare System
West Haven, Connecticut

Ching-Hon Pui, MD
Chair, Department of Oncology
St. Jude Children's Research Hospital
American Cancer Society Professor
Professor of Pediatrics
University of Tennessee Health
Science Center
Memphis, Tennessee

How You Will Learn

The symposium is held in a panel discussion format, incorporating case-based presentations, didactic lectures, and audience participation using audience response system (ARS).

You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit.



National Kidney
Foundation

Sponsored by the National Kidney Foundation.



Supported by an unrestricted medical educational grant from sanofi aventis.

YOU ARE INVITED TO:

A lunch symposium to be held at the National Kidney Foundation 2009 Spring Clinical Meetings

Thursday, March 26, 2009, 12:00 pm – 2:00 pm

Delta Ballroom B

Gaylord Opryland Hotel & Convention Center

Nashville, TN

Program Agenda

12:00 pm – 12:30 pm

Registration and Lunch

12:30 pm – 12:45 pm

Chair's Introduction

David M. Spiegel, MD, FACP

12:45 pm – 1:05 pm

Significance of Phosphorus Dysregulation in Early CKD

David M. Spiegel, MD, FACP

Professor of Medicine

University of Colorado Health Science Center, Denver, CO

1:05 pm – 1:25 pm

Elevated FGF-23: An Early Sign of Phosphate and Vitamin D Disturbances in CKD?

Orlando M. Gutiérrez, MD, MMSc

Assistant Professor of Medicine

Division of Nephrology and

Hypertension, University of Miami

Miller School of Medicine, Miami, FL

1:25 pm – 1:45 pm

Controlling Phosphate and Vitamin D Abnormalities in CKD: When to Intervene?

Donald A. Molony, MD

Professor of Medicine

University of Texas Health Science

Center, Houston, TX

1:45 pm – 2:00 pm

Questions and Answers



Sponsored by the
National Kidney Foundation.



Supported by an unrestricted
medical educational grant
from Genzyme.

Role of Abnormal Phosphate and Vitamin D Metabolism in CKD-MBD

Activity Purpose

The purpose of this symposium is to provide physicians with the latest evidence suggesting that disturbances of phosphorus metabolism occur early in CKD. The symposium will also discuss emerging data pointing to a key role for FGF-23 in the progression of CKD. Relatively small increases in serum phosphate, even those in the high-normal range, have been linked to the progression of CKD and an increased risk for myocardial infarction and mortality. FGF-23 is a hormone that promotes urinary phosphate excretion and helps maintain normal serum phosphate levels as renal function declines. A rise in FGF-23 signals that phosphorus dysregulation is present in early CKD, even when serum phosphate levels are normal. Elevated levels of FGF-23 also inhibit renal 1 α -hydroxylase, exacerbating calcitriol deficiency in early CKD and possibly contributing to the early development of SHPT. High FGF-23 levels have been strongly associated with increased mortality in patients starting hemodialysis. Finally, the symposium will examine the idea that phosphate restriction in early CKD may diminish the early rise in phosphate and FGF-23 levels and potentially lead to improved clinical outcomes.

Target Audience

Physicians, pharmacists, physician assistants, nephrology nurses, nurse practitioners, dietitians, nephrology social workers.

How You Will Learn

This CME activity will be a live symposium consisting of lectures with a question-and-answer session for the audience.

Learning Objectives

Upon completion of this session, participants will be able to:

- Describe how phosphorus dysregulation occurs early in the course of CKD
- Understand how high-normal serum phosphorus levels are associated with an increased risk for cardiovascular events and mortality
- Discuss how FGF-23 works to maintain normal serum phosphate levels in early-stage CKD by promoting increased urinary excretion of phosphate
- Describe how elevated FGF-23 levels inhibit renal 1 α -hydroxylase, worsening calcitriol deficiency in early CKD and possibly contributing to the early development of SHPT
- Explain why phosphate restriction in early CKD may diminish the early rise in FGF-23 levels and potentially improve bone health and clinical outcomes
- Describe the current clinical perspective on the need to initiate treatment to control phosphate levels and correct vitamin D deficiency in early CKD to reduce the risk of mortality

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The National Kidney Foundation designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™].

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit.

Declaration of Disclosure: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer: The faculty, National Kidney Foundation, and Genzyme do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

A New Direction In Anemia Management Beyond Erythropoietic Stimulating Agents



Thursday, March 26, 2009 | 7:30 PM – 9:30 PM | Gaylord Opryland, Nashville, TN | Delta Ballroom B

Program Purpose

Anemia is a significant source of morbidity and mortality in patients with end-stage renal disease (ESRD), with iron deficiency a major contributor to this anemia. There are many associated causes underlying the pathophysiology and subsequent contribution of absolute or functional iron deficiency in patients with ESRD. Detection of iron deficiency in erythropoiesis and avoidance of tissue iron overload remain controversial and unresolved issues in clinical management. However, interpreting results of iron status tests in this patient population poses a substantial challenge to clinicians and subsequently can lead to under treatment. Management of iron status in patients with ESRD requires a balance between providing adequate iron stores and subsequent maintenance of hemoglobin levels and avoiding iron overload. Iron supplementation is required to maintain adequate iron stores and support erythropoiesis in patients with ESRD. Intravenous iron also has associated risks so it is imperative to consider a risk versus benefit analysis of this therapy with the most recent evidence. This symposium will provide an overview of the pathophysiologic mechanisms of anemia in patients with ESRD along with a discussion of the clinical utility and limitations of iron status tests, and the implications for managing iron therapy. Given the controversies surrounding the use of erythropoietic stimulating agents, this program will provide a discussion of the optimal management of iron deficiency in ESRD patients.

Program Objectives

At the conclusion of the program, participants will be able to:

1. Discuss strategies for detection of iron stores and optimal targets in patients with ESRD.
2. Review the evidence for optimization of anemia therapy in patients with ESRD beyond erythropoietic stimulating agents.
3. Provide insight into the risk versus benefit of intravenous iron.

Symposium Registration

- Pre-registration for this symposium is not required. We recommend arriving early, as seating is limited and will be available on a first come, first serve basis.
- You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit.

Target Audience

Nephrology professionals

How you will learn

This CME activity will be a live symposium consisting of lectures with panel discussion with audience participation.

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Declaration of Disclosure

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, and Fresenius Medical Care do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Agenda and Speakers

7:30 p.m. Dinner

8:00 p.m. Introduction by Program Moderator

Lynda Szczech, MD, MSCE
Associate Professor of Medicine
Duke University Medical Center Director
Nephrology Research
Duke Clinical Research Institute
Durham, North Carolina

8:05 p.m. Overview of the Pathophysiology of
Iron Deficiency in ESRD Patients

Lynda Szczech, MD, MSCE

8:15 p.m. Strategies for Detecting Iron Deficiency
and Iron Excess in ESRD Patients

David B. Van Wyck, MD
Vice President of Clinical Services, DaVita, Inc.
Emeritus Professor of Medicine and Surgery
University of Arizona College of Medicine
Tucson, Arizona

8:35 p.m. Strategies for Optimizing Treatment of
Iron Deficiency in ESRD Patients

Chaim Charytan, MD
Chief of the Renal Division
New York Hospital Medical Center of Queens
Clinical Professor of Medicine
Cornell University College of Medicine
Flushing, New York

9:05 p.m. Question and Answer Panel Discussion
Faculty

9:30 p.m. Closing Remarks

Lynda Szczech, MD, MSCE

Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease

Program Purpose

Cardiovascular disease is a significant cause of mortality in patients with chronic kidney disease (CKD). Abnormalities in calcium, phosphorus, vitamin D, and parathyroid hormone have all been implicated in the development and progression of atherosclerotic cardiovascular calcification (CVC). Recent evidence shows that vascular smooth muscle cells acquire an osteoblast-like phenotype and that vascular calcification occurs by upregulation of inducers or downregulation of inhibitors of this process as part of atherosclerosis. Hyperphosphatemia has been identified as an important inducer of this system. Currently, published guidelines recommend aggressive control of serum phosphate but there are limited data on benefits to clinical outcomes. This session will provide a discussion of the recently published data related to the pathogenesis of cardiovascular calcifications in CKD and the affects of phosphate control on survival.

Program Objectives

At the conclusion of the program, participants will be able to:

1. Understand the role of calcium, phosphorus, vitamin D, and parathyroid hormone in the development of cardiovascular calcification in CKD
2. Discuss the impact of cardiovascular calcification on morbidity and mortality in CKD
3. Summarize the salient recent findings related to the impact of phosphorus binders on survival in hemodialysis patients

Symposium Registration

- Pre-registration for this symposium is not required. We recommend arriving early, as seating is limited and will be available on a first come, first serve basis.
- You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit.

Target Audience

Nephrology professionals

How you will learn

This CME activity will be a live symposium consisting of lectures with panel discussion with audience participation.

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The National Kidney Foundation designates this educational activity for a maximum of **1.5 AMA PRA Category 1 Credit(s)**[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Declaration of Disclosure

It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, and Fresenius Medical Care do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.



Agenda and Speakers

6:00 a.m. Breakfast

6:30 a.m. Introduction by Program Moderator

Vincent W. Dennis, M.D.
Senior Medical Advisor
Ambulatory Services of America
Brentwood, TN

6:35 a.m. Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease

Robert N. Foley, M.B.
Chronic Disease Research Group
Minneapolis, MN

7:00 a.m. Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease

Peter A. McCullough, M.D., M.P.H., F.A.C.C.
Consultant Cardiologist and Chief, Division of Nutrition and Preventive Medicine
William Beaumont Hospital
Royal Oak, MI

7:25 a.m. Question and Answer Session
Panel Discussion

Led by Vincent W. Dennis, M.D.

7:45 a.m. Closing Remarks

Vincent W. Dennis, M.D.



National Kidney Foundation
Sponsored by the National Kidney Foundation



Fresenius Medical Care
Supported by an unrestricted medical education grant from Fresenius Medical Care North America

A SYMPOSIUM TO BE CONDUCTED AT THE
NATIONAL KIDNEY FOUNDATION 2009 SPRING CLINICAL MEETINGS



Advances in the Management of Idiopathic Membranous Nephropathy

FRIDAY, MARCH 27, 2009

7:30 pm - 8:00 pm Registration and Dinner

8:00 pm - 9:30 pm Symposium

Delta Ballroom C • Gaylord Opryland • Nashville, TN

YOU MUST BE REGISTERED FOR THE NKF 2009 SPRING CLINICAL MEETINGS TO ATTEND THIS SYMPOSIUM AND RECEIVE CREDIT.

TARGET AUDIENCE

Nephrology professionals

HOW WILL YOU LEARN?

This CME activity will be a live symposium consisting of three lectures and a question and answer session.

ACTIVITY PURPOSE

The purpose of this symposium is to educate nephrology professionals and PCPs about current and emerging therapies and best practices in the management of progressive idiopathic membranous nephropathy (IMN) both in native and transplanted kidneys. The program will focus on the choice and duration of immunosuppressive therapies.

LEARNING OBJECTIVES

At the conclusion of the program, participants should be able to:

- Review the natural history of IMN
- Discuss risk factors for progressive renal disease in patients with IMN
- Outline the current and emerging options for immunosuppressive therapy in progressive IMN
- Outline an evidence-based treatment plan for progressive IMN
- Summarize the impact of de novo and recurrent IMN after renal transplantation and outline the evaluation and management of IMN post-renal transplantation

AGENDA AND FACULTY

8:00 – 8:05 pm	Welcome and Introductions	
8:05 – 8:30 pm	Idiopathic Membranous Nephropathy: All Patients Do Not Require Specific Therapy	Richard J. Glassock, MD The David Geffen School of Medicine Los Angeles, California
8:30 – 8:55 pm	Potential New Therapies for the Treatment of Membranous Nephropathies	Fernando C. Fervenza, MD, PhD Mayo Clinic Rochester, Minnesota
8:55 – 9:20 pm	Idiopathic Membranous Nephropathy in the Transplanted Kidney	Sundaram Hariharan, MD Medical College of Wisconsin Milwaukee, Wisconsin
9:20 – 9:30 pm	Questions and Answers	

Declaration of Disclosure: It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration: During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Accreditation Statement: The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement: The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Centers Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.

Disclaimer: The faculty, National Kidney Foundation, and Questcor[®] Pharmaceuticals, Inc., do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Please note that spouses, guests, or children are not permitted to attend. This is an educational program for healthcare professionals only.

For further information, please contact Wendy Heywood of DesignWrite at 609-865-5051 or whewoo@dwrite.com.



Supported by an educational grant from Questcor[®] Pharmaceuticals

Sponsored by the National Kidney Foundation



Bone Fracture in Chronic Kidney Disease: Clinical Issues and Expert Perspectives

Program Objectives

Upon completion of this session, participants will be able to:

1. Contrast the pathophysiology of fractures in patients with CKD to those with age-related or postmenopausal osteoporosis
2. Discuss appropriate diagnosis of bone disease in patients with CKD
3. Describe the current management of bone fractures in CKD
4. Analyze the fracture risk post renal transplantation and discuss appropriate treatment intervention

Program Synopsis

Patients with chronic kidney disease (CKD) have significant abnormalities of bone remodeling and mineral homeostasis and are at increased risk of fracture. The awareness of the fracture risk in patients with renal dysfunction has increased; however there are surprisingly few studies available that help identify the best approach for prevention and treatment. Although bisphosphonates are largely used in the treatment of osteoporosis there is concern regarding their safety in patients with CKD. In addition the fracture risk for a kidney transplant recipient is even higher than for a patient on dialysis. This symposium will provide a background on the pathophysiology of bone disease in CKD and after renal transplantation along with a discussion on the utility of various imaging modalities in predicting fracture across the spectrum of kidney disease. This session will explore the therapeutic possibilities for prevention and treatment of fractures in patients with CKD and following transplantation and look to the future for other possible interventions.

Symposium Registration

Pre-registration for this symposium is not required. We recommend arriving early, as seating is limited and will be available on a first come, first serve basis. You must be registered for the NKF 2009 Spring Clinical Meetings to attend this symposium and receive credit.

Target Audience

Nephrology professionals

How you will learn

This CME activity will be a live symposium consisting of lectures with panel discussion with audience participation.

Accreditation Statement

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The National Kidney Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. It has been assigned code 6EXQ7J-PRV-06.

This educational activity is approved for 1.5 contact hours.

This program is pending approval with the American Academy of Nurse Practitioners.



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.5 continuing professional education units (CPEUs) for completion of this program/material.

Declaration of Disclosure


It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity. If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest policy.

Unlabeled/Investigational Use Declaration

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, National Kidney Foundation, and Amgen Corporation do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.



Agenda and Speakers

7:30 p.m. **Dinner**

8:00 p.m. **Introduction**

Hartmut H. Malluche, MD, FACP
Robert G. "Robin" Luke Chair in Nephrology
Professor and Chief
Division of Nephrology
Bone & Mineral Metabolism
Department of Medicine
University of Kentucky Chandler Medical Center
Lexington, KY

8:05 p.m. **Importance of Bone Health in CKD**
Hartmut H. Malluche, MD, FACP

8:25 p.m. **Epidemiology, Prevention and Treatment in CKD**
Paul D. Miller, MD
Distinguished Clinical Professor of Medicine
University of Colorado Health Sciences Center
Medical Director
Colorado Center for Bone research
Lakewood, CO

8:45 p.m. **Bone Disease and Fracture Prevention in Kidney Transplant Patients**
Margaret Bia, MD
Professor of Medicine
Senior Transplant Nephrologist
Director Clinical Skills
Yale University School of Medicine
New Haven, CT

9:05 p.m. **Q & A Session with Audience Response Panel Discussion**
Led by Hartmut H. Malluche, MD, FACP

9:30 p.m. **Closing Remarks**
Hartmut Malluche, MD, FACP

DON'T MISS THE NKF STORE

The Place to Go for Educational Resources
for Kidney Health Care Professionals

NKF STORE HOURS:

Wednesday
March 25

12:00 p.m. – 6:00 p.m.

Thursday & Friday
March 26 & 27

7:00 a.m. – 6:00 p.m.

Saturday
March 28

7:00 a.m. – 12:00 p.m.

The store is located near the Registration Desk.


HUNDREDS OF CLINICAL SUPPORT TOOLS

- Anemia
- Cardiovascular Disease
- Children and Adolescents
- Chronic Kidney Disease
- Diabetes
- Dialysis
- High Blood Pressure
- Infectious Diseases
- Mineral and Bone Disorder
- Nutrition
- Transplantation



Bring Kidney
Cash to the NKF
store to save \$5 on
your purchase

www.kidney.org
800.622.9010





We offer the Nephrologist the opportunity to share in the ownership of dialysis centers and to build a business structure that meets their needs.

The Right Place for *Quality Care*

- Project Development
- Management
- Joint Venture
- Medicare Certification
- Award Winning Outcomes
- Total Financial Reporting

Our proven and successful business model allows the Nephrologist to focus on quality care for the patient and leave the management to us.


"We offer our Physicians and patients the capabilities of a large company with the responsiveness of a small company"
-Thomas J. Karl, CEO



To discuss opportunities please contact us at

888-PHYCHOICE • 888-749-2464

information@phychoice.com



How Does Your Practice Compare?

- *Do you ever wonder if other nephrologists are working as hard as you are?*
- *Would you like to know if your practice compensation package is comparable to other practices in your region?*
- *Are you over or under staffed?*
- *Do you think your overhead is too high?*

Evaluate current business processes within best practices — transform your current systems of operation into an ideal practice using comparison data!

Knowing how your practice compares to others nationwide is a key ingredient for the successful management of the business side of your practice. Now in the seventh year of conducting this survey; the RPA 2007 Nephrology Practice Business Benchmarking Survey has proven to be a unique and beneficial resource exclusively for the nephrology specialty based on real-world nephrology practice data. Since the 2005 publication, survey participation has dramatically increased by over 100%. As a result, the data that is reported in the latest publication includes a broader cross section of nephrology practices increasing its value even further.

Please visit the RPA booth in the Exhibit Hall to purchase your copy at the special conference price of **only \$200**, a tremendous savings off of the **regular price of \$495**.



1700 Rockville Pike, Suite 220 • Rockville, MD 20852
 Phone: 301-468-3515 • Fax: 301-468-3511 • email: rpa@renalmd.org
www.renalmd.org

DEAR COLLEAGUE



Beth Piriano, MD
Program Chair
SCM09

On behalf of the National Kidney Foundation, it is our great pleasure to welcome you to the 2009 Spring Clinical Meetings. The Program Committee has produced a meeting of outstanding scientific quality that encompasses cutting-edge research and timely topics designed to “put science into practice.”

Helping you to keep your kidney patients as healthy as possible is the foundation of the meeting. To that end, during the next few days you will experience a well rounded curriculum that includes the types of education activities that you and your colleagues have requested via feedback from previous NKF continuing education activities.



Kirsten Johansen, MD
Program Co-Chair
SCM09

There will also be some time to have fun—plan to join us for the Opening Ceremonies and Reception on Thursday evening and the Networking Reception on Friday evening, both to be held in the Expo Hall. During this time, you can mingle with your colleagues, visit with this year’s outstanding poster presenters and interact with many of our generous corporate supporters.

We look forward to hearing from you so please take a few moments to complete the individual session evaluations—your feedback really matters to us! We hope you find the next few days filled with activities that meet your objectives for attending SCM09. Have a great meeting and don’t forget to mark your calendars for SCM10—April 13–17 at the Walt Disney World Swan and Dolphin, Orlando, FL!

Best Wishes,



Bryan Becker, MD
President
National Kidney
Foundation

Beth Piriano, MD

Kirsten Johansen, MD

Bryan Becker, MD

WHAT'S INSIDE...

3	SCM09 Program Committee
4	NKF Leadership
5	NKF Distinguished Lecture and Award Recipients
12	NKF Professional Council Awards
14	Research Grant Recipients
15	General Information
17	Poster Presentation Information
17	Exhibit Hall
18	Corporate Partners
19	Corporate Supported Symposia
20	Disclosure Information
31	NKF Mission Statement
	Program Tracks
32	Physician
65	Advanced Practitioner
80	Nephrology Nurse and Technician
97	Renal and Clinical Dietitian
115	Nephrology Social Worker
130	Exhibit Hall Map
132	SCM09 Exhibitors
144	Hotel Map
145	Faculty

PROGRAM COMMITTEE

BETH PIRAINO, MD

Program Chair
University of Pittsburgh
Pittsburgh, PA

KIRSTEN JOHANSEN, MD

Program Co-Chair
San Francisco VA Medical Center
San Francisco, CA

SHARON ADLER, MD

SCM09 Residents' Program Coordinator
UCLA Medical Center
Torrance, CA

SRINIVASAN BEDDHU, MD

University of Utah
Health Sciences Center
Salt Lake City, UT

LAURIE E. BENTON, RN, PA-C, BS, MPAS

Advanced Practitioner
Program Chair
Scott and White Hospital
Temple, TX

SUSAN BRAY, MD

Drexel University College of Medicine
Philadelphia, PA

LEE A. CAUBLE, BSN, BSB, RN,

Nephrology Nurse and Technician
Program Co-Chair
Desert Dialysis Center
Tucson, AZ

JIM CURTIS, CHT

Nephrology Nurse and Technician
Program Chair
Home Dialysis Plus, Ltd.
Portland, OR

ANDREA DEKAM, LMSW

Nephrology Social Worker
Program Chair
University of Michigan Dialysis
Livonia, MI

LINDA FRIED, MD

VA Pittsburgh Healthcare System
Pittsburgh, PA

ELAINE GO, RN, NP

Advanced Practitioner
Program Co-Chair
St. Joseph Hospital
Laguna Niguel, CA

REBECCA HAYS, MSW, APSW

Nephrology Social Worker
Program Co-Chair
University of Wisconsin
Hospital and Clinics
Madison, WI

LI-LI HSIAO, MD, PHD

Brigham and Women's Hospital
Boston, MA

MARIANNE HUTTON, RD, CSR, CDE

Renal and Clinical Dietitian
Program Co-Chair
Fresenius Medical Services,
North America
Santa Rosa, CA

PAMELA S. KENT, MS, RD, CSR, LD

Renal and Clinical Dietitian
Program Chair
Genzyme Corporation
Vermilion, OH

KATHLEEN LIU, MD, PHD

University of California-San Francisco
San Francisco, CA

IVAN D. MAYA, MD

University of Alabama
Birmingham, AL

MICHELE H. MOKRZYCKI, MD, MS

Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY

MILAGROS D. SAMANIEGO, MD

University of Michigan Medical School
University of Michigan Transplant Center
Ann Arbor, MI

HEIDI M. SCHAEFER, MD

Vanderbilt University
Nashville, TN

HAROLD SZERLIP, MD

Medical College of Georgia
Augusta, GA

MARIA TAYLOR, PHARM D

University of Alabama
Birmingham, AL

JOHN KEVIN TUCKER, MD

Brigham and Women's Hospital
Boston, MA

BRADLEY A. WARADY, MD

Children's Mercy Hospital
Kansas City, MO

BESSIE YOUNG, MD, MPH

VA Puget Sound Health Care System
Seattle, WA

EX OFFICIO

BRYAN BECKER, MD

President, National Kidney Foundation
University of Wisconsin
Madison, WI

JOSEPH VASSALOTTI, MD

Chief Medical Officer
National Kidney Foundation
New York, NY

STAFF

BINA GEORGE, MS, CCMEP

Director, Continuing Medical Education
National Kidney Foundation
New York, NY

JESSICA JOSEPH

Professional Education Director
National Kidney Foundation
New York, NY

THE LEADERSHIP OF THE NATIONAL KIDNEY FOUNDATION



Over its 59-year history, the NKF has grown to become the preeminent voluntary health care organization dedicated to improving outcomes for people on dialysis and those with chronic kidney and urologic diseases.

The Foundation has made tremendous advances in its mission through the visionary leadership of the National Presidents and Chairmen.

The mission of the National Kidney Foundation is to prevent kidney and urinary tract diseases, improve the health and well-being of individuals and families affected by these diseases and increase the availability of all organs for transplantation.

PRESIDENT

Bryan Becker, MD 2008–2010

PAST PRESIDENTS

Allan Collins, MD, FACP	2006–2008
David Warnock, MD	2004–2006
Brian J.G. Pereira, MD	2002–2004
William F. Keane, MD	2000–2002
Joel D. Kopple, MD	1998–2000
Garabed Eknoyan, MD	1996–1998
Alan R. Hull, MD	1994–1996
Neil A. Kurtzman, MD	1992–1994
Shaul G. Massry, MD	1990–1992
Saulo Klahr, MD	1988–1990
Richard J. Glasscock, MD	1986–1988
Robert W. Schrier, MD	1984–1986
David A. Ogden, MD	1982–1984
Richard M. Freeman, MD	1980–1982
Stuart A. Kleit, MD	1978–1980
Arvin Weinstein, MD	1976–1978
James C. Hunt, MD	1973–1976
E. Lovell Becker	1970–1973

George E. Schreiner	1968–1970
George Lingua	1967–1968
William J. Jones, MD	1966–1967
Wallace W. McCrory, MD	1964–1966
Daniel P. Richman, MD	1960–1964
William A. Wargo	1959–1960
Henry Kessler, MD	1954–1959
Mrs. John E. Tedford	1952–1954
Mrs. Ada U. DeBold (<i>Founder</i>)	1950–1952

CHAIRMAN

Tom McDonough 2008–present

PAST CHAIRMEN

Charles B. Fruit	2005–2008
Fred L. Brown, MBA, FACHE	2003–2005
Andrew Baur	2001–2003
Frederick A. Herbert	1999–2001
Joseph L. Brand	1997–1999
Wendy Brown	1995–1997
A. Bruce Bowden	1993–1995
Donald R. Wilson	1991–1993
Charles E. Westcott	1989–1991
William P. Hunter, Jr.	1987–1989
The Honorable John N. Kirkendall	1985–1987
John Hoag	1983–1985
E. Burns McLindon	1981–1983
Oliver W. Porter	1979–1981
Harold D. Schwartz	1977–1979
Jack C. Kent	1975–1977
Jordan E. Ringel	1973–1975

The office of Chairman was created in 1973.

DISTINGUISHED LECTURE AND AWARD RECIPIENTS

THE SHAUL G. MASSRY DISTINGUISHED LECTURE

This lectureship was established to honor Dr. Shaul G. Massry for his scientific achievements and his contributions to the kidney healthcare community and the National Kidney Foundation. The 2009 honored lecturer is Mohamed Sayegh, MD. Dr. Sayegh will be presenting “Achieving Clinical Transplantation Tolerance: Myth No More, But!” on Thursday, March 26th.

Dr. Sayegh is a world leader in transplantation research. He has published more than 200 original articles in addition to a large number of reviews, editorial and book chapters. He has also edited several books in nephrology and transplantation.



Mohamed Sayegh, MD

Dr. Sayegh served as Council Member and President (2000–2001) of the American Society of Transplantation. He served as the Chair of the Transplant Advisory Board of the American Society of Nephrology.

Dr. Sayegh served as the Chair of AST Program, Education and Development Committees, as the Chair of the 2005 ASN Program Committee, and the Chair of the program committee of the 2006 World Transplant Congress and the 2007 World Congress of Nephrology. He is the active Co-Chair of the Steering Committee of the NIH Immune Tolerance Network and Member of the Executive Committee. He also served as Chair of the Steering Committee of the NIH consortium, Clinical Trials in Organ Transplantation (CTOT).

Past Shaul G. Massry Distinguished Lecture Recipients

2008	Tom Greene, PhD
2007	Eberhard Ritz, MD
2006	Giuseppe Remuzzi, MD, FRCP
2005	Edmund J. Lewis, MD
2004	Hans-Henrik Parving, MD, DMSc
2003	Robert Alpern, MD
2002	Joseph V. Bonventre, MD, PhD
2001	Andrzej S. Krolewski, MD, PhD
2000	Richard J. Glassock, MD
1999	Giuseppe Bianchi, MD
1998	Josephine Briggs, MD
1997	Gary E. Striker, MD
1996	Alfred Michael, MD

THE DONALD W. SELDIN AWARD

The Donald W. Seldin Award was established to recognize excellence in clinical nephrology in the tradition of one of the foremost teachers and researchers in the field, Dr. Donald W. Seldin. The 2009 award recipient is William F. Keane, MD.



William F. Keane, MD

Dr. Keane has contributed measurably to the field of nephrology throughout the course of his distinguished medical career. A graduate of Yale University School of Medicine, he completed his residency and served as Chief Medical Resident at Cornell-New York Hospital Medical Center.

Dr. Keane served as the Professor and Chairman of the Department of Medicine at Hennepin County Medical Center and the University of Minnesota in Minneapolis, for more than nine years. Additionally, Dr. Keane served as President of the National Kidney Foundation (NKF) from 2000 to 2002.

Dr. Keane was instrumental in helping NKF raise awareness of the importance of proteinuria as a risk factor for cardiovascular events and progression of kidney disease and the need for early detection and intervention. These efforts culminated during his term as NKF President when he played a major role in the expansion of NKF’s clinical practice guideline initiative from a focus on dialysis to encompass the entire spectrum of kidney disease with the Kidney Disease Outcomes Quality Initiative (KDOQI). The first KDOQI guideline, on Chronic Kidney Disease: Evaluation, Classification and Stratification, included algorithms from an NKF position paper he co-wrote on “Proteinuria, Albuminuria, Risk, Assessment, Detection and Elimination” (PARADE) in 1999. These guidelines have had a major impact on patient care over the last decade.

Another one of his key contributions to the field was the central role he played in the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study, conducted from 1996 to 2001. This landmark randomized clinical trial provided the opportunity to study kidney and cardiovascular outcomes, risk

DISTINGUISHED LECTURE AND AWARD RECIPIENTS

predictors and cost effectiveness in over 1,500 patients with Type 2 diabetes and kidney disease. The RENAAL study, published in the *New England Journal of Medicine* in 2001, provided critical information that will be valuable to those designing future clinical trials in this patient population.

Past Donald W. Seldin Award Recipients

2008	Thomas DuBose, Jr., MD
2007	L. Lee Hamm, MD, FACP
2006	Heine Murer, MD and Bernard Rossier, MD
2005	Roland C. Blantz, MD
2004	Gerhard H. Giebisch, MD
2003	William M. Bennett, MD
2002	Professor Carl Erik Mogensen
2001	Friedrich K. Port, MD, MS, FACP
2000	Tilman B. Drüeke, MD
1999	Shaul G. Massry, MD
1998	Alan R. Hull, MD
1997	Thomas F. Parker, III, MD
1996	Floyd C. Rector, MD
1995	Barry M. Brenner, MD
1994	Manuel Martinez-Maldonado, MD

DAVID M. HUME MEMORIAL AWARD

The David M. Hume Award was created in memory of one of the National Kidney Foundation's most distinguished members. The Hume Award is the highest honor given to a distinguished scientist-clinician in the field of kidney and urologic diseases. It is bestowed upon an individual who exemplifies the high ideals of scholarship and humanitarianism in an outstanding manner. The 2009 award recipient is Brian J.G. Pereira, MD, MBA.



Brian J.G. Pereira, MD, MBA

Dr. Pereira is Professor of Medicine at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences in Boston, and the President and CEO of AMAG Pharmaceuticals

in Cambridge, MA. He had previously served as President & CEO of the Physician Corporation and interim Chief Operating Officer at Tufts Medical Center. He was the past President and member of the Board of the National Kidney Foundation. He currently serves as Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program, Member of the Board of Advisors of the Harvard-MIT Health Sciences & Technology (HST) Program, and member of the Board of Directors of Satellite Health Care, Biodel, Kidney Care Partners and Youth That Care.

His research on hepatitis C and G in dialysis and transplantation have led to design of policies to reduce transmission in dialysis units, use of donors with HCV infection and management of the HCV infected transplant candidate. Dr. Pereira's work on cytokines and biocompatibility of dialysis membranes, impact of water quality and reuse, and gene polymorphisms and oxidative stress have opened the doors to understanding the role of inflammation in CKD. Also, his research on the impact of the timing of nephrology referral and optimization of pre-dialysis care on morbidity, mortality, and costs in CKD patients has led to greater focus on CKD care.

He received his MBBS from St. John's Medical College in India and MBA from the Kellogg School of Management at Northwestern University.

Past David M. Hume Memorial Award Recipients

2008	Lawrence Hunsicker, MD
2007	William G. Couser, MD
2006	Frank Delmonico, MD
2005	Roland C. Blantz, MD
2004	John Stewart Cameron, MD
2003	Franklin H. Epstein, MD
2002	Barry M. Brenner, MD
2001	William E. Mitch, MD
2000	[No Award]
1999	Neil A. Kurtzman, MD
1998	Jared J. Grantham, MD
1997	Thomas E. Andreoli, MD
1996	Edmund G. Lowrie, MD
1995	Joseph W. Eschbach, MD
1994	Wadi N. Suki, MD
1993	Joel D. Kopple, MD
1992	Saulo Klahr, MD
1991	Professor August Heidland
1990	Richard J. Glasscock, MD
1989	Professor Priscilla Kincaid-Smith
1988	Shaul G. Massry, MD
1987	Robert W. Schrier, MD
1986	Robert Heptinstall, MD
1985	Willem J. Jolff, MD
1984	Charles R. Kleeman, MD
1983	Robert W. Berliner, MD
1982	Professor Hugh E. de Wardener
1981	Donald W. Seldin, MD
1980	George E. Schreiner, MD
1979	John P. Merrill, MD
1978	Thomas E. Starzl, MD
1977	Henry L. Barnett, MD
1976	Carl W. Gottschalk, MD
1975	Belding Scribner, MD
1974	Robert M. Kark, MD
1973	Jean Hamburger, MD

THE GARABED EKNYAN AWARD

The Garabed Eknayan Award was created to recognize an individual who has promoted the mission of the National Kidney Foundation in Making Lives Better for people with kidney disease through exceptional contributions to key initiatives of NKF such as the Kidney Disease Outcomes Quality Initiative (KDOQI) or clinical research in the field of kidney disease. The 2009 award recipient is Sharon M. Moe, MD.



Sharon M. Moe, MD

Dr. Moe is Professor of Medicine and Vice-Chair for Research in the Department of Medicine at the Indiana University School of Medicine in Indianapolis, Indiana. She received her medical degree from the University of Illinois College of Medicine at Chicago. She completed her internship and residency in the Department of Internal Medicine at Loyola University Medical Center in Maywood, Illinois. Her research and clinical fellowships were completed in the Section of Nephrology of the Department of Medicine at the University of Chicago in Illinois. She has been a faculty member at Indiana University since 1992.

Dr. Moe is the principal investigator for several ongoing clinical and basic research studies funded by the Veterans Affairs Department, the National Institutes of Health, and Pharmaceutical Companies. She has authored over 100 scientific manuscripts, teaching manuscripts and textbook chapters about renal osteodystrophy and vascular calcification. Dr. Moe served on the National Kidney Foundation's Bone and Mineral metabolism KDOQI work group and is Co-Chair of the KDIGO Mineral and Bone guidelines to be released in 2009. She was a member of the American Society of Nephrology Program Committee in 2003, Chair of the National Kidney Foundation Annual Clinical Meeting in 2005, and a Councilor to the International Society of Nephrology from 2005–2007. She has delivered numerous invited lectures nationally and internationally.

DISTINGUISHED LECTURE AND AWARD RECIPIENTS

Past Garabed Eknoyan Award Recipients

2008 Adeera Levin, MD, FRCP(C)
2007 Norbert H. Lameire, MD
2006 Francesco Locatelli, MD
2005 Nathan W. Levin, MD, FACP
2004 Neil R. Powe, MD, MPH, MBA
2003 Bertram L. Kasiske, MD
2002 Andrew S. Levey, MD

JOEL D. KOPPLE AWARD

The Joel D. Kopple Award is an annual award honoring an individual who has made significant contributions to the field of renal nutrition. This year's Joel D. Kopple Award recipient is Raymond Hakim, MD who will be speaking on "The Critical Role of Dietary Counseling in the Outcome of ESRD Patients".



Raymond Hakim, MD

Dr. Raymond Hakim is an Adjunct Professor in the Division of Nephrology and Hypertension at Vanderbilt University and Senior Executive Vice President of Clinical and Scientific Affairs for Fresenius Medical Care-NA. He received a PhD

in Engineering from MIT in Boston, MA and his MD from McGill University in Montreal, Canada. He has been an invited speaker at numerous national and international conferences, held visiting professorships at several universities and sat on the editorial board of such journals as *Seminars in Dialysis*, *American Journal of Kidney Disease* and *Kidney International*. Dr. Hakim's career-long research attention to nutrition intervention in ESRD, including early work on serum albumin as a marker of poor nutritional status, and his investigation into the use of nutritional supplements in ESRD is well known and has laid the foundation for other studies in this area. Dr. Hakim was also instrumental in adding a nutrition component to the Right Start program to help improve patient outcomes. In addition to malnutrition in dialysis patients, Dr. Hakim's other research interests include growth factors in ESRD patients, trace metal toxicity in dialysis patients, chronic renal failure and blood materials interactions during extracorporeal therapy.

Past Joel D. Kopple Award Recipients

2008 Alison Steiber, PhD, RD, LC
2007 Kamyar Kalantar-Zadeh, MD, PhD, MPH
2006 Mary Pat Kelly, MS, RD, GNP
2005 Jerrilynn D. Burrowes, PhD
2004 Judith Beto, PhD, RD, FADA
2003 Linda M. McCann, RD, LD, CSR
2002 Linda Moore, RD, LDN

SCM09 INTERNATIONAL DISTINGUISHED MEDAL RECIPIENTS

The International Distinguished Medal was established in 1990 to honor the achievement of individuals who have made significant contributions to the field of kidney disease and extended the goals of the National Kidney Foundation. The Foundation President presents medals each year to recognize the accomplishments of individuals through their clinical work, roles in academia, scientific discoveries or volunteer work in organizations similar to the Foundation.

Guillermo Garcia Garcia, MD

Dr. Garcia graduated from the University of Guadalajara, Mexico, in 1974.



Guillermo Garcia Garcia, MD

He completed his internship and residency training in Internal Medicine at Cabrini Health Care Center, New York, NY and his fellowship in Clinical Nephrology at the University of Cincinnati, Ohio.

Upon his return to Mexico in 1981 he founded the Nephrology Department at the Hospital Civil de Guadalajara where he pioneered the delivery of renal care and transplantation for the poor in the state of Jalisco. In 1989 he opened a Fellowship Program in Nephrology sponsored by the University of Guadalajara, the first program outside Mexico City, which recently has been recognized as a center of excellence by the Mexican Council on Science and Technology (CONACYT).

He is a co-founder and coordinator of the Jalisco Dialysis and Transplant Registry (REDTJAL), the only renal registry in Mexico and a contributor to the USRDS and the Latin American Dialysis and Transplant Registry.

In 2006, Dr. Garcia began a large CKD screening program in Jalisco in collaboration with the Hospitales Civiles de Guadalajara Foundation. He has established a CKD Prevention Clinic in association with the University of Alberta, Edmonton, following the multidisciplinary Canadian model. Since its inception, he has led the organization of World Kidney Day in Jalisco.

Dr. Garcia is a former Councilor of the International Society of Nephrology (ISN) and current Chair of the ISN-COMGAN Committee on Kidney Health in Disadvantaged Populations. He is the recipient of the Jalisco Award in Health Sciences 2003 and the Enrique Díaz de León Award 2007, by the University of Guadalajara, and the Dr. Juan Lopez Award 2008 by the Hospital Civiles de Guadalajara, all because of academic excellence. He is currently working on a project to implement the NKF-KEEP Program in Mexico.

Donal O'Donoghue, MD

Dr. O'Donoghue was appointed as the first National Director for Kidney Care in January 2007.



Donal O'Donoghue, MD

He has been Consultant Renal Physician since 1992 and was the Clinical Director of Renal Services at Salford Royal NHS Foundation Trust in Greater Manchester between 1994 and 2007.

Dr. O'Donoghue is an honorary lecturer at the University of Manchester and publishes regularly on the epidemiology of chronic kidney diseases, progression of kidney disease, renal anaemia, models of service delivery and clinical outcomes.

He has been on numerous kidney service advisory groups and established the first managed clinical network for Renal services in Greater Manchester in 1999. He has championed the integration of kidney care into general vascular risk reduction strategies and care plans.

Dr. O'Donoghue lives with his wife Marie who is a primary school teacher and has three children, Daniel, Kathryn and James. Outside of work, Donal is a passionate Manchester United supporter.

Gregorio T. Obrador, MD, MPH

Dr. Obrador is Professor of Medicine and Dean at the Universidad Panamericana School of Medicine in Mexico



Gregorio T. Obrador, MD, MPH

City. He also serves as Adjunct Staff at the Division of Nephrology of the Tufts-New England Medical Center and Assistant Professor of Medicine at the Tufts University School of Medicine in Boston. He earned his medical degree from the University of Navarra (Pamplona, Spain), completed his medicine residency at the Western Pennsylvania Hospital (Pittsburgh) and his Nephrology fellowship at Boston University. While doing a clinical research fellowship at Tufts and a Master of Public Health at Harvard University, he demonstrated that the pre-ESRD management of patients with chronic kidney disease is suboptimal, and that this is an important factor for the high morbidity and mortality observed in these patients. Dr. Obrador has been a member of the KDOQI Advisory Board and of the Clinical Practice Guideline on Anemia Workgroup and has participated in several committees of the Kidney Disease Improving Global Outcomes (KDIGO) initiative, the American Society of Nephrology, the International Society of Peritoneal Dialysis, the Mexican Academy of Medicine and other Mexican nephrological societies. He is founding member of the Mexican Kidney Foundation and one of the leaders of the Mexico KEEP program. He has given 97 lectures in national and international forums and has several publications in the area of chronic kidney disease.

Kim Solez, MD

Dr. Solez is one of the medicine's foremost renal pathologists and a leader in Internet communications in medicine.

He came to the University of Alberta, in Edmonton, Canada in 1987 as Chairman of Pathology, and is currently Professor and Director of Experimental

DISTINGUISHED LECTURE AND AWARD RECIPIENTS



Kim Solez, MD

Pathology. Dr. Solez has served in the past as Director of NKF's cyberNephrology, a joint venture of the National Kidney Foundation (US) and the University of Alberta. Dr. Solez is the father of the Banff

Classification for Kidney Transplant Pathology.

As Chair of the ISN Commission on Acute Renal Failure from 1989 to 1997, Dr. Solez started the International Society of Nephrology Disaster Relief Task Force, which works in partnership with Doctors Without Borders.

Dr. Solez was recipient of the Boyd Award from the Canadian Society of Pathologists in 2002, and was Researcher of the Year for the Capital Health Authority in 2005.

He is the author of over 150 medical articles and eight books. He is also the author of highly popular essays for the general public on technology issues on ThinkerNet Blog <http://www.internetevolution.com>.

Dr. Solez was born and raised in upstate New York in the US, and received his MD from the University of Rochester, NY, and postgraduate training at the Johns Hopkins Hospital, in Baltimore, Maryland.

Past International Distinguished Medal Recipients **2008**

Bernard Charra, MD, Tassin, France
Wendy Hoy, MD, Queensland, Australia
Michel Jadoul, MD, Bruxelles, Belgium
Yves Vanrenterghem, MD, PhD, Leuven, Belgium

2007

Mona Al-Rukhaimi, MD, Dubai, United Arab Emirates
Dick de Zeeuw, MD, PhD, Groningen, The Netherlands
Sayyid Ali Jaffer Naqvi, MD, Karachi, Pakistan
Susumu Takahashi, MD, PhD, Tokyo, Japan
Christoph Wanner, MD, Wurzburg, Germany

2006

Jorge Cannata-Andia, MD, Oviedo, Spain
Prakesh Keshaviah, MD, Dehradun, Uttaranchal, India
Gabriel Mircescu, MD, Bucharest, Romania
Yusuke Tsukamoto, MD, Tokyo, Japan
Haiyan Wang, MD, Beijing, China

2005

John Dirks, MD, Toronto, Ontario, Canada
Saraladevi Naicker, MD, Johannesburg, South Africa
Luis Revert, MD, Barcelona, Spain
Wu Chang Yang, MD, Taiwan, China

2004

Peter G. Blake, MB, FRCP, Toronto, Canada
Kai-Uwe Eckardt, MD, Erlangen, Germany
S. Adibul Hasan Rizvi, MBBS, FRCS, FRCSE, FCPS, FRCP, Karachi, Pakistan
Bernardo Rodriguez-Iturbe, MD, Maracaibo, Venezuela
Claudio Ronco, MD, Vicenza, Italy

2003

Georgi Abraham, MD, Chennai, India
Shanyan Lin, MD, Shanghai, China
Nester Schor, MD, PhD, Sao Paulo, Brazil
Carmine Zoccali, MD, Reggio, Italy

2002

Gavin Becker, MD, Victoria, Australia
Francesco Locatelli, MD, Lecco, Italy
Sergio Mezzano, MD, Valdivia, Chile
Giuseppe Piccoli, MD, Torino, Italy
Wladyslaw Sulowica, MD, PhD, Krakow, Poland

2001

Elvira Emilia Arrizurieta, MD, Buenos Aires, Argentina
Hans-Henrick Parving, MD, DMSC, Copenhagen, Denmark
Yahya Sagliker, MD, Adana, Turkey
Fernando Valderrabano, MD, PhD, Madrid, Spain

2000

Vittorio Andreucci, MD, PhD, Naples, Italy
Norbert Lameire, MD, PhD, Gent, Belgium
Florian Lang, MD, PhD, Tübingen, Germany

1999

Jonas Bergström, MD, PhD, Huddinge, Sweden
Walter H. Hörl, MD, PhD, Vienna, Austria
Vincenzo Savica, MD, Messina, Italy
Gianfranco Guarnieri, MD, Trieste, Italy

1998

Professor Rosario Maiorca, Brescia, Italy
John Walls, MD, Leicester, England
Shaul M. Shasha, MD, Nahariya, Israel
Professor Jean-Pierre Grunfeld, Paris, France

1997

Professor Guido Bellinghieri, Sicily, Italy
Professor Hiroto Mori, Osaka, Japan
Professor Momir H. Polenakovic, Skopje, Macedonia
Professor Bolesław Rutkowski, Gdańsk, Poland

1996

Professor Judit Nagy, Pécs, Hungary
Professor Karel Opatrný, Písek, Czech Republic
Miguel C. Riella, MD, Curitiba, Brazil

1995

Maurice Slapak, MD, Hampshire, England
Guy Laurent, MD, Tassin, France
David N. Kerr, MD, London, England
Alexander P. Disney, MD, Adelaide, South Australia
Andrzej Książek, MD, Lublin, Poland

1994

Stefan Angielski, MD, Gdańsk, Poland
Natale G. De Santo, MD, Naples, Italy
Professor Miroslaw Mydlik, Kosice, Slovak Republic

1993

Jamie Herrera-Acosta, MD, Mexico City, Mexico
Jose L. Rodicio, MD, Madrid, Spain
Professor Sandor, Szekesfehervar, Hungary
Visith Sitprija, MD, Bangkok, Thailand

1992

Professor Albert Valek, Czechoslovakia
Professor Mary G. McGeown, Ireland
Professor Ori Better, Haifa, Israel
Professor Rashad, Barsoum, Egypt
Professor Karl M. Koch, Hanover, Germany
M. Derome Tremblay, France

1991

Professor Nobuhiro Sugino, Tokyo, Japan
Professor K.S. Chugh, Mumbai, India
Professor Renee Habib, Paris, France
Professor Franciszek Kokot, Poland
Professor Sevrin Ringoir, Ghent, Belgium

1990

Professor Kazimierz Baczyk, Poznań, Poland
Professor Vittorio Bonomini, Bologna, Italy
Professor J. Stewart Cameron, London, England
T.T. Durai, MD, Singapore
Professor Henri Jahn, Strasbourg-Cedex, France
Professor Eberhard Ritz, Heidelberg, Germany

NKF PROFESSIONAL COUNCIL AWARDS

Each year NKF Professional Councils recognize individuals who have made outstanding contributions in the field of renal health. It is an honor to announce some of those individuals who will be formally recognized at this year's meeting.

COUNCIL OF NEPHROLOGY SOCIAL WORKERS (CNSW)

CNSW ROBERT W. WHITLOCK LIFETIME ACHIEVEMENT AWARD

The CNSW Lifetime Achievement Award is being renamed in honor of Robert W. Whitlock, MSSW, MHA, LCSW, Director of the Missouri Kidney Program (MoKP) and leader in the kidney community, who passed away on July 20, 2008. Bob was a dedicated nephrology social worker and an outstanding contributor to research, teaching and clinical practice in nephrology social work. He will be missed by all in our community.

Judith Kari, MSSW, CISW

CNSW is especially pleased to present Judith Kari with this award. Her many achievements include involvement in the formation of CNSW, longtime efforts to communicate

renal issues to CMS and, most recently, contributing to the development of the new Conditions of Coverage and Interpretative Guidelines for the surveyors. Judith has been a pioneer and indeed helped pave the road for us all.

CNSW MERIT AWARD

Michelle Mayo, LISW DaVita University, St. Paul, MN

Michelle is Chair of her local Chapter where she encourages networking and educational activities. She is active with the local NKF, including sharing her singing talent. Michelle has also served on the Committee for the Local Partners' annual conference, and is also known for her willingness to go out of her way to help.

COUNCIL ON RENAL NUTRITION (CRN)

JOEL D. KOPPLE AWARD

Raymond Hakim, MD

See page 8 for Dr. Hakim's biographical sketch.

SUSAN KNAPP EXCELLENCE IN EDUCATION AWARD

Laura Byham-Gray, PhD, RD

Dr. Byham-Gray is Associate Professor in the Graduate Programs in Clinical Nutrition at the University of Dentistry and Medicine of New Jersey. She was Co-Editor of *A Clinical Guide to Nutrition Care in Kidney Disease* and *Nutrition in Kidney Disease*, and she is on the committee that is writing the *Standards of Practice and Standards of Professional Performance for Dietitians in Nephrology*. She has presented to professionals and students at both the undergraduate and graduate level. Dr. Byham-Gray

has also written articles for the lay community and participated as a faculty volunteer for the past five years at the Special Olympics in New Jersey. She was awarded the Outstanding Service Award by the American Dietetic Association Renal Practice Group in 2007. Dr. Byham-Gray feels the essential component of her teaching philosophy is the role of teacher as a mentor and coach in helping her students actualize their professional goals and instilling the importance of lifelong learning. In her letter of contribution, she elegantly quoted Pearl S. Buck in describing what she felt the Susan Knapp Excellence in Education Award meant: "The secret of joy in work is contained in one word—excellence. To know how to do something well is to enjoy it."

COUNCIL ON RENAL NUTRITION (CRN) CONTINUED

RECOGNIZED RENAL DIETITIAN

Deborah Benner, MA, RD, CSR

Debbie has been the National Director of Nutritional Services for DaVita, Inc in Irvine, CA, since 1999. Prior to that, she was a renal dietitian for 16 years. In her current position, Debbie has worked to improve and standardize dietitian practices for over 1,100 renal dietitians across the country by developing a 50-member Area Dietitian Team. She led the development and implementation of extensive renal dietitian training programs within the company, including one for new

renal dietitians, and worked closely with DaVita Clinical Research to encourage support for studies related to nutritional status in dialysis patients. She has been Secretary for the ADA-RPG and most recently served two terms as Region V Representative and Research Grant Committee Chair for NKF-CRN. Debbie is currently a member of the committee that is writing the *Standards of Practice and Standards of Professional Performance for Dietitians in Nephrology*. She has authored numerous articles and has been an invited speaker in renal nutrition at both national and international conferences.

COUNCIL OF NEPHROLOGY NURSES AND TECHNICIANS (CNNT)

DISTINGUISHED SERVICE AWARD

Diana Hlebovy, RN, BSN, CHN, CNN

CNNT is proud to announce that Diana Hlebovy, RN, BSN, CHN, CNN, is the recipient of the 2009 NKF CNNT Distinguished Service Award. Diana is the Clinical Director of HemaMetrics and has been actively involved in the dialysis community since 1976. She has devoted the last ten years to research; developing protocols and training programs for blood volume monitoring; and presenting on the effects of fluids, oxygen and anemia management on hemodialysis patients. She is affectionately known to her colleagues as the “Mother of Blood Volume Monitoring” for her contributions to the field. Diana’s efforts working

with the dialysis community and the U.S. government have ensured that blood volume monitoring and the importance of managing fluids are integral parts of the new CMS Interpretive Guidelines in two areas: that blood volume monitoring be mandatory for pediatrics, to identify the root cause of patient symptoms, and that “dry weight” should be defined by people who are normotensive with minimal hypertensive medications. CNNT congratulates Diana on her influence and education in these areas.

NKF'S PROFESSIONAL COUNCILS RESEARCH GRANT RECIPIENTS 2008–2009

COUNCIL OF NEPHROLOGY NURSES AND TECHNICIANS GRANTS

Cynthia Russell, PhD, RN

University of Missouri-Columbia
Columbia, MO

Title of Project: An Intervention to Improve Medication
Adherence in Adult Renal Transplant Recipients

Susan Walker, RN, MSN, DrNPc

Drexel University
Philadelphia, PA

Title of Project: Mindfulness-Based Stress Reduction
in Kidney Transplant Candidates

COUNCIL OF NEPHROLOGY SOCIAL WORKERS GRANTS

Kimberly Acquaviva, PhD, MSW

George Washington School of Medicine and
Health Sciences
Washington, DC

Title of Project: Social Support Intervention for
ESRD Patients

Erica Perry, MSW

National Kidney Foundation of Michigan
Ann Arbor, MI

Title of Project: Jump Starting the Life Journey of
Young Adults Interrupted by Kidney Failure

COUNCIL ON RENAL NUTRITION GRANT

Janeen León, MS, RD

MetroHealth Medical Center
Cleveland, OH

Title of Project: Phosphorus Content of Fast Food
Menu Items

GENERAL INFORMATION

MEETING OBJECTIVES

The National Kidney Foundation 2009 Spring Clinical Meetings Program Committee has developed an exciting program that will update the busy kidney health care provider on new developments related to all aspects of nephrology practice. Participants will learn about new and evolving concepts related to kidney disease through workshops, debates, interactive courses and traditional didactic sessions.

SCM09's learning objectives focus on increasing participants' understanding and knowledge in the following areas:

- Glomerulonephritis treatment approaches
- New trials in polycystic kidney disease
- Acute kidney injury especially in the ICU setting
- Causes of secondary hypertension
- Nephrogenic systemic fibrosis
- Kidney transplantation
- Newer therapies of diabetes and targets for control
- End of life issues in patients on dialysis
- Malnutrition and strategies to ameliorate it
- Recruitment for a home hemodialysis program
- Electrolyte disturbances
- Drug dosing in CKD
- Racial and ethnic disparities in CKD
- Nephrolithiasis
- Economics of renal disease
- An examination of mortality in both PD and HD patients with patterns over time

NKF'S EXPECTATION OF PRESENTERS

Through the National Kidney Foundation Spring Clinical Meetings and other continuing education activities, NKF promotes excellence in kidney health care education. NKF expects that all presenters affiliated with the NKF 2009 Spring Clinical Meetings will provide informative and fully accurate content that reflects the highest level of scientific rigor and integrity.

TARGET AUDIENCE

- Physicians
- Pharmacists
- Fellows and Residents
- Physician Assistants
- Nurse Practitioners
- Nurses and Technicians
- Dietitians
- Social Workers

HOW TO OBTAIN CME/CE CREDIT

NKF has established an online system for tracking your CME/CEU's. With an easy swipe of a badge, attendance at sessions will automatically be recorded. CME and CEU credit information will be uploaded to a Web site for easy viewing. You are able to print a certificate of attendance at your own convenience. Access this system by visiting www.expobadge.com/certification/nkf2009

The online service is available through July 1, 2009.

NKF REGISTRATION, TICKET SALES AND INFORMATION

Location: Presidential Lobby, Convention Center

Tuesday	3:00pm–8:00pm
Wednesday	6:30am–6:00pm
Thursday	5:30am–6:00pm
Friday	7:00am–5:00pm
Saturday	7:00am–5:00pm
Sunday	7:00am–1:00pm

Tickets for programs requiring separate registration and/or a separate fee are available at the Ticket Sales Booth in the Registration Area. Staff are available at the Meeting Information Booth to answer any questions that you may have.

BADGES

Please wear your registration badge for admission to all meetings activities. There is a \$10.00 replacement fee for lost badges.

POSTER PRESENTATIONS

Over 240 abstracts will be presented as posters. Take advantage of this outstanding opportunity to share in the authors' research experience and discuss significant areas of development in the ever evolving field of chronic kidney disease. Posters are available for viewing in the Exhibit Hall beginning on **Thursday, March 26 at 6:00pm** through **Saturday, March 28 at 12:30pm**.

GENERAL INFORMATION

NATIONAL KIDNEY FOUNDATION STORE

Location: Presidential Lobby, Convention Center

The NKF Store provides exceptional educational materials and products specifically for patients, professionals and public awareness developed by the Kidney Learning System (KLS).

Please stop by the NKF Store to...

- see our latest Chronic Kidney Disease (CKD) related tools, materials and resources available
- pick up single, complimentary copies of brochures, CME activities and tools
- use your Kidney Kash to purchase from many CKD resources available for your office

Wednesday	12:00pm–6:00pm
Thursday	7:00am–6:00pm
Friday	7:00am–5:00pm
Saturday	7:00am–12:00pm

MEMBERSHIP QUESTIONS

NKF professional membership provides numerous benefits for physicians, pharmacists, advanced practitioners, nurses, technicians, dietitians and social workers. Stop by the Membership Services Counter in the Registration area for questions and enrollment. Visit the NKF Professional Councils Booth (1622) located in the Exhibit Hall to learn more about NKF membership.

FELLOWS/RESIDENTS EVENT

Career Choices In Nephrology/Fellows Reception

*Held in association with Women in Nephrology
Supported by an unrestricted educational grant from
AMAG Pharmaceuticals, Inc.*

Saturday, March 28, 5:30pm–7:00pm

Moderators: Sharon M. Moe, MD and Heidi Schaefer, MD

Panelists: Bryan Becker, MD, Robert Brenner, MD,
Li-Li Hsiao, MD, Jamie Dwyer, MD, Stan Lee, MD,
Jeff Guillian, MD

“Career Choices in Nephrology” is a special session perfect for trainees in internal medicine and nephrology (of all genders) who are trying to decide what career path

to choose in nephrology. The session will begin with a panel discussion by individuals currently active in private practice, academic medicine and industry. Learn why these individuals decided on their career paths, their backgrounds, what they did to secure their jobs, and if (and how) they would do it again if they were starting over. After the panel discussion, there will be time for questions and answers followed by a reception with hors d’œuvres and beverages. Come join us to learn how others made career decisions and to meet your colleagues and the SCM09 faculty.

INTERNAL MEDICINE AND PEDIATRIC TRAINEES PROGRAM

We are pleased to welcome Internal Medicine and Pediatric Trainees to SCM09. This special program encourages highly qualified and interested individuals to enter the field of nephrology. The program provides Internal Medicine and Pediatric Trainees concentrated exposure to cutting edge clinical and experimental nephrology in a stimulating learning environment. The goals of the program are to shed light on the broader aspects of the subspecialty than what house staff experience on the wards in their daily routine.

THE LEARNING CONTINUES

Recordings

Most sessions will be audio taped.* Tapes and MP3 audio CD-ROMs will be sold in the Registration Area at the “Conference Copy, Inc.” table following the meeting. Please refer to the topic list included in your tote bag for more information or you can check the NKF website for this information.

*Speaker permission must be granted in order to tape a session or a particular speaker.

FACULTY SLIDE PRESENTATIONS

Final slide presentations* will be posted on the NKF website at the conclusion of the meeting and will be made available to the registrants of SCM09.

*Presentations available with faculty permission only.

2009 POSTER PRESENTATION & EXHIBIT HALL ACTIVITIES

THURSDAY, MARCH 26

TIME	SESSION
6:00pm–7:30pm	Opening Ceremonies and Faculty Reception—Poster Authors Available for Q&A

FRIDAY, MARCH 27

TIME	SESSION
7:00am–8:00am	Continental Breakfast and Posters/Exhibits
9:30am–2:00pm	Lunch (Served 12:00pm–1:15pm) and Posters/Exhibits
6:00pm–7:30pm	Networking Reception and Posters/Exhibits

SATURDAY, MARCH 28

TIME	SESSION
9:00am–12:30pm	Brunch (Served at 10:30am) and Posters/Exhibits
12:30pm	Exhibit Hall Closes

EXHIBIT HALL INFORMATION

Exhibits and posters are located in the Ryman Exhibit Hall. Exhibitors are a vital part of the NKF Spring Clinical Meetings. The NKF thanks our exhibitors for their continued support of our educational programs, and cordially invites attendees to the following receptions:

- **Thursday, March 26**, for the Exhibit Hall Opening Reception which will be held at **6:00pm** in the Exhibit Hall. Posters will also be on display with authors present. Top poster presenters announced.
- **Friday, March 27**, for a Networking Reception held in the Exhibit Hall from **6:00–7:30pm**. Meet colleagues for cocktails and hors d'oeuvres in a relaxed atmosphere before you attend one of the dinner symposia.

SCM09 EVALUATIONS—YOUR FEEDBACK REALLY MATTERS

Evaluations will be distributed at the beginning of each session and collected at the end. There will be evaluation drop-off boxes located around the meeting area or you can drop off your evaluations at the NKF Information Booth. Evaluations are very important. The planning and execution

of useful and sound continuing education programs are largely guided by input provided by program participants—such as yourself. In addition, your responses will help ensure that future programs are informative and meet your educational needs. Please take a few minutes to let us know what you think, because your feedback really matters!

NATIONAL YOUNG INVESTIGATORS' FORUM

Wednesday, March 25, 2009

The National Kidney Foundation is pleased to host the 4th National Young Investigators' Forum chaired by Kathleen Liu, MD and Li-Li Hsiao, MD. Participants include the winners of the four regional Young Investigators' Forums held in the first quarter of 2009. Presenters will compete in the Clinical Research or Basic Research categories. A panel of faculty judges will select the award winners in each category.

Participation by invitation only.

NKF gratefully acknowledges the support of Amgen who has made this program possible.

SPOTLIGHT ON OUR SUPPORTERS

The National Kidney Foundation gratefully acknowledges our corporate partners who have supported the Foundation and enabled us to work towards its mission of preventing kidney and urinary tract diseases, improving the health and well-being of individuals and families affected by these diseases, and increasing the availability of all organs for transplantation. A percentage of funds raised are also directed toward the foundation's research program.

Abbott Laboratories, Inc.	Golf Digest Publications	RED Development
Affymax, Inc.	Hardee's Food Service	Renal Associates
AMAG Pharmaceuticals	Health Care Foundation of Greater Kansas City	Roche
American Express	Horizon Media	Rochford Foundation
AmeriGroup Charitable Foundation	John C. & Eunice B. Morrison Charitable Foundation	Saint Louis University Hospital
Amgen	KenJo, Inc.	Sanford Health
Associated Wholesale Grocers	KD&E, Inc.	Satellite Healthcare, Inc.
Astellas Pharma US, Inc.	Lockheed Martin Corporation	Shire
AT&T	Mercedes-Benz of Kansas City	Southwest Bank
Avera McKennan Hospital & University Health Center	Merck & Co., Inc.	St. Mary's Health Systems, Inc.
Baxter	Missouri Kidney Program	Stan McCabe Family Trust
Bee Ready Fishbein Hatter & Donovan, LLP	Mountain States Health Alliance	Starcom MediaVest Group
Berg Motors	MTV Networks	Stephen & Mary Birch Foundation
Boehringer Ingelheim Pharmaceuticals, Inc.	Musculoskeletal Transplant Foundation	Takeda Pharmaceuticals Company Limited
Bristol-Myers Squibb Company	NBC Universal Sales and Marketing	TCF Bank
Carter Broadcast Group	Nephrology Consultants	The Breidenthal-Snyder Foundation
CB Richard Ellis	NephroPath	The Coca-Cola Company
CB Richard Ellis Foundation	New York State Department of Health	The Eller Company
Children's Mercy	NewsCorp/Fox	The Frank J. Antun Foundation
City Bank Texas	NFL Network & NFL.COM	The Jay and Rose Phillips Family Foundation
Covenant Health Systems	Nicholas Institute for Sports Medicine and Athletic Trauma	The Lucius N. Littauer Foundation
CSL Behring	North-Shore/Long Island Jewish Health System	The McCutchen Foundation
DaVita Inc.	Novartis Pharmaceuticals Corporation	The Nielsen Company
Discovery Communications	Novo Nordisk, Inc.	The Robert & Jane Cizik Foundation
Dream Factory	Ocean Spray Cranberries, Inc.	The Terry & Susan Anderson Foundation
EDS	Ortho Biotech	Turner Broadcasting Sales Inc.
Embassy of the United Arab Emirates	Pfizer Inc.	United Way of Greater Knoxville
Emerson	PharmaNet Development Group, Inc.	United Way of Blount County
Faribault Foods	Phi Sigma Sigma Foundation	University of Texas Health Science Center at San Antonio
First Republic Bank	PING	Wachovia Securities
Fitzgerald & Co.	Prism Research, Inc	Watson Pharmaceuticals, Inc.
Frank Kent Cadillac	ProHEALTH Care Associates, LLP	Westgate Cadillac
Fresenius Corporations	Quest Diagnostics Incorporated	Wyeth Pharmaceuticals
Genzyme Renal		Zurich
GlaxoSmithKline		

CORPORATE SUPPORTED BREAKFAST, LUNCH AND DINNER SYMPOSIA

WEDNESDAY, MARCH 25

7:30pm–9:30pm

**Impact of Special Populations and Vitamin D Therapy
in Chronic Kidney Disease Outcomes**

Supported by an educational grant from Abbott

THURSDAY, MARCH 26

6:00am–7:45am

**Preventing and Managing AKI in Patients with
Tumor Lysis Syndrome: A Team Approach**

Supported by an educational grant from
Sanofi-aventis U.S., Inc.

12:00pm–2:00pm

Role of Abnormal Phosphate Metabolism in CKD-MBD

Supported by an educational grant from Genzyme

7:30pm–9:30pm

**A New Direction in Anemia Management Beyond
Erythropoietic Stimulating Agents**

Supported by an educational grant from
Fresenius Medical Care—North America

FRIDAY, MARCH 27

6:00am–7:45am

**Exploring Recent Evidence Related to Cardiovascular
Calcification and Chronic Kidney Disease**

Supported by an educational grant from
Fresenius Medical Care—North America

7:30pm–9:30pm

**Advances in the Management of Idiopathic
Membranous Nephropathy**

Supported by an educational grant from
Questcor Pharmaceuticals, Inc.

7:30pm–9:30pm

**Bone Fracture in CKD: Clinical Issues and Expert
Perspectives**

Supported by an educational grant from Amgen

SCM09

NATIONAL KIDNEY FOUNDATION
SPRING CLINICAL MEETINGS
NASHVILLE, TN/MARCH 25-29, 2009

CONTRIBUTORS

The National Kidney Foundation gratefully acknowledges the support of the following companies who helped make the NKF 2009 Spring Clinical Meetings possible:

PRIMARY CONTRIBUTORS:

Corporate Symposia and other Educational Activities

Abbott

Amgen

AMAG Pharmaceuticals, Inc.

Fresenius Medical Care—North America

Genzyme

Merck & Co., Inc.

Questcor Pharmaceuticals, Inc.

Sanofi-aventis U.S. Inc.

GENERAL CONTRIBUTORS:

Additional Conference Materials and Events

Abbott

Amgen

AMAG Pharmaceuticals, Inc.

Bard Access Systems

MedComp

Shire Pharmaceuticals

Watson Nephrology

DISCLOSURE OF FACULTY COMMERCIAL RELATIONSHIPS

The National Kidney Foundation is required by the Accreditation Council for Continuing Medical Education to disclose any relevant support or financial relationships between any individual in a position to control content and commercial entities for all Continuing Medical Education (CME) activities.

The NKF sent a "Disclosure Form" to the faculty and planning committee members participating in the 2009 Spring Clinical Meetings (March 25–29, 2009, in Nashville, TN). All faculty members participating in a National Kidney Foundation-sponsored activity are expected to disclose to the participants prior to the educational activity the existence of any significant financial or other relationships held by themselves, and/or family members, with the manufacturer(s) of any commercial products(s) or provider(s) of any commercial service(s) discussed in an educational presentation.

The faculty member is also required to disclose to the activity audience when an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during an educational activity. The intent of this disclosure is to provide attendees with information prior to their participation in the educational activity.

All invited speakers for the National Kidney Foundation 2009 Spring Clinical Meetings are expected to complete a "Faculty Disclosure Form." Speakers who did respond but have nothing to disclose are listed with no information next to their name. Speakers who do not provide this information will not be allowed to present. Meeting participants may also refer to the Session Chair introductory remarks for each session for final listings of disclosures and off-label or unapproved usages of a product.

FACULTY AND PLANNING COMMITTEE DISCLOSURE LISTING

KENNETH ABREO

SHARON ADLER

Grant/Research Support: Novartis Pharmaceuticals, Fibrogen, Genentech Genzyme

ANIL AGARWAL

ANUPAM AGARWAL

Consultant/Scientific Advisor: Genzyme

RAJIV AGARWAL

Speaker's Bureau: Merck, Astra Zeneca, Boehringer-Ingelheim

ZALMAN AGUS

EJAZ A. AHSAN

Grant/Research Support: Sanofi-aventis

ENVER AKALIN

Speaker's Bureau: Novartis

ALEJANDRO ALVAREZ

Speaker's Bureau: Novartis

CHESTER AMEDIA, JR.

SATARA ARMSTRONG

STEPHEN ASH

Officer, Director, or Holder: Principal, Chairman of Board of Ash Access Technology

Other Financial or Material Support: AAT receives a royalty payment from Angiodynamics on the new Centros CVC for dialysis

ARIF ASIF

SARITA BAJPAI

GEORGE BAKRIS

Grant/Research Support: JDRF, GSK, Forest
Consultant/Scientific Advisor: Abbott, Boehringer-Ingelheim, BMS/Sanofi-aventis, Forest Glaxo-Smith, Kline-Merck, Novartis, Walgreens, Gileada-Daiichi/Sankyo, Takeda

LYNDA BALL

AARON BATTLE

CAROLYN BAUER

BRYAN BECKER

SRINIVASAN BEDDHU

Consultant/Scientific Advisor: Pentec Health

DEBBIE BENNER

Full time or Part time Employment: DaVita Inc.

LAURIE BENTON

Speaker's Bureau: Amgen

ANATOLE BESARAB

Consultant/Scientific Advisor: Vasc Alert

JUDITH BETO

Speaker's Bureau: Amgen

MARGARET BIA

ROB BLASER

KATHY BLOOD

ROY BLOOM

W. KLINE BOLTON

TERI BORHO

DEBBIE BRADY

REBECCA BRASHLER

EMMANUEL BRAVO

SUSAN BRAY

ROBERT BRAY

*Consultant/Scientific Advisor: One Lambda, Inc.
Canoga Park, CA.*

DONALD BROPHY

Grant/Research Support: Novo Nordisk A/S, Amgen

TERI BROWNE

OLGA BRUSILOVSKY

JOHN BURKART

*Grant/Research Support: Baxter Healthcare, NxStage,
Genzyme*

*Consultant/Scientific Advisor: Baxter Healthcare, NxStage,
Genzyme*

Speaker's Bureau: Baxter Healthcare

JULIE BURNETT

JOHN BURNETT*

JERRILYNN BURROWES

LAURA BYHAM-GRAY

MARY BETH CALLAHAN

AMY CANTER

JACKIE CARDER

HELEN CARR

LEE CAUBLE

KERRI CAVANAUGH

SHELDON CHAFFER

CHRISTOPHER CHAN

ARLENE CHAPMAN

Consultant/Scientific Advisor: Novartis Pharma AG

CHAIM CHARYTAN

*Grant/Research Support: Amgen, Roche, American
Regent Labs*

*Consultant/Scientific Advisor: Amgen, Roche, American
Regent Labs*

Speaker's Bureau: American Regent Labs

DOLPH CHIANCHIANO

MICHAEL CHOI

LOUISE CLEMENT

CAROLYN COCHRAN

MARSHIA COE

FACULTY AND PLANNING COMMITTEE DISCLOSURE LISTING

ALLAN COLLINS

Grant/Research Support: Amgen, NxStage, Baxter
Consultant/Scientific Advisor: Amgen, NxStage

DEBORAH COLLINSWORTH

RAYMOND COMENZO

Grant/Research Support: Millenium, Celgene, J&J
Consultant/Scientific Advisor: Millenium, Celgene, Ortho Oncology

DANILO B. CONCEPCION

LUIS CONCEPCION

CAROLE CONN

DEBRA CONNEELY

SANDRA COOROUGH

ANN COTTON

SHARRIE CRANFORD

EDWARD CREAMER

Officer, Director, or Holder: DisastersNet

JACKIE CROUCH

JIM CURTIS

Officer, Director, or Holder: Home Dialysis Plus, Ltd
Full time or Part time Employment: Jim Curtis & Associates, LLC

WILLIAM DANT

STEPHEN DAVIS

Grant/Research Support: Sanofi-aventis, Amylin Pharmaceuticals

ANDREA DEKAM

KATHERINE DELL

LAURA DEMBER

Grant/Research Support: Neurochem, Inc., Proteon Therapeutics
Consultant/Scientific Advisor: Neurochem, Inc., Pervasis

VINCENT DENNIS

Consultant/Scientific Advisor: Fresenius Medical Care

MARY AMANDA DEW

Grant/Research Support: Astellas

DAVID DEWALCH

MARY ANNE DOOLEY

Grant/Research Support: Aspreva TEVA, Bristol Meyers Squibb, Genentech

JAMIE DWYER

JOHANNA DWYER

ANDREA EASOM

Consultant/Scientific Advisor: Abbott Labs, Watson, Amgen
Speaker's Bureau: Abbott Labs, Watson, Amgen

STEPHEN FADEM

Officer, Director, or Holder: Medical Director and Joint Venture Participant at DaVita Inc.
Full time or Part time Employment: Kidney Associates-CMO

ROSE FARATRO

JESSICA FARRELL

LISA FARRIS

HARVEY FELDMAN

CARLOS FERRARIO

MARIA FERRIS

FERNANDO FERVENZA

Grant/Research Support: Genentech, Questcor Pharmaceutical, Roche
Consultant/Scientific Advisor: Genentech, Questcor Pharmaceutical

FREDRIC FINKELSTEIN

ROBERT FOLEY

Consultant/Scientific Advisor: Amgen, Baxter, Abbott
Speaker's Bureau: Roche, Janssen, Ortho, Baxter

CHARLES FOULKS

Grant/Research Support: Roche Laboratories

DAVID FRACALOSSY

STANLEY FRANKLIN

Consultant/Scientific Advisor: Bristol-Meyers Squibb

BARRY FREEDMAN

LINDA FRIED

Grant/Research Support: Merck

Consultant/Scientific Advisor: Pfizer, Bayer

Speaker's Bureau: Pfizer

ELI FRIEDMAN

PAULA FROST

Speaker's Bureau: Shire, Amgen

MELISSA FRY

WENDY FUNK SCHRAG

GUILLERMO GARCIA GARCIA

CATHY GARVEY

ROBERT GASTON

Grant/Research Support: Astellas, Roche Labs LifeCycle

BioPharma Isotechnika

Consultant/Scientific Advisor: Astellas, Roche Labs

LifeCycle BioPharma Isotechnika, Novartis Genzyme

DENIS GEARY

Consultant/Scientific Advisor: Genzyme

HOWARD GEBEL

Grant/Research Support: One Lambda, Inc.

BINA GEORGE

GREG GERMINO

NANCY GINSBERG

JEFF GIULLIAN

WILLIAM GLASS

Full time or Part time Employment: Bostwick Laboratories

RICHARD GLASSOCK

Consultant/Scientific Advisor: Genentech, La Jolla Pharm,

Aspreva, Novartis

CATHERINE GOEDDEKE-MERICKEL

DAVID GOLDFARB

Consultant/Scientific Advisor: Altusm, OxThera

STUART GOLDSTEIN

THOMAS GOLPER

Consultant/Scientific Advisor: Roche Ortho, Baxter

Speaker's Bureau: Baxter, Genzyme

JANELLE GONYEA

CRAIG GORDON

Consultant/Scientific Advisor: AMAG

JOHN GOWAN

KAREN GRIFFIN

ORLANDO GUTIÉRREZ

Consultant/Scientific Advisor: Abbott

MARY HAGAR

RAYMOND HAKIM

LISA HALL

YOSHIO HALL

KAY HALL

Officer, Director, or Holder: DaVita

RICHARD HAMBURGER

SUNDARAM HARIHARAN

PAUL HARRIS

CHARLOTTE HARRISON

PAM HAVERMANN

REBECCA HAYS

Consultant/Scientific Advisor: Amgen, Novartis, Astellas,

ASTS, Southwest Nephrology Conference

ELIZABETH HENRY

GARY HILL

DIANA HLEBOVY

Officer, Director, or Holder: Hema Metrics

FACULTY AND PLANNING COMMITTEE DISCLOSURE LISTING

MICHAEL HOFMANN

Speaker's Bureau: Novartis

JEFFREY HOGGARD

Speaker's Bureau: Novartis, Baxter

Full time or Part time Employment: RMS Lifeline

NORMAN HOLLENBERG

Grant/Research Support: Novartis, Mars Inc.

JEAN HOLLEY

PETER HOSSEINPOUR

Officer, Director, or Holder: Pfizer, Nektar

SUSAN HOU

Officer, Director, or Holder: Amgen, Sanofi

TRICIA HOWARD

ANDREW HOWARD

LI-LI HSIAO

Grant/Research Support: Genzyme

Consultant/Scientific Advisor: Palladium Health, LLC

ADRIANA HUNG

Grant/Research Support: NIH-NIDDK-R21, National Kidney Foundation

Speaker's Bureau: Nutrapletion Inc.

LAWRENCE HUNSICKER

Grant/Research Support: Bristol-Myers Squibb, Sanofi

Consultant/Scientific Advisor: Synthelabo

Speaker's Bureau: Synthelabo

MARRIANNE HUTTON

Consultant/Scientific Advisor: Shire Pharmaceuticals

Speaker's Bureau: Shire Pharmaceuticals

Full time or Part time Employment: Fresenius Medical Care—North America

T. ALP IKIZLER

Grant/Research Support: Amgen, Fresenius Medical Care, Satellite Health, NIH, Novo-Nordisk, Medical Nutrition Therapy

Consultant/Scientific Advisor: Amgen, Abbott Renal Care, Orthobiotech, Novo-Nordisk

Speaker's Bureau: Amgen, Fresenius Medical Care, Abbott Renal Care

AJAY ISRANI

Grant/Research Support: Roche, Amgen, BMS

JOSEPH IZZO, JR.

Grant/Research Support: Daiichi-Sankyo

Consultant/Scientific Advisor: Daiichi-Sankyo, Medical Education Consultants, SCS Healthcare

Speaker's Bureau: Daiichi-Sankyo, Medical Education Consultants, SCS Healthcare

BERNARD JAAR

BERTRAND JABER

Consultant/Scientific Advisor: NxStage Medical, Inc., AMAG Pharmaceuticals, Inc.

KATHY JABS

AIMEE JAREMOWICZ

CAROLINE JENNETTE

PETER JEURGENSON

Grant/Research Support: Watson

Speaker's Bureau: Amgen, Abbott, Watson

KIRSTEN JOHANSEN

Grant/Research Support: Abbott, Amgen

RICHARD J. JOHNSON

Consultant/Scientific Advisor: Tap, Inc

Speaker's Bureau: Merck

STEPHANIE JOHNSTONE

JESSICA JOSEPH

MICHELLE JOSEPHSON

Grant/Research Support: Wyeth, Astellas, NIH

Consultant/Scientific Advisor: Digitas Health, NKSAP

Speaker's Bureau: ASN, Roche

KAMEL KAMEL

NORMAN KAPLAN

Speaker's Bureau: Boehringer-Ingelheim Pharmaceutical Co, Pfizer Pharmaceuticals

MARIA KARALIS

Full time or Part time Employment: Abbott Laboratories

MIREY KARAVETIAN

JUDITH KARI

BERTRAM KASISKE

Grant/Research Support: Bristol-Myers Squibb,
Merck-Sherring Plough
Consultant/Scientific Advisor: LithoLink (Labcorp), Wyeth,
Astellas, Novartis

WILLIAM F. KEANE

Officer, Director, or Holder: Merck Inc
Full time or Part time Employment: Merck Inc

MARY PAT KELLY

PAMELA KENT

Full time or Part time Employment: Genzyme

MARRIE KETCHUM

DIANNE KILLEBREW

CHRISTINA KLEIN

MYRA KLEINPETER

Speaker's Bureau: Boehringer-Ingelheim, Glaxo-Smith
Kline, Pfizer, Inc

ALAN KLIGER

NELSON KOPYT

FRED KOURI

HOLLY KRAMER

RONALD KRAMER

Speaker's Bureau: Boehringer-Ingelheim, GSK, Cephalon,
Sanofi-aventis, Takeda, Sepracor

ZIPPORAH KRISHNASAMI

Grant/Research Support: Gilead, Baxter, Amgen

DANA KUMJIAN

JANE KWATCHER

ANTHONY LANGONE

DERRICK LATOS

Consultant/Scientific Advisor: Renal Solutions, Inc.
Officer, Director, or Holder: Renal Solutions, Inc.

JANICE LEA

STANLEY LEE

ALAN LEICHTMAN

JUNE LEUNG FUNG

RICHARD LEVINE

ANNE LILES

NITA LIMDI

Grant/Research Support: UCB Pharma, Abbott Laboratories
Speaker's Bureau: UCB Pharma

KATHLEEN LIU

Officer, Director, or Holder: Amgen, Procter and Gamble

ROBERT LOCKRIDGE

Consultant/Scientific Advisor: Fresenius Medical Care —
North America

CHARMAINE LOK

VALERIE LUYCKX

Grant/Research Support: Amgen

JENNIFER LYON

HARTMUT MALLUCHE

GLENN MARKOWITZ

Consultant/Scientific Advisor: Salix Pharmaceuticals
Speaker's Bureau: Genzyme, Astellas

TEJ MATTOO

IVAN MAYA

Consultant/Scientific Advisor: Bard Peripheral Vascular, Inc.

MAUREEN MCCARTHY

PETER MCCULLOUGH

MATTHEW MCDONOUGH

JOHN MCGINNITY

Consultant/Scientific Advisor: Novartis, Omron, Pfizer

JENNIFER MCGUIRK FILSON

Full time or Part time Employment: Abbott Laboratories

FACULTY AND PLANNING COMMITTEE DISCLOSURE LISTING

BETH MCQUISTON

ROXANA MEHRAN

Grant/Research Support: Bracco, Guerbert
Consultant/Scientific Advisor: Bracco, Guerbert, Flowmedica

RAJ MEHROTRA

Grant/Research Support: Baxter HealthCare

HEATHER MERCER

JOE MERIGHI

ANTHONY MESSANA

Consultant/Scientific Advisor: NxStage Medical System, Roche Laboratories

MIRIAM MICHAELS

Speaker's Bureau: Genzyme

PAUL MILLER

Grant/Research Support: Procter & Gamble, Sanofi-aventis, Roche, Eli Lilly, Merck, Novartis, Amgen
Speaker's Bureau: Procter & Gamble, Sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche, GlaxoSmithKline

SHARON MOE

Grant/Research Support: Genzyme, Amgen, Shire
Consultant/Scientific Advisor: Genzyme, Amgen, Shire, Litholink, Ineos, Welpoint
Officer, Director, or Holder: Amgen
Other Financial or Material Support: Amgen

MICHELE MOKRZYCKI

Grant/Research Support: Ash Technologies, Inc., Abbott Renal
Consultant/Scientific Advisor: Cormedics Inc

DONALD MOLONY

Speaker's Bureau: Genzyme, Amgen

LINDA MOORE

DWIGHT MORGAN

ANDREW NARVA

ANNE NEFF

JOEL NEUGARTEN

MARIANNE NEUMANN

MARK NEUMANN

VO NGUYEN

Officer, Director, or Holder: Fresenius Medical Company

VANDANA NIYYAR

KEITH NORRIS

Consultant/Scientific Advisor: Abbott, Amgen, Merck

DONAL O'DONOGHUE

GREGORIO OBRADOR

NAIMA OGLETREE

ANN O'HARE

JEAN OLSON

CHARLES O'NEIL

SUZANNE OPARIL

JEFFREY PACKER

EMIL PAGANINI

Consultant/Scientific Advisor: NxStage Medical, Inc., Biosite Medical, Quark

PAUL PALEVSKY

HEATHER PARADIS

CHIRAG PARIKH

Grant/Research Support: Abbott Diagnostics
Consultant/Scientific Advisor: Abbott Diagnostics

CAROL REES PARRISH

WILLIAM PAULSON

JESSIE PAVILINAC

GLENDA PAYNE

MARGARET PEARLE

ALDO PEIXOTO

MARC PENN

Grant/Research Support: Athersys, Diasome
Consultant/Scientific Advisor: AcellerX Therapeutics,
Prognostix
Officer, Director, or Holder: AcellerX Therapeutics
Other Financial or Material Support: AcellerX Therapeutics

BRIAN PEREIRA

Officer, Director, or Holder: AMAG Pharma,
Satellite Healthcare, Bidel Inc

ANNALISA PEREZ**DOREEN PERKINS****DIANE PERRY****CRAIG PETERS****GARY PETINGOLA****BETH PIRAINO**

Consultant/Scientific Advisor: Baxter Healthcare Corp.

MARC POHL

Consultant/Scientific Advisor: Novartis
Speaker's Bureau: Merck, Sanofi

POLLY PORTER**MEGAN PRESCOTT****CHING-HON PUI**

Speaker's Bureau: Sanofi-aventis

SUSAN QUAGGIN

Consultant/Scientific Advisor: Roche, Genentech

LUIS (PHIL) RAMOS**PANDURANGA RAO****LLOYD RATNER****ROBERT REILLY****BETHANY ROBERTS****BRUCE ROBINSON**

Grant/Research Support: Amgen, Kyowa Hakko Kirin,
Genzyme

MICHAEL ROCCO**WENDY RODGERS****RUDY RODRIGUEZ****CAROL ROE****DAVID ROTH****BHARAT SACHDEVA****NASIA SAFDAR****JEFF SALAND**

Officer, Director, or Holder: Johnson and Johnson

LOAY SALMAN**WILLIAM SALZER**

Speaker's Bureau: Schering, Merck, Ortho-McNeil

ANTHONY SAMAHA**MILAGROS SAMANIEGO**

Speaker's Bureau: Astellas Pharmaceutical,
Genzyme Corporation

PAUL SANDERS**RAJIV SARAN**

Grant/Research Support: Amgen, Abbott
Consultant/Scientific Advisor: Amgen

MARK SARNAK**MOHAMMED SAYEGH**

Consultant/Scientific Advisor: Genzyme

HEIDI SCHAEFER**DORI SCHATELL**

Grant/Research Support: Amgen
Consultant/Scientific Advisor: Amgen

BRIGETTE SCHILLER

Full time or Part time Employment: Satellite
Laboratory Services

KATHY SCHIRO HARVEY**DONALD SCHON**

Consultant/Scientific Advisor: Medcomp, AngioDynamics

ROBERT SCHRIER

FACULTY AND PLANNING COMMITTEE DISCLOSURE LISTING

DONNA SECKER

ADRIAN SEQUEIRA

VAHAKN SHAHINIAN*

AMIT SHARMA

Consultant/Scientific Advisor: Renal Solution, Amgen

THERESE SHUMAKER

DOMENIC SICA

EDWARD SIEW

Consultant/Scientific Advisor: Theravance, Inc.

GARRETT SMITH

Speaker's Bureau: Abbott Laboratories

BEVERLY SNEED

Full time or Part time Employment: Abbott Laboratories

KIM SOLEZ

SANDEEP SOMAN

DAVID SPIEGEL

Consultant/Scientific Advisor: Genzyme, Amgen

Speaker's Bureau: Genzyme, Amgen

CHRISTOPHER SPRADLEY

*Speaker's Bureau: Actelion Pharmaceuticals,
Gilead Pharmaceuticals*

WILLIAM STEIN

STEPHANIE STEWART

JOHN STIVELMAN

Grant/Research Support: Watson

KRISTIN STOCKARD

MATT STRICHERZ

MARY SUNDELL

MARK SUPIANO

JOHN SWEENEY

*Full time or Part time Employment: Baxter
Healthcare Corp.*

LYNDA SZCZECH

Consultant/Scientific Advisor: FMC-NA, AMAG

PAUL SZCZYBOR

HAROLD SZERLIP

Grant/Research Support: Pfizer, Genzyme

Speaker's Bureau: Boehringer-Ingelheim

MANJULA TAMURA

Grant/Research Support: Amgen

ERIC TAYLOR

Consultant/Scientific Advisor: Altus Pharmaceuticals

KAY TAYLOR

MARIA TAYLOR

ISAAC TEITELBAUM

Consultant/Scientific Advisor: Baxter Healthcare

Speaker's Bureau: Baxter Healthcare

FRANCESCA TENTORI

Grant/Research Support: BoneCare, Genzyme

Speaker's Bureau: Amgen, Genzyme

PAUL TESCHAN

STEPHEN TEXTOR

JEANNE THACKER

CHER THOMAS

*Speaker's Bureau: Philips Oral Health/Sonicare, Teledyne/
Waterpik, HuFriedy, Inc.*

DAVID THOMAS

Full time or Part time Employment: Nephrocor

KATHRYN TINCKAM

ASHITA TOLWANI

Speaker's Bureau: Gambro

JOSE TORREALBA

RAYMOND TOWNSEND

Grant/Research Support: Novartis NIH

*Consultant/Scientific Advisor: NiCox Roche Spacelabs,
GlaxoSmithKline*

Speaker's Bureau: Merck Bristol-Myers-Squibb

MANDY TROLINGER

JOHN TUCKER

Consultant/Scientific Advisor: Amgen, Genzyme

MARK UNRUH

Grant/Research Support: Baxter, DCI, Satellite, Merck

Consultant/Scientific Advisor: Satellite, Merck

DAVID VAN WYCK

Consultant/Scientific Advisor: American Regent

Officer, Director, or Holder: DaVita, Inc.

Full time or Part time Employment: DaVita, Inc.

JOSEPH VASSALOTTI

JOE VERBALIS

Grant/Research Support: Otsuka

Consultant/Scientific Advisor: Astellas, CardioKine, Otsuka

Speaker's Bureau: Astellas

JULIE VONDERHOFF

BRADLEY WARADY

Consultant/Scientific Advisor: Watson Pharmaceuticals, Amgen

Speaker's Bureau: Amgen, Genentech

RICHARD WARD

Grant/Research Support: Gambro, Rockwell Medical Technologies

Consultant/Scientific Advisor: Gambro, Fresenius

Speaker's Bureau: Fresenius

BARBARA WEIS MALONE

Consultant/Scientific Advisor: Novartis

Speaker's Bureau: Amgen

LAWRENCE WEISBERG

Grant/Research Support: Mitsubishi-Kureha

STEVEN WEISBORD

Speaker's Bureau: GE Healthcare

ADAM WHALEY-CONNELL

JOHN JASON WHITE

Grant/Research Support: Genzyme

KAREN WIESEN

Speaker's Bureau: Abbott Labs, Shire Labs

KATE WILLCUTTS

CRAIG WILLIAMS

Speaker's Bureau: Merck, Schering-Plough

JAY WISH

BETH WITTEN

LESLIE WONG

Consultant/Scientific Advisor: Baxter Healthcare

Speaker's Bureau: Baxter Healthcare

JACK WORK

Consultant/Scientific Advisor: Pervasis

Speaker's Bureau: Hemospere

STEVEN WU

JERRY YEE

Consultant/Scientific Advisor: Genzyme

Speaker's Bureau: Sanofi-aventis, Genzyme, Merck

Officer, Director, or Holder: Merck

ALEXANDER YEVZLIN

BESSIE YOUNG

Officer, Director, or Holder: NxStage, Amgen

CAMILLE YUSCAK

JAN ZOLKOWER

KIM ZUBER

KDOQI: A New Era

Saturday, March 28, 2009 • 11:30 AM – 1:00 PM

Attend a special presentation highlighting the exciting new KDOQI initiatives that are well underway and hear about the “hot off the press” update of the **KDOQI Pediatric Nutrition Clinical Practice Guideline**. Session topics include:

Chairs: *Michael Rocco, MD and Holly Kramer, MD*

- New KDOQI Initiatives: A Natural Progression
Michael Rocco, MD
- Premiering KDOQI Clinical Practice Guideline on “Nutrition in Children with CKD: Update 2008 – A Case-Based Presentation”
Donna Secker, PhD, RD, and Bradley A. Warady, MD
- NKF KDOQI Research Grants – Moving Clinical Care Forward
Holly Kramer, MD



For more information about KDOQI, visit the NKF booth **#1629**

© 2009 National Kidney Foundation, Inc. All rights reserved. 02-77-704A_AA



*Celebrating
Five Years*

KDIGO Celebrates its Fifth Anniversary

Stop by the NKF/KDIGO booth to learn about the significant progress that KDIGO has made in uniting the global nephrology community to improve the care and outcomes of kidney disease patients worldwide. Also, please plan to join us for the sessions below featuring two of the KDIGO Clinical Practice Guidelines.

KDIGO Guideline for the Care of the Kidney Transplant Recipient

Thursday, March 26 at 4:00 pm – 5:30 pm

Presenters: Bertram Kasiske, MD, Michelle Josephson, MD, and Cathy Garvey, RN

KDIGO Guideline for Hepatitis C in CKD

Friday, March 27 at 2:30 pm – 4:00 pm

Presenters: Brian Pereira, MD, David Roth, MD, and Craig Gordon, MD

Visit KDIGO at Booth #1629

www.kdigo.org

©2009 National Kidney Foundation, Inc. All rights reserved. 02-77-703A

NATIONAL KIDNEY FOUNDATION CONTINUING MEDICAL EDUCATION (CME) PROGRAM MISSION STATEMENT

The mission of the National Kidney Foundation (NKF) Continuing Medical Education Program is to provide education for academic as well as private practitioners in nephrology and related disciplines. These education activities are offered to regional, national and international audiences.

Purpose:

To provide all members of the kidney healthcare community with current, state-of-the-art science information on prevention, diagnosis and treatment of kidney and urinary tract diseases in order to improve the care of individuals with chronic kidney disease (CKD) and those at risk for developing it.

Content Area:

Topics are selected based on physician gaps in knowledge regarding the care and treatment of individuals with kidney disease. KDOQI evidence-based guidelines and the latest peer-reviewed clinical science provide the foundation for developing much of the content as well as professional interests, expert opinions, literature reviews and needs assessment data from patients and caregivers that identify gaps in quality of care relative to physician implementation of the science.

Target Audiences:

Practicing physicians, residents, and fellows in nephrology, internal medicine, cardiology, endocrinology, family practice, physician assistants, nurse practitioners and other specialties who care for individuals who are at increased risk for, or affected by, CKD.

Types of Activities:

Live activities include conferences, symposia, courses, hands-on workshops, audience response sessions, and debates. Enduring materials include monographs, videotapes, CD-ROM, web-based, PDA/Pocket PC software and audiotape. Adult learning principles and critical thinking strategies are incorporated into all education activities by ensuring that participants are given an opportunity to explore new applications and or strategies.

Expected Results:

Improve physician practice patterns in order to maximize the quality of care given to patients and improve patient outcomes. This will be accomplished by providing comprehensive educational activities that are current, largely based on evidence-based practice guidelines and expert opinion and by offering a variety of learning formats to meet the diverse needs of our participants. Results will be evidenced by post testing and reviewing responses from activity evaluations that ask if participants plan to make any changes in their practice as a result of this activity and to identify these changes. Following our annual Spring Clinical Meeting, participants will be sent additional web-based evaluation questions which include if they are willing to provide contact information for follow-up. Telephone surveys will then be conducted three to six months following an activity with those who have agreed to follow-up contact.

PHYSICIAN PROGRAM

ACCREDITATION

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Kidney Foundation takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME CREDIT

The National Kidney Foundation designates this educational activity for a maximum of 31.5 *AMA PRA Category I Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Note: Acquiring 31.5 credits requires continuous participation from Wednesday morning through Sunday morning. Many participants opt for periodic breaks, which make their reported credit hours somewhat less. Additional credits are provided for courses requiring separate registration, as noted on the right.

Pharmacists: See CME/CEU information handout located in your meeting tote bag for ACPE approved activities.

The Management of the High-Risk Kidney Transplant Recipient: The State-of-the-Art	6.5 credit hours
Integrated Hemodialysis/Peritoneal Dialysis Course	9.5 credit hours
Interventional Nephrology Course	7.5 credit hours
Dialysis Unit Management Course	7.5 credit hours
Nephrology Recertification: An Audience Participation Forum for Fun, Education and ABIM Credit	8.0 credit hours
Ray W. Gifford Jr., MD Hypertension Symposium	7.5 credit hours
CKD Clinics: If You Built It Will They Come?—Practitioners' Challenge! Mini Course	4.0 credit hours
Home Hemodialysis Mini Course	3.5 credit hours
Renal Pathology Mini Course	4.25 credit hours

PRE-CONFERENCE COURSES

THE MANAGEMENT OF THE HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS: THE STATE-OF-THE-ART

Course Directors: Milagros D. Samaniego, MD and Heidi Schaefer, MD

Wednesday, March 25

7:30am–5:15pm

Session 220, 6.5 credit hours

Target Audience: This course is designed for community nephrologists, transplant nephrologists, nephrology fellows, transplant coordinators, transplant pharmacists and other professionals involved in the care of the kidney transplant patient.

Course Description: The changing population patterns of CKD in America and the success of dialysis and transplantation have generated a new pool of kidney transplant recipients with ever growing biological and immunological risks. This pool includes older recipients, diabetic patients, re-transplants and highly sensitized patients.

This course will explore all aspects of diagnosis, pre-transplant and post-transplant management of high-risk patients with emphasis on definition and assessment of immunological risk, role of protocol biopsies in the clinical management of these patients, impact in the access to kidney transplantation of new organ allocation policies, management of high-risk patients on the wait list and treatment options for highly sensitized patients.

PRE-CONFERENCE COURSES

Course Objectives: Upon completion of this course the attendee should be able to:

- Identify immunological risk factors in kidney transplant candidates.
- Integrate new histocompatibility techniques into the risk assessment of patients before and after transplant.
- Discuss the use of protocol biopsies as guidance for therapy in patients with high immunological risk.
- Define the diagnostic criteria of antibody-mediated rejection and its treatment.
- Examine the impact of organ allocation policies in the transplantation of high-risk patients with emphasis in the calculation life years from transplant (LYFT) proposal.
- Select the best interventions for the management of patients in the deceased donor waiting list.
- Recognize the different transplant options for diabetic and highly sensitized patients.

REQUIRED: Additional registration fee of \$175/\$75 for fellows and residents; \$225 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:30am–7:50am Breakfast	
7:50am–8:00am Introduction	Milagros D. Samaniego, MD
8:00am–8:35am Immunological Risk: Definition and Its Use in Decision-Making	Kathryn Tinkam, MD MMSc FRCPC
8:40am–9:40am Histocompatibility Techniques: From Cells to Beads	Robert Bray, PhD Howard Gebel, PhD
9:45am–10:15am Coffee Break	
10:15am–11:00am Allograft Histology in High-Risk Kidney Transplant Recipients	Jose Torrealba, MD
11:05am–11:55am Antibody-Mediated Rejection: Treatment and Outcomes	Milagros D. Samaniego, MD
12:00pm–1:00pm Lunch with Faculty	

1:00pm–1:30pm

New Organ Allocation Proposals: What the Stimulation Models Predict the Impact Will Be on High-Risk Kidney Transplant Candidates Alan Leichtman, MD

1:40pm–2:10pm

Diabetic Nephropathy: Transplant Options, Management and Outcomes Roy Bloom, MD

2:20pm–2:50pm

Management of the High-Risk Patient on the Waiting List R. Michael Hofmann, MD

2:50pm–3:15pm

Break

3:15pm–4:35pm

Debate: Best Treatment Options for Highly Sensitized Patients Ajay Israni, MD
Enver Akalin, MD
Lloyd E. Ratner, MD

4:40pm–5:15pm

Round Table: Q&A with All Faculty Members All Faculty

INTEGRATED HEMODIALYSIS/PERITONEAL DIALYSIS COURSE

Course Director: John Burkart, MD

Wednesday, March 25

7:00am–8:00pm

Session 221, 9.5 credits

TARGET AUDIENCE

This course is designed for practicing nephrologists and nephrology fellows in training.

COURSE OBJECTIVES

Upon completion of this course, the attendees should be able to:

- Identify the physiology and techniques of peritoneal dialysis and hemodialysis.
- Distinguish the relationship between clinical outcomes and different renal replacement modalities to treat chronic kidney disease.
- State the basis and practical application of dialysis dose prescription in peritoneal and hemodialysis.
- Recall the infectious and noninfectious complications of peritoneal and hemodialysis.

- Describe the importance of proper access in both peritoneal dialysis and hemodialysis and potential complications of access problems.
- Identify treatment related complications in peritoneal and hemodialysis and discuss potential treatment strategies.

REQUIRED: Additional registration fee of \$175/\$75 for fellows and residents; \$225 when registering for the course only. Includes syllabus, breakfast, boxed lunch dinner and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:00am–7:30am Breakfast	
7:30am–7:45am Introduction	John Burkart, MD
7:45am–8:15am Modality Education on Dialysis Choices	TBD
8:15am–8:45am Physics of Solute Removal (Differences and Similarities Between PD and HD)	John Burkart, MD
8:45am–9:15am PD Access (Emphasis on Avoiding Temporary HD)	Raj Mehrotra, MD, FASN, MBBS
9:15am–10:00am Vascular Access and the Initiation of HD (Avoid TDC and Hospitalization)	Anatole Besarab, MD
10:00am–10:30am Break	
10:30am–11:15am HD Prescription/Dialyzers and Monitoring Adequacy—Case Studies	TBD
11:15am–12:00pm PD Prescription and Monitoring Adequacy; Importance of Monitoring RKF	Isaac Teitelbaum, MD
12:00pm–1:00pm Lunch	

1:00pm–1:30pm BP, Volume Control. CV Risk in PD, Reasons for Transfer to HD—Case Studies	Raj Mehrotra, MD, FASN, MBBS
1:30pm–2:00pm Blood Pressure, Euvolemia, CV Risk in HD	Laura Dember, MD
2:00pm–2:30pm Case Studies in HD Including Dialyzer Reactions, What to Do When HD Access Fails	Anatole Besarab, MD
2:30pm–3:00pm Noninfectious Complications of PD Case Studies	Isaac Teitelbaum, MD
3:00pm–3:30pm Break	
3:30pm–4:00pm Prevention and Management PD-Related Infections	Beth Piraino, MD
4:00pm–5:00pm Prevention and Management HD-Related Infections	Laura Dember, MD
5:00pm–5:30pm HD Water Quality and PD GDPs	John Burkart, MD
6:00pm–8:00pm Dinner with Discussion Based on Literature of Mortality in HD vs PD	John Burkart, MD Beth Piraino, MD Thomas A. Golper, MD

INTERVENTIONAL NEPHROLOGY COURSE

Course Co-Directors: Ivan D. Maya, MD and Bharat Sachdeva, MD
 Wednesday March 25
 7:45am–5:00pm
 Session 222, 7.5 credits

TARGET AUDIENCE

This course is designed for nephrologists, nephrology fellows, physician assistants, nurse practitioners and other kidney health care professionals.

PRE-CONFERENCE COURSES

COURSE DESCRIPTION

The course is an introduction to a variety of interventional and diagnostic procedures being used by interventional nephrologists to establish, monitor and maintain a healthy/functional dialysis access. These procedures include: diagnostic and ultrasound guided renal biopsy (native and transplant), placement of temporary and permanent central venous catheters for hemodialysis, placement of peritoneal dialysis catheters, vascular mapping, monitoring and surveillance of vascular access, salvage procedures for failing or thrombosed arterio-venous fistulas and grafts along with the indications and contraindications of deployment of intravascular coils and stents, and evaluation and management of hand ischemia. In addition, workshops (hands-on training) will allow the participant to appreciate the full extent of the course by focusing on physical exam of the vascular access plus dummy training in insertion of tunneled dialysis catheters, percutaneous balloon angioplasty and mechanical thrombectomy procedures. An audience response system will be used for feedback after each lecture.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Describe the anatomy of the vasculature for hemodialysis access.
- Identify the basic techniques used to diagnose and treat vascular access dysfunction.
- Recall the techniques for vascular and peritoneal catheter placement.
- State the pathophysiology of hand ischemia in hemodialysis patients.
- Discuss the approach for central venous stenosis and the role of intravascular stents.

REQUIRED: Additional registration fee of \$175/\$75 for fellows and residents; \$225 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:45am–8:00am	
Welcome and Introduction	Ivan D. Maya, MD Bharat Sachdeva, MD
8:00am–8:15am	
Know Your Vessels (Anatomy)	Kenneth Abreo, MD

8:15am–8:30am	
Vascular Access Examination	Jack Work, MD
The Art of Physical Exam	
8:30am–8:45am	
Vascular Access Surveillance:	Anatole Besarab, MD
Detection of Access Dysfunction	
8:45am–9:00am	
Conscious Sedation:	Bharat Sachdeva, MD
Minimizing the Risk	
9:00am–9:15am	
Will My Patient Get a Fistula?	Alejandro Alvarez, MD
US vs Venogram	
9:15am–9:30am	
Salvage of the Immature	Jeffrey Packer, DO,
Fistula	FACOI, FASN
9:30am–9:45am	
Percutaneous Balloon	Steven Wu, MD
Angioplasty: Where and When	
9:45am–10:15am	
Break	
10:15am–10:30am	
Arteriovenous Access	Jeffrey Hoggard, MD
Thrombectomy	
10:30am–10:45am	
Diagnosis & Treatment of	Ivan D. Maya, MD
Central Vein Stenosis	
10:45am–11:00am	
When and Where,	Donald Schon, MD
to Place Stents and	
Stent Grafts	
11:00am–11:15am	
Arterial Angioplasty	Alexander Yevzlin, MD
11:15am–11:30am	
Hand Ischemia:	Arif Asif, MD
What To Do About It?	
11:30am–11:45am	
Diagnostic Renal Ultrasound	Charles O'Neill, MD
11:45am–12:00pm	
US Guided-Percutaneous	Charles O'Neill, MD
Kidney Biopsy	
12:00pm–1:00pm	
Lunch	
1:00pm–1:15pm	
Contrast Safety:	Adrian Sequeira, MD
Interventional Nephrology	

1:15pm–1:30pm	Secondary AV Fistulae	Anthony Samaha, MD
1:30pm–1:45pm	Tunneled Hemodialysis Catheters: Overview	Stephen Ash, MD
1:45pm–2:00pm	Noninfectious Complications of Tunneled Hemodialysis Catheters: A Case Illustration Series	Anil Agarwal, MD
2:00pm–2:15pm	Peritoneal Dialysis: You Can Do It!	Loay Salman, MD
2:15pm–2:30pm	The Practice of Interventional Nephrology—You Can Do It!	Vandana Niyyar, MD
2:30pm–4:45pm	Workshops (45 Minutes Each)	
	Workshop A—Ryman Ballroom A/D	
	Physical Exam	
	Leader: Arif Asif, Kenneth Abreo, Jack Work, Alexander Yezvlin, Adrian Sequeira	
	Workshop B—Ryman Studio M/N/O	
	Endovascular Procedures	
	Leader: Donald Schon, Alejandro Alvarez, Ivan Maya, Steve Wu, Loay Salman	
	Workshop C—Ryman Studio F/G	
	Tunneled Hemodialysis Catheter Insertion	
	Leader: Stephen Ash, Jeffrey Hoggard, Anil Agarwal, Jeffrey Packer, Anthony Samaha	
	Workshop D—Ryman Studio D/E	
	Renal Ultrasound	
	Leader: Charles O'Neill, Bharat Sachdeva, Loay Salman, Vandana Niyyar	
4:45pm–5:00pm	Questions/Answers & Closing Remarks	

DIALYSIS UNIT MANAGEMENT COURSE

Course Director: Thomas A. Golper, MD, FACP, FASN
Wednesday, March 25
7:30am–5:30pm
Session 223, 7.5 Credits

TARGET AUDIENCE

This course is designed for physician directors and nurse managers. The course will also be of interest to patient care supervisors, administrators and quality managers.

COURSE DESCRIPTION

The emphasis of this course will be on updating the national issues as they relate to facility management, including patient care quality measures, safety, economics and logistics. Since reimbursement is becoming contingent on achieving quality outcomes, the facility will be increasingly faced with choices and tradeoffs.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- List the national quality goals.
- Recall the trade-offs in cost, quality, value.
- Recognize the ethical dilemmas created by quality contingent reimbursement.
- State the impact of bundling on facility revenue.
- Define the role of the key professionals in measuring and managing quality.
- Identify the new AAMI water standards and water system disaster recovery.
- Describe how operating margins are used in academic and private settings.

REQUIRED: Additional registration fee of \$175/\$75 for fellows and residents; \$225 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:30am–8:00am	
Welcome and Breakfast	
8:00am–9:00am	
News Issues as They Relate to Dialysis Facilities	Rob Blaser Mark Neumann

PRE-CONFERENCE COURSES

9:00am–10:00am	
The National Quality Agenda Pay for Performance and the Ethics of Adverse Selection	Jay B. Wish, MD
10:00am–10:15am	
Break	
10:15am–11:00am	
The Role of the Medical Director in Quality and Safety	John Stivelman, MD
11:00am–11:45am	
The Role of the Nursing and Technician Staff in Quality and Safety	Carol Roe, RN, JD
11:45am–1:00pm	
Lunch Break	
1:00pm–1:30pm	
The Role of the Facility Administrator	Marshia Coe, RN, BSN
1:30pm–2:00pm	
The Role of the Advanced Practitioner in Dialysis Unit Quality Outcomes	Andrea Easom, MNSC, APN, CS, CNN
2:00pm–2:30pm	
Panel Addressing Role Conflicts	John Stivelman, MD Andrea Easom, MNSC, APN, CS, CNN Carol Roe, RN, JD Marshia Coe, RN, BSN
2:30pm–3:00pm	
Operating Margins for the Academic Mission	Barry Freedman, MD
3:00pm–3:30pm	
Operating Margins for Private Practice	Stephen Fadem, MD
3:30pm–3:45pm	
Break	
3:45pm–4:30pm	
Update on AAMI Water Standards and Water System Disaster Recovery	Richard Ward, PhD
4:30pm–5:15pm	
Research in Dialysis Facilities	T. Alp Ikizler, MD

5:15pm–5:30pm
Questions and Closing Comments

8TH ANNUAL RAY W. GIFFORD, JR. HYPERTENSION SYMPOSIUM

Supported by an unrestricted educational grant from Merck & Co., Inc.

Course Director: Marc A. Pohl, MD

Wednesday, March 25

7:30am–5:30pm

Session 225, 7.5 credits

TARGET AUDIENCE

This activity is designed for advanced nephrologists, physicians in training, as well as other physicians who are interested and involved with the management of hypertension and cardiovascular disease.

COURSE DESCRIPTION/OBJECTIVES

This symposium is designed to provide participants with the latest advances in basic physiology, biochemistry, and molecular biology relative to hypertension, vascular damage, myocardial infarction and heart failure. Participants will be able to acquire the latest information and new direction in the management of atherosclerosis and cardiovascular disease, review the pathophysiology of hypertension and the implications for therapy, and examine recent clinical trials in hypertension.

REQUIRED: Additional registration fee of \$50/\$25 for fellows and residents. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:15am	
Registration and Continental Breakfast	
8:00am	
Welcome, Introduction, and Some Reflections on Ray W. Gifford, Jr., MD	Marc A. Pohl, MD and Carlos Ferrario, MD, FACC, FACA

8:15am	The Impact of Hypertension on the Vascular Continuum	Carlos Ferrario, MD, FACC, FACA
8:40am	Carbon Monoxide Rescues Vascular Thrombosis in Aortic Transplantation	Anupam Agarwal, MD
9:05am	Discussion	
9:15am	Innovations in Cardiovascular Disease—Stem Cells, Use of Inflammatory Markers and Percutaneous Valve Repair	Marc Penn, MD, PhD
9:45am	Clinical Assessment of Vascular Function: Fact and Fancy	Joseph L. Izzo, Jr., MD
10:10am	Commentary	Stanley Franklin, MD
10:20am	Discussion	
10:30am	Break	
10:45am	The Sea Within Us: Clinical Disorders of Water Homeostasis	Robert W. Schrier, MD
11:15am	Hemodynamic and Neurohumoral Alterations in the Cardiorenal Syndrome	John C. Burnett, MD
11:45am	Discussion	
11:55am	Hypertension in the Elderly	Norman M. Kaplan, MD
12:20pm	Clinical Practice Guidelines for the Detection, Diagnosis, and Management of Primary Aldosteronism: Can We Reach a Consensus?	Emmanuel L. Bravo, MD
12:45pm	Discussion	

1:00pm	Luncheon	
2:00pm	Sugar, Uric Acid and the Epidemic of Hypertension and Obesity: Is There a Link?	Richard J. Johnson, MD, FACP
2:30pm	Hormones and the Heart: Promises, Problems and Unresolved Issues	Suzanne Oparil, MD
2:55pm	Vitamin P and Death from Ischemic Heart Disease, Stroke, Diabetes Mellitus, and Cancer	Norman K. Hollenberg, MD, PhD
3:20pm	Discussion	
3:35pm	Break	
3:50pm	Ischemic Glomerulosclerosis in Hypertension	Gary S. Hill, MD
4:15pm	Hypertension and the Progression Chronic Kidney Disease	Karen A. Griffin, MD
4:40pm	Does RAAS Blockade Affect Renal and/or Cardiac Outcomes? Short-term and Long-term?	Lawrence G. Hunsicker, MD
5:05pm	Discussion	
5:20pm	Concluding Remarks	
5:30pm	Adjourn	

PRE-CONFERENCE COURSES CONTINUED

NEPHROLOGY RECERTIFICATION: AN AUDIENCE PARTICIPATION FORUM FOR FUN, EDUCATION & ABIM CREDIT

Course Director: Harold M. Szerlip, MD
Faculty: John Jason White, MD
Wednesday, March 25
7:30am–5:00pm
Session 224, 8.0 credits

COURSE DESCRIPTION

One of the requirements for nephrology recertification is to successfully obtain a total of 100 points with a minimum of 20 points in medical knowledge. This hurdle must be cleared before taking the secure exam. Participation in the NKF's "Nephrology Recertification Audience Participations Test for Credit" is a painless, fun and educational way to complete one of those booklets. Each multiple choice question will be answered by the audience using a computerized response system. The results will be displayed and then an expert will discuss the question, present appropriate background information and make a conclusion as to what he/she thinks is the correct answer. Audience discussion will be encouraged. At this time, each member of the audience will have the opportunity to record their "official" answer for credit. At the end of the day you will have completed one of the requirements for recertification, learned a great deal and have fun doing it!

COURSE REQUIREMENTS

The Nephrology Recertification Course will review SEP Nephrology Module 27-R as well as the 2008 update. **For those attendees already enrolled in the ABIM Maintenance of Certification Program (MOC), please confirm that you bring these booklets and the answer sheets on site.**

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Identify aspects of general nephrology.
- Identify new developments in the field.
- Obtain credit towards recertification in nephrology.

COURSE FACULTY

John Jason White, MD
Harold Szerlip, MD

REQUIRED: Additional registration fee of \$175/\$75 for fellows and residents; \$225 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time	Topic
7:30am–8:00am	Breakfast
8:00am–11:30am	Review of SEP Nephrology Module 27-R
11:30am–12:00pm	Question and Answer Session
12:00pm–1:00pm	Lunch
1:00pm–4:30pm	Review of the 2008 Update
4:30pm–5:00pm	Question and Answer Session Closing Remarks

WORKSHOPS

Separate Registration and Fee Required

An additional fee of \$40 per workshop is required (includes a box lunch). Tickets for these workshops may be purchased at the NKF Ticket Sales Booth in the Registration Area. Space is limited, so participation is available on a first-come, first-served basis.

**THURSDAY
MARCH 26**

30 QUESTION BOARD EXAM

Presenter: Harold Szerlip, MD
(repeated on Friday, March 27)
12:00pm–2:00pm
Session 230

Test your knowledge of nephrology. Come and see how you compare to your colleagues. During this workshop you will have the opportunity to answer 30 Board-type questions that will cover a wide range of topics including: electrolytes, acid-base, AKI, acute and chronic dialysis, CKD management and transplantation. Responses will be anonymously tallied using an audience response system. You are guaranteed to have fun and learn at the same time.

ELECTROLYTES—CASES

Chair: Lawrence Weisberg, MD
Presenters: Kamel Kamel, MD, FRCPC, Ashita Tolwani, MD and Lawrence Weisberg, MD
(repeated on Friday, March 27)
12:00pm–2:00pm
Session 231

Experts will present interesting electrolyte cases and challenge the audience to make the diagnosis and choose the appropriate treatment. This is an excellent review of renal pathophysiology. The audience will gain a better understanding of electrolyte disorders and review mechanism of electrolyte transport in the kidney.

A CASE-BASED APPROACH TO PROBLEM SOLVING IN PD

Chair: John Burkart, MD
Presenters: Leslie Wong, MD, Bradley A. Warady, MD and Zipporah Krishnasami, MD
12:00pm–2:00pm
Session 232

This interactive workshop is based on interesting cases representing problems faced by PD patients and their doctors. Solutions and management options will be presented. The format will allow for audience involvement. The participants will be able to present PD problems they have faced for group discussion. The PD experts will help solve these problems.

THE NUTS AND BOLTS OF PRACTICE: LEGAL CONTRACTS/RENAL BILLING

Chair: Susan Bray, MD
Presenters: Emil Paganini, MD and Richard Hamburger, MD
12:00pm–2:00pm
Session 233

This workshop will discuss issues regarding proper coding and billing for nephrologic and dialytic services. Participants will also learn about some of the pitfalls encountered by nephrologists attempting to bill correctly.

THE IMPORTANCE AND IMPACT OF CYBER MEDICINE ON THE PRACTICE OF NEPHROLOGY

Presenter: Kim Solez, MD
12:00pm–2:00pm
Session 234

Successful medical care has much to do with communication, and so the way to be a successful health professional in the future has many analogies with the way to be a successful writer. Embrace the Internet, text messaging, Twitter, and whatever else comes along in new communication technology. The workshop will indicate what these myriads of technologies are today and will be in the future, and how they will directly impact the lives of every health care professional.

METABOLIC WORK-UP OF KIDNEY STONES

Chair: Michael J. Choi, MD
Presenters: Eric Taylor, MD, David Goldfarb, MD and Michael J. Choi, MD
12:00pm–2:00pm
Session 235

This workshop will take a case-based approach to the metabolic workup of kidney stones. Noted experts in the field will discuss the diagnostic and therapeutic approaches to patients with nephrolithiasis based upon serum and urine biochemical profiles. Surgical management will also be discussed.

WORKSHOPS

DIFFICULT ISSUES IN ICU NEPHROLOGY

Chair: Kathleen Liu, MD
Presenters: Mark Unruh, MD, Joe Verbalis, MD and Emil Paganini, MD
12:00pm–2:00pm
Session 236

This workshop will focus on management challenges in the intensive care unit. Specifically, the appropriate timing of initiation of dialysis for acute kidney injury and the management of patients with acute kidney injury and pulmonary hypertension will be reviewed. An update in the management of severe hyponatremia will also be provided.

FRIDAY
MARCH 27

30-QUESTION BOARD EXAM

Presenter: Harold Szerlip, MD
12:00pm–2:00pm
(repeated from Thursday, March 26)
Session 237

Test your knowledge of nephrology. Come and see how you compare to your colleagues. During this workshop you will have the opportunity to answer 30 Board type questions that will cover a wide range of topics including: electrolytes, acid-base, AKI, acute and chronic dialysis, CKD management and transplantation. Responses will be anonymously tallied using an audience response system. You are guaranteed to have fun and learn at the same time.

ELECTROLYTES—CASES

Chair: Lawrence Weisberg, MD
Presenters: Kamel Kamel, MD, FRCPC, Ashita Tolwani, MD and Lawrence Weisberg, MD
12:00pm–2:00pm
(repeated from Thursday, March 26)
Session 238

Experts will present interesting electrolyte cases and challenge the audience to make the diagnosis and choose the appropriate treatment. This is an excellent review of renal pathophysiology. The audience will gain a better understanding of electrolyte disorders and review mechanism of electrolyte transport in the kidney.

PROBLEM SOLVING IN HOME HD

Presenter: Robert Lockridge, MD
12:00pm–2:00pm
Session 239

This interactive workshop will address several issues relating to setting up home hemodialysis. These issues include the types of access to be used with home HD, water requirements, co-morbid conditions that prohibit home hemodialysis, the educational level required for patients, and necessary housing requirements. A series of cases will be presented.

PREPARING TO SEARCH FOR THE PRACTICE OF YOUR DREAM

Chair: Susan Bray, MD
Presenters: Derrick L. Latos, MD, MACP, Susan Bray, MD and Jean Holley, MD
12:00pm–2:00pm
Session 240

This workshop will help focus on factors necessary to prepare for finding a practice as well as will discuss several aspects of practices to evaluate and question. Some of these include the number of people in the practice, the number of hospitals and dialysis facilities, opportunities to expand and the “culture” of the practice.

VASCULAR ACCESS: FROM A (AGGRENOX) TO V (VEIN MAPPING)

Chairs: Michele H. Mokrzycki, MD, MS
William Paulson, MD, and Ivan D. Maya, MD
Presenters: Laura Dember, MD, Charmaine Lok, MD and William Paulson, MD
12:00pm–2:00pm
Session 241

This is an interactive workshop that focuses on current controversies and problems nephrologists are encountering in hemodialysis patients whose vascular access is an arteriovenous fistula or arteriovenous graft. The speakers will be reviewing recently published clinical trials and discuss strategies to optimize AVF and AVG patency. The topics will be case-based and audience participation will be implemented so as to encourage a shared learning experience.

FRIDAY
MARCH 27 (CONTINUED)

**LONG-TERM COMPLICATIONS OF KIDNEY
TRANSPLANTATION**

Chairs: R. Michael Hofmann, MD and
Michelle Josephson, MD
Presenters: Nasia Safdar, MD, Heidi Schaefer, MD and
Michelle Josephson, MD
12:00pm–2:00pm
Session 242

The success of kidney transplantation has resulted in improved long-term patient survival. With longevity, kidney transplant patients face multiple co-morbidities resulting from CKD vintage and prolonged exposure to immunosuppressive drugs. In this workshop, we will

discuss the epidemiology and management of infectious diseases and cardiovascular disease—the two most common causes of patient mortality after kidney transplantation—and bone disease, an increasingly recognized cause of patient morbidity and mortality.

WHAT'S NEW IN AKI

Chair: Kathleen Liu, MD
Presenters: Chirag Parikh, MD, Roxana Mehran, MD and
Paul Palevsky, MD
12:00pm–2:00pm
Session 243

This workshop will focus on management updates for the patient with contrast nephropathy and the patient with dialysis requiring acute kidney injury. Novel methods to detect AKI will also be reviewed.

**SUNDAY MINI
COURSES**

**THE CKD CLINIC: IF YOU BUILD IT WILL THEY
COME?—PRACTITIONERS' CHALLENGE!**

*Supported by an unrestricted educational grant from
AMAG Pharmaceuticals*

Course Directors: Jerry Yee, MD, Sandeep Soman, MD and
Nelson Kopyt, DO
Sunday, March 29
7:30am–12:30pm
Session 210, 4.0 credits

TARGET AUDIENCE

This mini course is designed for physicians.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Perform a needs assessment for an efficient, guideline-based CKD clinic that is scaled to available resources.
- List the economic and business principles of setting up and monitoring a CKD clinic.

- Recognize the benefits of implementing technology in a CKD clinic, including the synergies of guideline adoption and adherence with automation and computerized clinical decision support systems.
- Provide successful strategies to mid-level practitioners that optimize results for CKD patients.
- Discuss revenue cycles and deploy billing strategies that are efficient and coordinated with clinical care.

REQUIRED: Additional registration fee of \$80 (\$100 when registering for the course only); includes syllabus, breakfast, snack and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:30am–8:00am	
Breakfast	
8:00am–8:05am	
Introduction/Welcome	Jerry Yee, MD

SUNDAY MINI COURSES

8:05am–8:30am

The CKD Epidemic— What We Can Do

W. Kline Bolton, MD

8:30am–9:00am

Rationale for CKD Clinic

Andrew Narva, MD

9:00am–9:30am

Planning for a CKD Clinic

Carolyn Bauer, MD

9:30am–10:00am

Technology in the CKD Clinic

Sandeep Soman, MD

10:00am–10:30am

Break

10:30am–11:00am

Role of Advanced Practitioners in CKD Clinic

Naima Ogletree, MSN,
APRN, BC

11:00am–11:30am

Billing Practices

Jerry Yee, MD

11:30am–12:00pm

Economics of a CKD Clinic— Present and Future

Nelson Kopyt, DO

12:00pm–12:30pm

Wrap-Up Session: Questions and Answers

HOME HEMODIALYSIS

Course Director: Christopher Chan, MD

Sunday March 29

7:30am–12:30pm

Session 211, 3.5 credit hours

TARGET AUDIENCE

Designed for nephrologists, nurses, advanced practitioners and trainees.

COURSE DESCRIPTION

This course is designed with multiple goals for the kidney health care professional involved or interested in the practice of home hemodialysis. The practical aspects of delivering home hemodialysis will be reviewed. The attendee will gain further understanding of the clinical advantages of intensive hemodialysis. The important aspect of psychosocial care in delivering complex home technology will also be reviewed.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- State the essentials of delivering home hemodialysis.
- List the clinical data of intensive home hemodialysis.
- Discuss the various important aspects of caring for home hemodialysis patients.

REQUIRED: Additional registration fee of \$80 (\$100 when registering for the course only); includes syllabus, breakfast, snack and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:30am–8:00am Welcome and Breakfast	
8:00am–8:10am Introduction	Christopher Chan, MD
8:10am–8:40am Essentials of Setting Up Home Hemodialysis Program	Christopher Chan, MD
8:45am–9:15am Recruiting for Your Home Hemodialysis Program	Robert Lockridge, MD
9:15am–10:00am Training Home Hemodialysis in the US—Practical Aspects and Technical Details	Rose Faratro, RN
10:00am–10:30am Break	
10:30am–11:00am Clinical Advantages of Home HD	Christopher Chan, MD
11:05am–11:35am Quality of Life or Too Much Burden	Mark Unruh, MD, MSc
11:35am–12:00pm Meet the Experts— Questions and Answers	

SUNDAY MINI COURSES

RENAL PATHOLOGY

Course Directors: Bessie Young, MD, MPH and Jean Olson, MD
 Sunday March 29
 7:30am–12:30pm
 Session 212, 4.25 credit hours

TARGET AUDIENCE

Physicians, pediatric and adult nephrology fellows, residents, physician's assistants, nurse practitioners and other health professionals involved in the care of patients with glomerular kidney disease.

COURSE DESCRIPTION

Acute and chronic glomerulonephritis remains one of the most challenging aspects of an active renal practice or teaching service and present the practitioner with many diagnostic complexities and dilemmas regarding patient diagnosis and treatment. This course is designed to discuss interesting and challenging clinical cases, review pathologic renal biopsy findings, and review treatment options and new therapies that may be applicable for specific clinical cases.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Describe clinical findings, pathologic correlates, and treatment options for resistant FSGS and other resistant glomerulonephritides.
- State the clinical characteristics, histologic presentation, and treatment options for IgA nephropathy and discuss the role of immunosuppressants in IgA nephropathy.
- Review the clinical presentation and pathology associated with challenging pediatric nephropathy cases.
- Summarize challenging glomerulonephritis cases and discuss pathologic correlates.

REQUIRED: Additional registration fee of \$80 (\$100 when registering for the course only); includes syllabus, breakfast, snack and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:30am–8:00am Welcome and Breakfast	
8:00am–8:45am Case & Pathology of FSGS	Jean Olson, MD Bessie Young, MD
Treatment of Resistant GN	Fernando Fervenza, MD
8:45am–9:30am Cases & Pathology of IgA Nephropathy	Jean Olson, MD Bessie Young, MD
IgA Nephropathy in Adults: Should Immunosuppression Be Used in All Patients?	Richard Glassock, MD
9:30am–9:45am Break	
9:45am–10:30am Pediatric Cases	Bradley Warady, MD
10:30am–12:15pm Series of GN Case Discussions	Jean Olson, MD Bessie Young, MD
12:15pm–12:30pm Question & Answer Session Closing Remarks	

PROGRAM

WEDNESDAY
MARCH 25

TIME/LOCATION	SESSION #	SESSION	NOTES	COURSE DIRECTOR(S)	CREDITS
7:30am–5:15pm					
Hermitage C	220	The Management of the High-Risk Kidney Transplant Recipient: The State-of-the-Art	■	Milagros D. Samaniego, MD Heidi Schaefer, MD	6.5
7:00am–8:00pm					
Governors Ballroom B	221	Integrated Hemodialysis/Peritoneal Dialysis Course	■	John Burkart, MD	9.5
7:45am–5:00pm					
Ryman Ballroom A/D	222	Interventional Nephrology Course	■	Ivan D. Maya, MD Bharat Sachdeva, MD	7.5
7:30am–5:30pm					
Hermitage A/B	223	Dialysis Unit Management Course	■	Thomas A. Golper, MD	7.5
7:30am–5:00pm					
Washington B	224	Nephrology Recertification Course	■	Harold M. Szerlip, MD, FACP, FASN John Jason White, MD	8.0
7:30am–5:30pm					
Governors Ballroom E	225	Ray W. Gifford, Jr., MD Hypertension Symposium <i>Supported by an unrestricted educational grant from Merck & Co., Inc.</i>	■	Marc A. Pohl, MD	7.5
7:30pm–9:30pm					
Delta Ballroom B	800	Impact of Special Populations and Vitamin D Therapy in Chronic Kidney Disease Outcomes <i>Supported by an unrestricted educational grant from Abbott</i>		Chair: Keith Norris, MD	1.5
		Welcome and Introduction		Keith Norris, MD	
		The Relationship of Special Populations and Cardiovascular Outcomes in CKD Patients		Janice Lea, MD	
		Special Population Differences in CKD and Dialysis Patients: Impact on Survival		Keith Norris, MD	
		Special Population Differences in CKD: The Impact of Vitamin D Therapy		Rajnish Mehrotra, MD, FACP, FASN	
		Discussion with Questions and Answers		All Faculty	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

**THURSDAY
MARCH 26**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	801	Preventing and Managing Acute Kidney Injury in Patients with Tumor Lysis Syndrome: A Team Approach <i>Supported by an unrestricted educational grant from Sanofi-aventis U.S., Inc.</i>	Chair: A. Ahsan Ejaz, MD, FACP, FASN		1.5
		Welcome and Introduction	A. Ahsan Ejaz, MD, FACP, FASN		
		TLS: An Oncologic and Nephrologic Emergency	Ching-Hon Pui, MD		
		Acute Kidney Injury and TLS	A. Ahsan Ejaz, MD, FACP, FASN		
		Prevention and Treatment of Acute Kidney Injury	Aldo J. Peixoto, MD		
		A Case-Based Interactive Debate — Question and Answer Session	All Faculty		
6:00am–7:45am					
Governors Ballroom A/E	295	Breakfast Symposium: Kidney and Vascular Risk Factor Control in KEEP	Chair: Peter McCullough, MD, MPH		1.5
		Blood Pressure Targets	George Bakris, MD		
		Optimizing Cardiometabolic Risk: Impact on Kidney Outcomes	Adam Whaley-Connell, DO		
		Relevance of CKD Stages 1 and 2	Allan J. Collins, MD, FACP		
8:00am–9:30am					
Washington B	260	Pre-emptive Transplantation and the “Transplant First” Initiative	Co-Chairs: Roy Bloom, MD Anthony Langone, MD		1.5
		The Transplant First Initiative	Robert Gaston, MD		
		Pre-emptive Transplantation: Who, When and How	Panduranga Rao, MD, DNB, MS		
		Pre-emptive Transplantation: A Community Nephrology Perspective	Andrew Howard, MD, FACP		
8:00am–9:30am					
Governors Ballroom D	261	Issues of Dialysis Economics	Co-Chairs: Susan Bray, MD Derrick L. Latos, MD, MACP		1.5
		New Medicare Guidelines for Dialysis Units and Impact	Derrick L. Latos, MD, MACP		
		Medicare Bundling	Rob Blaser		
		Joint Venture for Dialysis Ownership	Chester Amedia Jr, MD, FACP		
8:00am–9:30am					
Presidential Ballroom A	262	Acute Kidney Injury: Identification and Treatment	Co-Chairs: Kathleen Liu, MD Emil Paganini, MD, FACP, FRCP		1.5
		Epidemiology of AKI	Edward Siew, MD		
		New Interventions	Kathleen Liu, MD		
		Role of Biomarkers in AKI	Chirag Parikh, MD		

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
9:30am–10:00am		Break			
10:00am–11:30am					
Governors Ballroom B	263	Amyloidosis and Multiple Myeloma	Co-Chairs: Li-Li Hsiao, MD, MPH Michele H. Mokrzycki, MD, MS	1.5	
		A Review of Amyloid Renal Disease	Laura Dember, MD		
		Is There a Role for Plasma Exchange in Myeloma Kidney/Glomerulonephritis?	Paul Sanders, MD		
		Stem Cell Transplant for Amyloidosis	Raymond L. Comenzo, MD		
10:00am–11:30am					
Presidential Ballroom A	264	Adolescents and CKD: Transition to Adult Nephrology	Co-Chairs: Bradley Warady, MD Kathy Jabs, MD	1.5	
		Transition of Adolescents to Adult Care: A “How To” Approach From a Successful Program	Maria Ferris, MD, MPH, PhD		
		What Is the Medical Psychosocial Status of Adolescents with CKD at Time of Transition to Adult Care: Results from the CKiD Study	Bradley Warady, MD		
		The Social Worker Is Crucial to a Successful Transition	Fred Kouri, LMSW		
		Discussion with Audience Participation	All Faculty		
10:00am–11:30am					
Governors Ballroom D	265	Health Disparities in CKD/ESRD/Transplant	Co-Chairs: Bessie Young, MD, MPH Heidi Schaefer, MD	1.5	
		Access to Dialysis/Transplantation—Are We Making Any Progress in Disparities?	Bessie Young, MD, MPH		
		Rural Patients	Rudy Rodriguez, MD		
		Chronic Kidney Disease and the Uninsured	Yoshio N. Hall, MD		
12:00pm–2:00pm					
Cheekwood A/B	230	Workshop: 30-Question Board Exam	■ Chair: Harold M. Szerlip, MD, FACP, FASN	2.0	
12:00pm–2:00pm					
Cheekwood G/H	231	Workshop: Electrolytes—Cases	■ Chair: Lawrence Weisberg, MD Lawrence Weisberg, MD Kamel Kamel, MD FRCP(C) Ashita Tolwani, MD	2.0	
12:00pm–2:00pm					
Hermitage A	232	Workshop: A Case-Based Approach to Problem Solving in PD	■ Chair: John Burkart, MD Leslie Wong, MD Bradley Warady, MD Zipporah Krishnasami, MD	2.0	

Joint with Councils

■ Separate Registration and/or Fee Required

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
12:00pm–2:00pm					
Hermitage B	233	Workshop: The Nuts and Bolts of Practice: Legal Contracts/Renal Billing	■ Chair: Susan Bray, MD Emil Paganini, MD, FACP, FRCP Richard Hamburger, MD, FACP, FASN		2.0
12:00pm–2:00pm					
Hermitage E	234	Workshop: The Importance and Impact of Cyber Medicine on the Practice of Nephrology	■ Chair: Kim Solez, MD, FRCP(C)		2.0
12:00pm–2:00pm					
Hermitage C	235	Workshop: Metabolic Work-up of Kidney Stones	■ Chair: Michael J. Choi, MD Eric Taylor, MD, MSc Michael J. Choi, MD David Goldfarb, MD, FACP, FASN		2.0
12:00pm–2:00pm					
Hermitage D	236	Workshop: Difficult Issues in ICU Nephrology	■ Chair: Kathleen Liu, MD		2.0
		Managing the Patient with Pulmonary Hypertension and AKI in the ICU Setting	Mark Unruh, MD, MSc		
		Managing Hyponatremia in the ICU setting	Joe Verbalis, MD		
		Timing of Initiation of Dialysis for AKI	Emil Paganini, MD, FACP, FRCP		
12:00pm–2:00pm					
Delta Ballroom B	802	Role of Abnormal Phosphate and Vitamin D Metabolism in CKD-MBD <i>Supported by an unrestricted educational grant from Genzyme</i>	Chair: David M. Spiegel, MD		1.5
		Significance of Phosphorus Dysregulation in Early CKD	David M. Spiegel, MD		
		Elevated FGF-23: An Early Sign of Phosphate and Vitamin D Disturbance in CKD?	Orlando Gutierrez, MD		
		Controlling Phosphate and Vitamin D Abnormalities in CKD: When to Intervene?	Donald A. Molony, MD		
		Discussion with Questions and Answers	All Faculty		
		2:00pm–2:30pm		Break	
2:30pm–3:30pm					
Presidential Ballroom C/D/E	266	NKF Presidential Address: Transformers: Your NKF and You	Bryan Becker, MD		1.0
		Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!	Mohammed Sayegh, MD		

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
3:30pm–4:00pm		Break			
4:00pm–5:30pm					
Presidential Ballroom C/D/E	267	KDIGO Guideline for the Care of the Kidney Transplant Recipient	Co-Chairs: Bertram Kasiske, MD Cathy Garvey, RN, CCTC		1.5
		Overview of KDIGO and the Guideline Process	Bertram Kasiske, MD		
		Examples of Guidelines	Michelle Josephson, MD		
		Examples of Guidelines	Cathy Garvey, RN, CCTC		
		Panel Discussion	All Faculty		
4:00pm–5:30pm					
Presidential Ballroom A	268	Literature Review 2008	Chair: Harold M. Szerlip, MD, FACP, FASN		1.5
		CKD	John Jason White, MD		
		ESRD	T. Alp Ikizler, MD		
		Hypertension	Raymond Townsend, MD		
		AKI	Paul Palevsky, MD		
4:00pm–5:30pm					
Governors Ballroom B	269	Diabetes Mellitus	Co-Chairs: William F. Keane, MD Maria Taylor, PharmD		1.5
		Introduction	William F. Keane, MD		
		Pandemic of Diabetic Nephropathy Is Declining	Eli A. Friedman, MD, MACP, FRCP		
		Use of Combination Therapies for Diabetic Nephropathy and Proteinuria	Jamie Dwyer, MD		
		Update on Newer Treatments for Diabetic Control	Craig Williams, PharmD		
6:00pm–7:30pm		Opening Ceremonies and Reception in the Exhibit Hall—Visit Posters/Exhibits			
7:30pm–9:30pm					
Delta Ballroom B	803	A New Direction in Anemia Management Beyond Erythropoietic Stimulating Agents <i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>	Chair: Lynda Szczech, MD, MSCE		1.5
		Welcome and Introduction	Lynda Szczech, MD, MSCE		
		Overview of Pathophysiology of Iron Deficiency in ESRD Patients	Lynda Szczech, MD, MSCE		
		Strategies for Detecting Iron Deficiency and Iron Excess in ESRD Patients	David B. Van Wyck, MD		
		Strategies for Optimizing Treatment of Iron Deficiency in ESRD Patients	Chaim Charytan, MD		
		Question and Answer Panel Discussion	All Faculty		

Joint with Councils

Separate Registration and/or Fee Required

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	805	Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease <i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>		Chair: Vincent W. Dennis, MD	1.5
		Welcome and Introduction		Vincent W. Dennis, MD	
		Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease		Peter A. McCullough, MD, MPH, FACC	
		Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease		Robert N. Foley, MD	
		Question and Answer Panel Discussion		All Faculty	
7:00am–8:00am		Continental Breakfast in the Exhibit Hall			
8:00am–9:30am					
Presidential Ballroom B	270	Debate: Treatment of Lupus Nephritis with IV Cyclophosphamide		Co-Chairs: Bessie Young, MD, MPH Donal O'Donoghue, MD	1.5
		Pro		Mary Anne Dooley, MD, MPH	
		Con		Michael J. Choi, MD	
		Debate and Discussion		All Faculty	
8:00am–9:30am					
Presidential Ballroom C/E	271	Polycystic Kidney Disease		Chair: Bradley Warady, MD	1.5
		Trials of New Therapies to Slow the Progression of PKD		Arlene Chapman, MD	
		What We Have Learned About the Pathogenesis of PKD		Greg Germino, MD	
		Caring for Young Adults with ARPKD and ADPKD		Katherine Dell, MD	
8:00am–9:30am					
Presidential Ballroom A	272	Hypertension Management Related to CKD Stage		Co-Chairs: Kirsten Johansen, MD Ruth Campbell, MD	1.5
		Impact of CKD Stage 1 and 2 on Hypertension		Ruth Campbell, MD	
		Hypertension in Stage 2–4		Raymond Townsend, MD	
		Hypertension in Stage 5 and ESRD		Rajiv Agarwal, MBBS, MD, FAHA, FASN	
9:30am–10:00am		Break			
10:00am–11:30am					
Presidential Ballroom A	273	Difficult Issues in HUS/TTP		Chair: Bradley Warady	1.5
		ESRD Management of Atypical Hemolytic-Uremic Syndrome		Jeff Saland, MD, MS	
		New Perspectives on Thrombotic Nephropathy		Susan Quaggin, MD	
		A Review of HUS/TTP		Anne T. Neff, MD	

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
10:00am–11:30am					
Presidential Ballroom B	274	Issues in Secondary Hypertension		Co-Chairs: John Kevin Tucker, MD Paul Sanders, MD	1.5
		Obstructive Sleep Apnea and Effects on Blood Pressure		Mark Unruh, MD, MSc	
		Hyperaldosteronism		Raymond Townsend, MD	
		Drug Induced Secondary Hypertension (Legal and Illegal)		Domenic Sica, MD	
10:00am–11:30am					
Presidential Ballroom C/E	275	Debate: Peritoneal Dialysis		Chair: Allan J. Collins, MD, FACP	1.5
		PD Has Better Survival		John Burkart, MD	
		HD Has Better Survival		Bernard Jaar, MD, MPH	
		When is the Best Time to Transition from PD to In/Center/Home HD		John Kevin Tucker, MD	
11:30am–12:00pm		Break			
12:00pm–1:15pm		Lunch in the Exhibit Hall—Visit Posters/Exhibits			
12:00pm–2:00pm					
Cheekwood A/B	237	Workshop: 30-Question Board Exam	■	Chair: Harold M. Szerlip, MD, FACP, FASN	2.0
12:00pm–2:00pm					
Cheekwood G/H	238	Workshop: Electrolytes—Cases	■	Chair: Lawrence Weisberg, MD Lawrence Weisberg, MD Kamel Kamel, MD, FRCP(C) Ashita Tolwani, MD	2.0
12:00pm–2:00pm					
Hermitage E	239	Workshop: Problem Solving in Home HD	■	Chair: Robert Lockridge, MD	2.0
12:00pm–2:00pm					
Hermitage B	240	Workshop: Preparing to Search for the Practice of Your Dream	■	Chair: Susan Bray, MD Derrick L. Latos, MD, MACP Jean Holley, MD	2.0
12:00pm–2:00pm					
Hermitage C	241	Workshop: Vascular Access: From A (Aggrenox) to V (Vein Mapping)	■	Co-Chairs: Michele H. Mokrzycki, MD, MS William Paulson, MD Ivan D. Maya, MD	2.0
		Early AVF Failure: Novel Strategies for Prevention and Management		Laura Dember, MD	
		Strategies for Maintaining AVG Patency: What Works, What Doesn't?		Charmaine Lok, MD	
		Prospective Monitoring of AVF and AVGs: Is It Efficacious?		William Paulson, MD	
		Panel Discussion		All Faculty	

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
12:00pm–2:00pm					
Hermitage D	242	Workshop: Long-Term Complications of Kidney Transplantation	■ Co-Chairs: Michael R. Hofmann, MD	Michelle Josephson, MD	2.0
		Infectious Complications in Kidney Transplantation	Nasia Safdar, MD		
		Cardiovascular Disease in Kidney Transplant Patients	Heidi Schaefer, MD		
		Bone Disease in CKD and Kidney Transplantation	Michelle Josephson, MD		
12:00pm–2:00pm					
Hermitage A	243	Workshop: What’s New in AKI	■ Co-Chairs: Kathleen Liu, MD	Chirag Parikh, MD, PhD	2.0
		New Methods to Identify AKI	Chirag Parikh, MD, PhD		
		Contrast Nephropathy: Prevention	Roxana Mehran, MD, FACC		
		Dose of Dialysis for AKI: Lessons Learned from the ATN Study and Other Trials	Paul Palevsky, MD		
2:00pm–2:30pm		Break			
2:30pm–4:00pm					
Presidential Ballroom B	276	KDIGO and Hepatitis C and CKD	Co-Chairs: Michael Rocco, MD	Brian Pereira, MD	1.5
		Evolution of HCV as a Problem in CKD/ESRD/Trxplt Disease	Brian Pereira, MD		
		HCV KDIGO Guideline	David Roth, MD		
		KDOQI Commentary on Hepatitis C Guideline	Craig Gordon, MD, MS		
2:30pm–4:00pm					
Presidential Ballroom A	277	CKD/ESRD and Anticoagulation	Co-Chairs: Maria Taylor, PharmD	Guillermo Garcia Garcia, MD	1.5
		The Risk Benefit Ratio of Anti-Coagulation in ESRD Patients	Donald Brophy, PharmD, MSc		
		Pharmacogenetics Influence of CYP2C9 and VKORC1 on Warfarin Response in Patients with Renal Insufficiency	Nita Limdi, PharmD, PhD		
		HIT	Robert Reilly, MD		
2:30pm–4:00pm					
Governors Ballroom C	278	Geriatric Nephrology	Co-Chairs: Linda Fried, MD, MPH	Gregorio Obrador, MD	1.5
		Hypertension in the Elderly	Mark Supiano, MD		
		CKD in the Elderly—Physiologic Aging or a Disease?	Linda Fried, MD, MPH		
		Cognitive Function/Dementia in Dialysis Patients—Prevalance/Screening, Etiology	Manjula Tamura, MD		
4:00pm–4:30pm		Break			

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
4:30pm–5:30pm					
Presidential Ballroom C/D/E	279	Challenging Dialysis Patients		Chair: Jean Holley, MD	1.0
		Panel Discussion on Challenging Dialysis Patients		Fredric Finkelstein, MD Stephanie Johnstone, LCSW Lee A. Cauble, BSN, BSB, RN, Pam Havermann	
4:30pm–5:30pm					
Presidential Ballroom A	280	Wasting Syndrome in CKD		Co-Chairs: Kirsten Johansen, MD Srinivasan Beddhu, MD	1.0
		Is Malnutrition a Misnomer?		Srinivasan Beddhu, MD	
		Anabolic Hormones in Uremic Wasting		Kirsten Johansen, MD	
		Inflammation and Uremic Wasting		Adriana M. Hung, MD, MPH	
6:00pm–7:30pm					
Networking Reception in Exhibit Hall—Visit Posters/Exhibits					
7:30pm–9:30pm					
Delta Ballroom B	804	Bone Fractures in CKD: Clinical Issues and Expert Perspectives		Chair: Hartmut H. Malluche, MD, FACP	1.5
		Supported by an unrestricted educational grant from Amgen			
		Introduction		Hartmut H. Malluche, MD, FACP	
		Fractures in CKD: Epidemiology, Prevention and Treatment		Paul D. Miller, MD	
		Emerging Concepts in Prevention and Treatment		Hartmut H. Malluche, MD, FACP	
		Bone Disease in Kidney Transplant Patients		Margaret Bia, MD	
Questions and Answers		All Faculty			
7:30pm–9:30pm					
Delta Ballroom C	806	Advances in the Management of Idiopathic Membranous Nephropathy		Chair: Richard J. Glassock, MD	1.5
		Supported by an unrestricted educational grant from Questcor Pharmaceuticals			
		Idiopathic Membranous Nephropathy: All Patients Do Not Require Specific Therapy		Richard J. Glassock, MD	
		Potential New Therapies for the Treatment of Membranous Nephropathies		Fernando C. Fervenza, MD	
		Idiopathic Membranous Nephropathy in the Transplanted Kidney		Sundaram Hariharan, MD	
Questions and Answers		All Faculty			

Joint with Councils

Separate Registration and/or Fee Required

**SATURDAY
MARCH 28**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom A	281	Vascular Access—Extremes of Age	Co-Chairs: Charmaine Lok, MD William Paulson, MD	1.5	
		Debate: All Pediatric HD Patients (>20 kg) Should Have a Fistula (vs a Catheter)	Stuart Goldstein, MD Denis Geary, MB, MRCP, FRCPC		
		Access in the Very Old: Hemocatheter vs AVF/AVG	Ann O’Hare, MD		
8:00am–9:30am					
Presidential Ballroom D	282	Tubulo-Interstitial Diseases	Co-Chairs: Li-Li Hsiao, MD, PhD Valerie Luyckx, MD	1.5	
		Aristolochic Acid Nephropathy (Chinese Herbs): A Review	Li-Li Hsiao, MD, PhD		
		Lithium Nephropathy	Joel Neugarten, MD		
		Acute Phosphate Nephropathy	Glenn Markowitz, MD		
8:00am–9:30am					
Governors Ballroom B	283	Pregnancy and Renal Disease	Co-Chairs: Heidi Schaefer, MD Susan Hou, MD	1.5	
		Hypertension in Pregnancy	Heidi Schaefer, MD		
		Pre-eclampsia with Focus on Novel Findings Re Pathogenesis and Diagnosis	Richard Levine, MD, MPH		
		CKD, ESRD and Pregnancy: Recommendations	Susan Hou, MD		
9:30am–11:30am					
Visit Posters/Exhibits Hall (Brunch Served at 10:30am)					
11:30am–1:00pm					
Presidential Ballroom A	284	Controversies in HD Catheter Related Bacteremia	Co-Chairs: Michele H. Mokrzycki, MD, MS Ann O’Hare, MD	1.5	
		Debate: Catheter Related Bacteremia: To Lock or Not to Lock...That Is the Question	Ivan D. Maya, MD vs Michele H. Mokrzycki, MD, MS		
		Debate: Use of Prophylactic Antibiotics in ESRD Patients: Is the Concern for Emerging Resistance Well Founded or an Obstruction to Improving Outcomes?	William Salzer, MD vs Charmaine Lok, MD		

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
11:30am–1:00pm					
Presidential Ballroom C/D/E	285	KDOQI: A New Era		Co-Chairs: Michael Rocco, MD Holly Kramer, MD	1.5
		New KDOQI Initiatives: A Natural Progression		Michael Rocco, MD, FACP	
		KDOQI Clinical Practice Guideline on Nutrition in Children with CKD: Update 2008—A Case-Based Presentation		Donna Secker, PhD, RD Bradley Warady, MD	
		NKF KDOQI Research Grants—Moving Clinical Care Forward		Holly Kramer, MD Research Grantees: Chester H. Fox, MD Josef Coresh, MD	
1:00pm–1:30pm					
		Break			
1:30pm–3:00pm					
Presidential Ballroom B	287	Reflux Nephropathy		Chair: Bradley Warady, MD	1.5
		Management of Reflux Nephropathy in the Early Years		Craig Peters, MD, FACS, FAAP	
		What Clinicians Need to Know About Reflux Nephropathy and Pregnancy		Susan Hou, MD	
		Can Reflux Nephropathy Be Prevented?—Preliminary Data from the RIVUR Study		Tej Mattoo, MD, FRCP	
1:30pm–3:00pm					
Governors Ballroom B	288	Work-Up and Interventions in Renovascular and Cardiovascular Disease in 2009: Pick Your Poison		Co-Chairs: Joel Neugarten, MD Marc A. Pohl, MD	1.5
		Renal Vascular Disease: What is the Safest Approach to Diagnosis/Treatment?		Marc A. Pohl, MD	
		Renal Vascular Disease: Does Intervention Improve HTN and Preservation of Renal Function		Stephen Textor, MD	
		Contrast-Induced Nephropathy: Review of Prevention and Mortality Risk		Steven Weisbord, MD, MSc	
1:30pm–3:00pm					
Presidential Ballroom A	289	Home Hemodialysis		Co-Chairs: Christopher Chan, MD Jim Curtis, CHT	1.5
		How to Grow Your Home HD Program		Robert Lockridge, MD	
		Update from the Frequent Hemodialysis Network Randomized Controlled Trial		Michael Rocco, MD, FACP	
		Home/Frequent HD: The Pediatric Perspective		Denis Geary, MB, MRCP, FRCP	
3:00pm–3:30pm					
		Break			

Joint with Councils

Separate Registration and/or Fee Required

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
3:30pm–5:00pm					
Presidential Ballroom C/D/E	290	Ongoing Clinical Trials in Nephrology: Updates		Chair: Kirsten Johansen, MD	1.5
		New Trials in Diabetes		Linda Fried, MD, MPH	
		New Trials in Transplantation		Vahakn Shahinian	
		New Trials in CKD		Jerry Yee, MD	
3:30pm–5:00pm					
Governors Ballroom B	286	Diabetic Nephropathy, Cardiovascular Risk and Metabolic Syndrome		Co-Chairs: Mark Sarnak, MD Manjula Tamura, MD, MPH	1.5
		Is the Metabolic Syndrome an Independent Risk Factor for Kidney Disease or Does This Represent Hypertension/Glycemia?		Manjula Tamura, MD, MPH	
		Cardiac Biomarkers in CKD—Issues with Interpretation and Practical Points		Mark Sarnak, MD	
		Update on Glycemic Control and Cardiovascular Outcomes and Implications for Target HbA1C		Stephen N. Davis, MD, FRCP	
5:30pm–7:00pm					
Washington B	100	Fellows/Residents Reception – Career Choices in Nephrology <i>Held in association with Women in Nephrology Supported by an unrestricted educational grant from AMAG Pharmaceuticals, Inc.</i>		Co-Chairs: Sharon M. Moe, MD Heidi Schaefer, MD Panelists: Bryan Becker, MD Robert Brenner, MD Li-Li Hsiao, MD, PhD Jamie Dwyer, MD Stan Lee, MD Jeff Guillian, MD	N/A

SUNDAY
MARCH 29

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
7:00am–12:30pm					
Lincoln B	210	The CKD Clinic: If You Build It Will They Come?—Practitioners' Challenge! Mini Course <i>Supported by an unrestricted educational grant from AMAG Pharmaceuticals, Inc.</i>	■	Chairs: Jerry Yee, MD Sandeep Soman, MD Nelson Kopyt, DO	4.0
7:30am–12:30pm					
Jackson E/F	211	Home Hemodialysis Mini Course	■	Chair: Christopher Chan, MD	3.5
7:30am–12:30pm					
Lincoln E	212	Renal Pathology Mini Course	■	Co-Chairs: Jean Olson, MD Bessie Young, MD, MPH	4.25

SUNDAY
MARCH 29, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom B	291	End of Life Care for the ESRD Patient	Chair: Jean Holley, MD		1.5
		The Choice of Hospice Care	Camille Yuscak, LCSW-R, ACSW		
		The Choice of No Dialysis for the Elderly Patient	Jean Holley, MD		
		Pain Control in the ESRD Patient	Steven Weisbord, MD		
8:00am–9:30am					
Presidential Ballroom D	292	Kidney Stones	Co-Chairs: John Kevin Tucker, MD Eric Taylor, MD, MSc		1.5
		Assessment of Risk Factors for Stone Disease/Dietary Treatment of Stone Disease	Eric Taylor, MD, MSc		
		Indications for Urologic Intervention	Margaret Pearle, MD, PhD		
		Kidney Stones in Pregnancy	Susan Hou, MD		
9:45am–11:15am					
Presidential Ballroom B	293	Electrolytes	Chair: Harold M. Szerlip, MD, FACP, FASN		1.5
		Hypokalemia	Kamel Kamel, MD, FRCP(C)		
		Disorders of Calcium Sensor	Zalman Agus, MD		
		Hypomagnesemia	Robert Reilly, MD		
		Hypernatremia: Hospital Acquired	Paul Palevsky, MD		
9:45am–11:15am					
Presidential Ballroom D	294	Acute Kidney Injury/ICU Nephrology	Co-Chairs: Kathleen Liu, MD T. Alp Ikizler, MD		1.5
		Dialysis and AKI: Who, What, When and How?	Paul Palevsky, MD		
		Long-Term Outcomes of AKI	T. Alp Ikizler, MD		
		Management of the Critically Ill ESRD Patient	Steven Weisbord, MD		
12:30pm					
		Meeting Adjourns			

Joint with Councils

Separate Registration and/or Fee Required

PHYSICIAN SESSION OBJECTIVES

THURSDAY
MARCH 26

SESSION #	SESSION	OBJECTIVES
260	Pre-emptive Transplantation and the “Transplant First” Initiative	<ol style="list-style-type: none"> 1) Summarize the recommendations of the “Transplant First” Initiative Consensus Conference. 2) Identify all patients in your practice who would benefit from pre-emptive kidney transplantation. 3) Recognize the obstacles to pre-emptive transplantation in your practice. 4) Discuss the impact that the implementation of the “Transplant First” Initiative might have in your clinical practice.
261	Issues of Dialysis Economics	<ol style="list-style-type: none"> 1) Review practices and policies of government and private payors. 2) Differentiate between the policies of the Medicare and Medicaid programs. 3) Describe the basic coding and billing issues in dialysis. 4) Review payment issues in dialysis, including recent legislation affecting payment practices.
262	Acute Kidney Injury: Identification and Treatment	<ol style="list-style-type: none"> 1) Discuss the epidemiology of acute kidney injury, including recent temporal trends in the incidence of and outcomes from AKI. 2) Review the potential role of biomarkers for the diagnosis of acute kidney injury. 3) Identify novel biomarkers and review novel interventions for the treatment of acute kidney injury.
263	Amyloidosis and Multiple Myeloma	<ol style="list-style-type: none"> 1) Recognize the various types of amyloidosis and its pathophysiological features. 2) Review the available treatment options.
264	Adolescents and CKD: Transition to Adult Nephrology	<ol style="list-style-type: none"> 1) Identify novel risk factors in the adolescent population for CKD progression. 2) Comprehend the impact of CKD on growth, cognition, behavior and cardiovascular disease. 3) Examine the role of the pediatric nephrologist, adult nephrologist and ancillary staff in the transition of CKD adolescents to adult nephrology. 4) Recognize the key elements of a successful transition program.
265	Health Disparities in CKD/ESRD/ Transplant	<ol style="list-style-type: none"> 1) Identify race, gender and socioeconomic disparities in the CKD population. 2) Examine disparities in access to care and modality of dialysis treatment. 3) List factors leading to access and late referral to kidney transplantation. 4) Recognize aspects of health literacy and its role in CKD/ESRD/ Transplant.
230	Workshop: 30-Question Board Exam	<ol style="list-style-type: none"> 1) Demonstrate general nephrology knowledge. 2) Review renal pathophysiology through self-testing.
231	Workshop: Electrolytes—Cases	<ol style="list-style-type: none"> 1) Discuss case-studies that will provide an understanding of renal transport mechanisms. 2) Review electrolyte disorders caused by newer medications.

THURSDAY
MARCH 26, CONTINUED

SESSION #	SESSION	OBJECTIVES
232	Workshop: A Case-Based Approach to Problem Solving in PD	<ol style="list-style-type: none"> 1) Review interactive case-studies representing problems faced by PD patients and their doctors with solutions and management options. 2) Formulate solutions for actual PD problems with interactive group discussion facilitated by PD experts.
233	Workshop: The Nuts and Bolts of Practice: Legal Contracts/Renal Billing	<ol style="list-style-type: none"> 1) Review basic information regarding billing codes and documentation. 2) List important issues to notice when evaluating a contract. 3) Identify the issues to discuss with a contract lawyer when evaluating a contract.
234	Workshop: The Importance and Impact of Cyber Medicine on the Practice of Nephrology	<ol style="list-style-type: none"> 1) Explain new insights into the use of the web to learn new aspects of nephrology and effective search methods. 2) Outline methods on how to interact and communicate with patients through the web.
235	Workshop: Metabolic Work-up of Kidney Stones	<ol style="list-style-type: none"> 1) State the risk factors for stone formation and how those risk factors impact diagnostic work-up. 2) List how to use urine studies in working up kidney stones. 3) Discuss the role of diet and dietary intervention in the management of kidney stones.
236	Workshop: Difficult Issues in ICU Nephrology	<ol style="list-style-type: none"> 1) Review novel treatments for pulmonary hypertension and the challenges in the management of the patient with pulmonary hypertension with acute kidney injury. 2) Identify the treatment of hypernatremia and the evidence for the initiation of dialysis for acute kidney injury.
266	NKF Presidential Address: Transformers: Your NKF and You	<ol style="list-style-type: none"> 1) Discuss NKF's organizational structure and goals of the 2007–2010 NKF strategic plan various program offerings. 2) Review the goals of the 2007–2010 NKF strategic plan. 3) Identify areas of progress and various programs available to assist in successfully meeting these goals. 4) List areas of continued emphasis to achieve the goals of the NKF strategic plan.
	Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!	<ol style="list-style-type: none"> 1) Describe approaches that lead to clinical transplantation tolerance in kidney transplant recipients. 2) Identify the scientific barriers to achieving clinical transplantation tolerance. 3) Review the non-scientific challenges to achieving clinical transplantation tolerance. 4) Summarize the mechanisms and assay development to measure tolerance. 5) List the advantages of tolerance over immunosuppression.
267	KDIGO Guideline for the Care of the Kidney Transplant Recipient	<ol style="list-style-type: none"> 1) Review the KDIGO Clinical Practice Guideline development process. 2) Describe the GRADE system for rating evidence and strength of recommendations. 3) Discuss recommended initial and maintenance immunosuppressive agents for kidney transplant recipients. 4) Recognize the basic infection prophylaxis strategies for kidney transplant recipients.
268	Literature Review 2008	<ol style="list-style-type: none"> 1) Identify the most important recent articles relating to hypertension, acute kidney failure, CKD and end-stage renal disease.

THURSDAY
MARCH 26, CONTINUED

SESSION #	SESSION	OBJECTIVES
269	Diabetes Mellitus	<ol style="list-style-type: none"> 1) Recognize the new classes of medications for diabetic control and the targeted groups for their use. 2) Discuss approaches targeting the renin angiotensin system with combination therapy, including the status and limitations of the current data on slowing progression of nephropathy. 3) Review the epidemiology of diabetic nephropathy and projections for ESRD. 4) Differentiate between the targets for prevention of microvascular and macrovascular diabetic complications.

FRIDAY
MARCH 27

SESSION #	SESSION	OBJECTIVES
270	Debate: Treatment of Lupus Nephritis with IV Cyclophosphamide	<ol style="list-style-type: none"> 1) Recognize the weaknesses and limitations of the literature on the use of immunosuppression to treat lupus nephritis. 2) Identify the risks, especially death and infectious complications of the use of different approaches. 3) Review the long-term sequelae of cyclophosphamide.
271	Polycystic Kidney Disease	<ol style="list-style-type: none"> 1) Describe the impact of new therapies designed to decrease the progression of PKD. 2) List the current information regarding the primary factors involved in the genesis of PKD. 3) Describe key components of patient care in adolescents and young adults with two inherited renal disorders (eg, cystinosis and ARPKD).
272	Hypertension Management Related to CKD Stage	<ol style="list-style-type: none"> 1) State the recommended blood pressure targets for different stages of CKD and the evidence that supports them. 2) Identify the evidence supporting the advantages and disadvantages of using different antihypertensive agents in different stages of CKD. 3) Describe the role of achieved blood pressure and of specific antihypertensive agents in reducing proteinuria.
273	Difficult Issues in HUS/TTP	<ol style="list-style-type: none"> 1) Explain current treatment options for patients with Atypical Hemolytic-Uremic Syndrome. 2) Describe and compare clinical and pathological features of HUS and TTP. 3) Describe the differential diagnosis associated with Thrombotic Nephropathy.
274	Issues in Secondary Hypertension	<ol style="list-style-type: none"> 1) State the common causes of secondary hypertension and when to suspect them. 2) Discuss the impact of sleep apnea on blood pressure and cardiovascular disease. 3) Review the work-up of hyperaldosteronism. 4) Recognize the impact of medications and illicit drugs on blood pressure. 5) Interpret the relationship between the early stages of CKD and hypertension.
275	Peritoneal Dialysis Debate	<ol style="list-style-type: none"> 1) Recognize the complexities and problems of comparing mortality in HD and PD. 2) Identify that the risk of death over time is not constant but changing. 3) Recognize that both modalities are still associated with an unacceptably high risk of death.

SESSION #	SESSION	OBJECTIVES
237	Workshop: 30-Question Board Exam	<ol style="list-style-type: none"> 1) Demonstrate general nephrology knowledge. 2) Review renal pathophysiology through self-testing.
238	Workshop: Electrolytes—Cases	<ol style="list-style-type: none"> 1) Discuss case-studies that will provide an understanding of renal transport mechanisms. 2) Review electrolyte disorders caused by newer medications.
239	Workshop: Problem Solving in Home Hemodialysis	<p>The participants in the workshop will address the following areas associated with the different cases:</p> <ol style="list-style-type: none"> 1) List the types of access that can be used with home hemodialysis and any associated complications. 2) Recognize the issues and requirements for use of city, country, well or spring water. 3) Compare the benefits of reverse osmosis (RO) or deionized (DI) water for home hemodialysis. 4) List the patient requirements necessary for hemo hemodialysis.
240	Workshop: Preparing to Search for the Practice of Your Dream	<ol style="list-style-type: none"> 1) Identify the issues to address in preparation for the search of your practice dream. 2) Categorize the factors of most importance to address in interviews for practice position. 3) State some basic accounting and business points to use when searching. 4) List the basic contract pitfalls to avoid.
241	Workshop: Vascular Access: From A (Aggrenox) to V (Vein Mapping)	<ol style="list-style-type: none"> 1) Apply the techniques used for monitoring and surveillance of hemodialysis vascular access in the clinic setting. 2) Select the appropriate method for surveillance of vascular access. 3) Identify the role of interventional procedures in the salvage of a failing vascular access. 4) Predict the appropriate time for referral of an immature fistula to either a surgeon or an interventionalist.
242	Workshop: Long-Term Complications of Kidney Transplantation	<ol style="list-style-type: none"> 1) Recognize risk factors for infections, cardiovascular and bone disease in kidney transplant patients in your practice. 2) Identify the microbial pathogens responsible for acute and chronic infections in kidney transplant recipients. 3) Discuss the management of infectious diseases in kidney transplant recipients with emphasis in newly identified pathogens and prevention. 4) Examine and compare the natural history and management of cardiovascular disease in kidney transplant recipients. 5) Appraise the incidence/prevalence of different forms of bone disease in your kidney transplant patients and summarize their treatment.
243	Workshop: What's New in AKI	<ol style="list-style-type: none"> 1) List novel biomarkers that may allow for the early identification of patients with acute kidney injury. 2) Identify prevention strategies for contrast nephropathy. 3) Review the evidence base for the dose of dialysis in acute kidney injury.
276	KDIGO and Hepatitis C	<ol style="list-style-type: none"> 1) Discuss the epidemiology and impact that Hepatitis C has on the CKD/ESRD population. 2) Identify the pathogenesis and treatment of Hepatitis C. 3) Review issues to consider when transplanting Hep C positive patients. 4) State the new HCV KDIGO guidelines with respect to the treatment and management of Hepatitis C CKD/ESRD patients.

FRIDAY
MARCH 27, CONTINUED

SESSION #	SESSION	OBJECTIVES
277	CKD/ESRD and Anticoagulation	<ol style="list-style-type: none"> 1) Recognize the mechanisms by which genetic differences can influence the response to warfarin in CKD patients. 2) Compare the risk/benefit of anticoagulation in ESRD patients. 3) Describe the pathogenesis of heparin induced thrombocytopenia and the reliability of antibody tests in predicting thrombotic events.
278	Geriatric Nephrology	<ol style="list-style-type: none"> 1) Discuss the epidemiology of aging and loss of kidney function. 2) Recognize the benefits and challenges of treating hypertension in the elderly. 3) Recall the high prevalence of cognitive impairment in CKD and dialysis patients and the implications for care.
279	Challenging Dialysis Patients	<ol style="list-style-type: none"> 1) State different approaches in dealing with the difficult dialysis patient. 2) Recognize that in some cases the difficult dialysis patient is dealing with loss of autonomy and control, as well as depression and anger. 3) Summarize how the dialysis team can and must work effectively together to deal with the difficult dialysis patient.
280	Wasting Syndrome in CKD	<ol style="list-style-type: none"> 1) Review the literature on the role of anabolic and catabolic processes in causing wasting syndrome in uremic patients. 2) State the effects of anabolic hormones on muscle mass in dialysis patients. 3) Discuss the literature on inflammation and anti-inflammatory therapy for wasting syndrome in uremia.

SATURDAY
MARCH 28

SESSION #	SESSION	OBJECTIVES
281	Vascular Access – Extremes of Age	<ol style="list-style-type: none"> 1) List controversies that exist in the Pediatric HD population with respect to vascular access referral. 2) Discuss the present state of vascular access in the Pediatric population. 3) Review the controversies that exist in the Geriatric HD population with respect to vascular access referral. 4) State the controversies that exist about timing of access referral in the Geriatric population. 5) Explain the present state of vascular access in the geriatric population.
282	Tubulo-Interstitial Diseases	<ol style="list-style-type: none"> 1) Recognize fundamental clinical features of specific renal diseases and their pathologic patterns. 3) Identify the mechanisms responsible for the nephrotoxic effects. 4) Review the impact of interstitial disease on chronic kidney disease.
283	Pregnancy and Renal Disease	<ol style="list-style-type: none"> 1) Explain the renal physiologic changes in normal pregnancy. 2) Identify the classification system of hypertension in pregnancy and gain knowledge regarding appropriate therapies. 3) Review the pathogenesis and diagnosis of pre-eclampsia with focus on novel findings. 4) List the recommendations regarding pregnancy in CKD/ESRD/Transplant populations. 5) Discuss renal and fetal outcomes associated with pregnancy and kidney disease.

SESSION #	SESSION	OBJECTIVES
284	Controversies in HD Catheter Related Bacteremia	<ol style="list-style-type: none"> 1) Recall the importance of prevention and treatment of catheter related bacteremia (CRB). 2) Discuss the pathophysiology of CRB and the role of biofilm formation. 3) Review the optimal management of CRB with regard to what to do with the catheter. 4) List the use of both topical and intraluminal antibiotics for the prevention and treatment of CRB. 5) State the risks associated with prophylactic antibiotic use in the hemodialysis setting.
285	KDOQI: A New Era	<ol style="list-style-type: none"> 1) Review the new KDOQI initiatives in areas outside of guideline development. 2) List the changes to the KDOQI Nutritional Guideline for Children with CKD: Update 2008. 3) State aspects of the new KDOQI research grant program.
286	Diabetic Nephropathy, Cardiovascular Risk and Metabolic Syndrome	<ol style="list-style-type: none"> 1) Review the new data from studies of glucose control and cardiovascular outcomes and the implications for care and target HbA1c. 2) Identify the use and interpretation of cardiac biomarkers in the setting of CKD. 3) State the prevalence of the metabolic syndrome, its association with cardiovascular disease and the potential mediators of the risk of CVD.
287	Reflux Nephropathy	<ol style="list-style-type: none"> 1) Describe current treatment recommendations for children and adolescents with vesico-ureteral reflux. 2) Describe current treatment recommendations for the pregnant patient with reflux nephropathy. 3) Review the objectives and preliminary clinical data from the RIVUR study.
288	Work-up and Interventions in Renovascular and Cardiovascular Disease in 2009: Pick Your Poison	<ol style="list-style-type: none"> 1) Differentiate between the risks/benefits of MRA gadolinium, duplex, captopril renal scan and IV angiogram for the diagnosis of renovascular disease. 2) Recognize the efficacy of angioplasty/stenting of renal artery stenosis on improving hypertension and CKD progression. 3) Review the risk associated with IV contrast agents, with respect to AKI and mortality. 4) State the efficacy of various regimens/therapies used to prevent contrast nephropathy. 5) Review the safety of isoosmolar versus low osmolar contrast agents for cardiac catheterization.
289	Home Hemodialysis	<ol style="list-style-type: none"> 1) State two specific steps that can be taken to help set up a home dialysis program. 2) Identify at least two clinical benefits of more frequent dialysis therapies. 3) Learn of the progress and results of the ongoing randomized NIH clinical trials. 4) Understand how more frequent dialysis impacts pediatric dialysis patients.
290	Ongoing Clinical Trials in Nephrology	<ol style="list-style-type: none"> 1) State the objectives and expected contribution of current trials in diabetic nephropathy. 2) Discuss the aims and expected new information to be gained from ongoing trials in chronic kidney disease. 3) Review the design and goals of ongoing trials in dialysis.

SESSION #	SESSION	OBJECTIVES
210	The CKD Clinic: If You Build It Will They Come?—Practitioners' Challenge! Mini Course	<ol style="list-style-type: none"> 1) Perform a needs assessment for an efficient, guideline-based CKD clinic that is scaled to available resources. 2) List the economic and business principles of setting up and monitoring a CKD clinic. 3) Recognize the benefits of implementing technology in a CKD clinic, including the synergies of guideline adoption and adherence with automation and computerized clinical decision support systems. 4) Provide successful strategies to mid-level practitioners that optimize results for CKD patients. 5) Discuss revenue cycles and deploy billing strategies that are efficient and coordinated with clinical care.
211	Home Hemodialysis Mini Course	<ol style="list-style-type: none"> 1) State the essentials of delivering home hemodialysis. 2) List the clinical data of intensive home hemodialysis. 3) Discuss the various important aspects of caring for home hemodialysis patients.
212	Renal Pathology Mini Course	<ol style="list-style-type: none"> 1) Describe clinical findings, pathologic correlates, and treatment options for resistant FSGS and other resistant glomerulonephritides. 2) State the clinical characteristics, histologic presentation, and treatment options for IgA nephropathy and discuss the role of immunosuppressants in IgA nephropathy. 3) Review the clinical presentation and pathology associated with challenging pediatric nephropathy cases. 4) Summarize challenging glomerulonephritis cases and discuss pathologic correlates.
292	Kidney Stones	<ol style="list-style-type: none"> 1) List the important risk factors for nephrolithiasis. 2) Identify the role of diet and dietary intervention in the management of stone disease. 3) Describe the role of urologic intervention in the management of stone disease. 4) Recall the unique diagnostic and management strategies for kidney stones in a pregnant woman.
291	End of Life Care for the ESRD Patient	<ol style="list-style-type: none"> 1) Recognize that not starting dialysis is an option that should be presented to the elderly patient with co-morbidities. 2) Identify that dialysis patients have many physical complaints and that the dialysis team can address these and ameliorate some of these. 3) State the role of hospice in managing the end of life care of the dialysis patient.
293	Electrolytes	<ol style="list-style-type: none"> 1) Discuss the causes and treatment of hypernatremia in hospitalized patients. 2) List the mechanisms and appropriate treatment of hypomagnesemia. 3) Review the pathophysiology of hypokalemia. 4) Identify the disorders associated with defects in the calcium sensor.
294	Acute Kidney Injury/ICU Nephrology	<ol style="list-style-type: none"> 1) Review the evidence supporting the initiation of dialysis for AKI. 2) State the evidence supporting dialysis characteristics, including dose, modality and choice of membranes in patients with AKI. 3) List the long-term outcomes of patients with acute kidney injury. 4) Describe issues in the management of the critically ill patient with end-stage renal disease, including nutrition, intravenous access and dialytic support.

ADVANCED PRACTITIONER PROGRAM

PROGRAM COMMITTEE

Laurie E. Benton, RN, PA-C, BS, MPAS

Scott and White Hospital, Temple, TX

Program Chair

Elaine Go, RN, NP

St. Joseph Hospital, Renal Center

Laguna Niguel, CA

Program Co-Chair

Tricia Howard, MHS, PA-C

South University, Savannah, GA

Jeanne Thacker RN, MSN, CNS-C, FNP-C

Renal Associates, Lakehills, TX

HOST COMMITTEE

Sallyanne Meier, RN, MSN, ACNP

Nephrology Associates, P.C. Nashville, TN

PROGRAM GOAL

To improve patient outcomes by enhancing the advanced practitioners' knowledge base and skills that affects the kidney and clinical practice.

CONTINUING EDUCATION INFORMATION

AAPA accepts Category I credit from AOACCME, prescribed credit from AAFP, and *AMA Category I Credits™* for the PRA from organizations accredited by ACCME.

The National Kidney Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Kidney Foundation designates this educational activity for a maximum of 29.0 *AMA PRA Category I Credits™*.

Physicians should claim credit commensurate with the extent of their participation in the activity.

This program is approved for up to 30.6 contact hour(s) of continuing education (which includes up to 3.5 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 0902052

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

PRE-CONFERENCE COURSES:

Nephrology 201 for Advanced Practitioners Program ID 0901014	7.75 credits
Interventional Nephrology Course Program ID 0902058	7.5 credits
The Management of the High-Risk Kidney Transplant Recipient: The State-of-the-Art Program ID 0901042	6.6 credits
Integrated Hemodialysis/ Peritoneal Dialysis Program ID TBD	9.5 credits
Dialysis Unit Management Course Program ID TBD	7.5 credits

For final CME/CE information, please refer to the handout located in your meeting tote bag.

PRE-CONFERENCE COURSES & THE NNCC EXAM

NEPHROLOGY 201 FOR ADVANCED PRACTITIONERS

*Supported by an unrestricted educational grant from
AMAG Pharmaceuticals, Inc.*

Course Director: Laurie Benton, RN, PA-C, BS, MPAS
and Kim Zuber, PA-C

Wednesday, March 25

7:30am–5:30pm

Session 620, 7.75 credit hours

TARGET AUDIENCE

This course is designed for physician assistants and nurse practitioners in the field of nephrology.

COURSE DESCRIPTION

This course is designed for the Advanced Practitioner to help evaluate, diagnose, and treat patients with renal disease. Topics ranging from proteinuria, cardiac disease, transplant to laboratory medicine are presented by physicians and advanced practitioners specializing in the field of nephrology. The content is selected to help participants understand, diagnose and treat the basic to the most complex nephrology patients. Whether a beginning or seasoned practitioner, this course provides an outstanding opportunity to learn through case studies relevant to everyday clinical practice.

***REQUIRED:** Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.*

COURSE AGENDA

Time/Topic	Faculty
7:30am–8:00am Continental Breakfast	
8:00am–8:15am Welcome and Introductions	Kim Zuber, PA-C Laurie Benton, RN, PA-C, BS, MPAS
8:15am–9:00am The Cardio-Renal Syndrome	Alan Kliger, MD
9:00am–9:45am Pearls and Puzzles of Laboratory Testing in Patients with CKD	Brigette Schiller, MD

9:45am–10:00am

Break

10:00am–11:00am

**Transplant Pearls for the
Private Nephrology Practice**

Barbara Weis Malone,
RN, FNP, CFNP

11:00am–12:00pm

**Resistant Hypertension in the
Nephrology Patient:
CKD/Dialysis**

Charles Foulks, MD

12:00pm–1:00pm

Lunch

1:00pm–2:00pm

Anemia/Iron Lecture

Myra Kleinpeter, MD

2:00pm–3:00pm

**Metabolic Bone Disease/
Vitamin D Update**

Peter Jeurgenson, PA-C

3:00pm–3:15pm

Break

3:15pm–4:15pm

Proteinuria: Finding the Source

Harvey Feldman, MD

4:15pm–5:15pm

**Medication Induced
Renal Failure**

Luis Concepcion, MD

5:15pm–5:30pm

Closing Remarks/Adjourn

THE MANAGEMENT OF HIGH-RISK KIDNEY TRANSPLANT RECIPIENT: THE STATE OF THE ART

Wednesday, March 25

7:30am–5:15pm

Session 220

See page 32 for course details.

Separate Registration and Fee Required.

PRE-CONFERENCE COURSES & THE NNCC EXAM

INTEGRATED HEMODIALYSIS/PERITONEAL DIALYSIS COURSE

Wednesday, March 25
7:00am–8:00pm
Session 221

See page 33 for course details.

Separate Registration and Fee Required.

INTERVENTIONAL NEPHROLOGY

Wednesday, March 25
7:45am–4:45pm
Session 222

See page 34 for course details.

Separate Registration and Fee Required.

DIALYSIS UNIT MANAGEMENT COURSE

Wednesday, March 25
7:30am–5:30pm
Session 223

See page 36 for course details.

Separate Registration and Fee Required.

NNCC EXAM

Nephrology Nursing Certification Commission's (NNCC) will be offering its certification exam for Certified Nephrology Nurse-Nurse Practitioner (CNN-NP) at SCM09 on

Sunday, March 29, 8:00am–12:00pm. Attendees must be registered in advance in order to sit in for this exam.

RENAL PATHOLOGY MINI COURSE

Sunday, March 29
7:30am–12:30pm
Session 212

See page 44 for course details.

Separate Registration and Fee Required.

PROGRAM

WEDNESDAY
MARCH 25

TIME/LOCATION	SESSION #	SESSION	NOTES	COURSE DIRECTOR(S)	CREDITS
7:30am–5:30pm					
Presidential Ballroom A	620	Nephrology 201 for Advanced Practitioners <i>Supported by an unrestricted educational grant from AMAG Pharmaceuticals, Inc.</i>	■	Laurie Benton, MPAS, BS, PA-C, RN Kim Zuber, PA-C	7.75
7:30am–5:15pm					
Hermitage C	220	The Management of the High-Risk Kidney Transplant Recipient: The State-of-the-Art	■◆	Milagros D. Samaniego, MD Heidi Schaefer, MD	6.6
7:00am–8:00pm					
Governors Ballroom B	221	Integrated Hemodialysis/Peritoneal Dialysis Course	■◆	John Burkart, MD	9.5
7:45am–4:45pm					
Ryman Ballroom A/D	222	Interventional Nephrology Course	■◆	Ivan D. Maya, MD Bharat Sachdeva, MD	7.5
7:30am–5:30pm					
Hermitage A/B	223	Dialysis Unit Management Course	■◆	Thomas A. Golper, MD	7.5
6:00pm–7:00pm					
Hermitage D	102	Advanced Practitioner Welcome Reception <i>Supported by an unrestricted educational grant from Watson Nephrology</i>			
7:30pm–9:30pm					
Delta Ballroom B	800	Impact of Special Populations and Vitamin D Therapy in Chronic Kidney Disease Outcomes <i>Supported by an unrestricted educational grant from Abbott</i>	◆	Chair: Keith Norris, MD	1.5
		Welcome and Introduction		Keith Norris, MD	
		The Relationship of Special Populations and Cardiovascular Outcomes in CKD Patients		Janice Lea, MD	
		Special Population Differences in CKD and Dialysis Patients: Impact on Survival		Keith Norris, MD	
		Special Population Differences in CKD: The Impact of Vitamin D Therapy		Rajnish Mehrotra, MD, FACP, FASN	
		Discussion with Questions and Answers		All Faculty	

**THURSDAY
MARCH 26**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	801	Preventing and Managing Acute Kidney Injury in Patients with Tumor Lysis Syndrome: A Team Approach <i>Supported by an unrestricted educational grant from Sanofi-aventis U.S., Inc.</i>	◆ Chair: A. Ahsan Ejaz, MD, FACP, FASN		1.5
		Welcome and Introduction	A. Ahsan Ejaz, MD, FACP, FASN		
		TLS: An Oncologic and Nephrologic Emergency	Ching-Hon Pui, MD		
		Acute Kidney Injury and TLS	A. Ahsan Ejaz, MD, FACP, FASN		
		Prevention and Treatment of Acute Kidney Injury	Aldo J. Peixoto, MD		
		A Case-Based Interactive Debate—All Faculty Question and Answer Session	All Faculty		
8:00am–9:30am					
Washington B	260	Pre-emptive Transplantation and the “Transplant First” Initiative	◆ Co-Chairs: Roy Bloom, MD Anthony Langone, MD		1.5
		The Transplant First Initiative	Robert Gaston, MD		
		Pre-emptive Transplantation: Who, When and How	Panduranga Rao, MD, DNB, MS		
		Pre-emptive Transplantation: A Community Nephrology Perspective	Andrew Howard, MD, FACP		
8:00am–9:30am					
Jackson A/B	660	The Team Approach to the Nephrology Patient: Pre and Post			1.5
		Setting up a CKD Clinic	Fredric Finkelstein, MD		
		The Team Approach to Rounding in the Dialysis Units: Physician Perspective	Dana Kumjian, MD		
8:00am–9:30am					
Jackson C	661	Problems to Solutions in HD/PD			1.5
		The Top Ten Things I Hate About Hemodialysis	Kim Zuber, PA-C		
		Update on Home and PD	Luis Concepcion, MD		
9:30am–10:00am		Break			
10:00am–11:30am					
Jackson C	662	Snap, Crackle Pop: Ortho in the Dialysis Unit			1.5
		Understanding Orthopedic Problems in the Nephrology Patient	William Stein, PA-C		
		Orthopedic Exam in the Dialysis Chair	Polly Porter, PA-C, MPAS, ATC		

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
10:00am–11:30am					
Jackson A/B	663	Complete Package of Diabetic Care in the Nephrology Patient			1.5
		Diabetic Care in the Renal Patient		Myra A. Kleinpeter, MD, MPH	
		Diabetic Medications		Peter Hosseinpour, PharmD	
11:30am–12:00pm		Break			
12:00pm–2:00pm					
Governors Ballroom C	664	Council of Advanced Practitioners Networking Luncheon—All Are Welcome! <i>Supported by an unrestricted educational grant from AMAG Pharmaceuticals</i>			N/A
2:30pm–3:30pm					
Presidential Ballroom C/D/E	266	NKF Presidential Address: Transformers: Your NKF and You	◆	Bryan Becker, MD	1.0
		Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!		Mohammed Sayegh, MD	
3:30pm–4:00pm		Break			
4:00pm–5:30pm					
Presidential Ballroom C/D/E	267	KDIGO Guideline for the Care of the Kidney Transplant Recipient	◆	Co-Chairs: Bertram Kasiske, MD Cathy Garvey, RN, CCTC	1.5
		Overview of KDIGO and the Guideline Process		Bertram Kasiske, MD	
		Examples of Guidelines		Michelle Josephson, MD	
		Examples of Guidelines		Cathy Garvey, RN, CCTC	
		Panel Discussion		All Faculty	
4:00pm–5:30pm					
Governors Ballroom B	269	Diabetes Mellitus	◆	Co-Chairs: William F. Keane, MD Maria Taylor, PharmD	1.5
		Introduction		William F. Keane, MD	
		Pandemic of Diabetic Nephropathy Is Declining		Eli A. Friedman, MD, MACP, FRCP	
		Use of Combination Therapies for Diabetic Nephropathy and Proteinuria		Jamie Dwyer, MD	
		Update on Newer Treatments for Diabetic Control		Craig Williams, PharmD	
6:00pm–7:30pm					
Opening Ceremonies and Reception in the Exhibit Hall—Visit Posters/Exhibits					

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS	
7:30pm–9:30pm						
Delta Ballroom B	803	A New Direction in Anemia Management Beyond Erythropoietic Stimulating Agents	◆	Chair: Lynda Szczech, MD, MSCE	1.5	
		<i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>				
		Welcome and Introduction		Lynda Szczech, MD, MSCE		
		Overview of Pathophysiology of Iron Deficiency in ESRD Patients		Lynda Szczech, MD, MSCE		
		Strategies for Detecting Iron Deficiency and Iron Excess in ESRD Patients		David B. Van Wyck, MD		
		Strategies for Optimizing Treatment of Iron Deficiency in ESRD Patients		Chaim Charytan, MD		
Question and Answer Panel Discussion		Chaim Charytan, MD				

FRIDAY
MARCH 27

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	805	Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease	◆	Chair: Vincent W. Dennis, MD	1.5
		<i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>			
		Welcome and Introduction		Vincent W. Dennis, MD	
		Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease		Peter A. McCullough, MD, MPH, FACC	
		Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease		Robert N. Foley, MD	
		Question and Answer Panel Discussion		All Faculty	
7:00am–8:00am					
Continental Breakfast in the Exhibit Hall— Visit Posters/Exhibits					
8:00am–9:30am					
Presidential Ballroom C/E	271	Polycystic Kidney Disease	◆	Chair: Bradley Warady, MD	1.5
		Trials of New Therapies to Slow the Progression of PKD		Arlene Chapman, MD	
		What We Have Learned About the Pathogenesis of PKD		Greg Germino, MD	
		Caring for Young Adults with ARPKD and ADPKD		Katherine Dell, MD	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Magnolia Ballroom	665	Demystifying the Metabolic Panel/Acid Base Review		Charles Foulks, MD Paul Szczybor, PA-C	1.5
9:30am–10:00am					
Break					
10:00am–11:30am					
Magnolia Ballroom	666	Restless Leg Syndrome and Autoimmune Caused Nephrology Conditions			1.5
		Restless Leg Syndrome		Ronald Kramer, MD	
		Autoimmune Caused Nephrology Conditions		Miriam Michael, MD	
10:00am–11:30am					
Presidential Ballroom D	274	Issues in Secondary Hypertension	◆	Co-Chairs: John Kevin Tucker, MD Paul Sanders, MD	1.5
		Obstructive Sleep Apnea and Effects on Blood Pressure		Mark Unruh, MD, MSc	
		Hyperaldosteronism		Raymond Townsend, MD	
		Drug Induced Secondary Hypertension (Legal and Illegal)		Domenic Sica, MD	
10:00am–11:30am					
Presidential Ballroom C/E	275	Debate: Peritoneal Dialysis	◆	Chair: Allan J. Collins, MD, FACP	1.5
		PD Has Better Survival		John Burkart, MD	
		HD Has Better Survival		Bernard Jaar, MD, MPH	
		When Is the Best Time to Transition from PD to In Center/Home HD		John Kevin Tucker, MD	
11:30am–12:00pm					
Break					
12:00pm–1:00pm					
Lunch Served in the Exhibit Hall—Visit Posters/Exhibits					
1:00pm–2:30pm					
Magnolia Ballroom	667	Transplant: Making Sense Out of Transplant Medications and Other Follow-up Pearls		Christina Klein, MD Barbara Weis Malone, RN, FNP, CFNP	1.5
1:00pm–2:30pm					
Ryman Studio M/N/O	670	Nephrology Care: National and International			1.5
		Nephrology Care in Developing Countries		Zipporah Krishnasami, MD	
		Nephrology Care in a National Disaster and International Disaster		Sheldon Chaffer, MD	

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
2:30pm–4:00pm					
Magnolia Ballroom	675	Clinical Practices Associated with Improved Outcomes for Hemodialysis Patients in the DOPPS	● Chair: Bruce Robinson, MD, MS		1.5
		Details of Nutritional Intake and Associated Outcomes in the U.S.	Nancy Ginsberg, MS, RD		
		Cardiovascular Practices and Improved Outcomes	Rajiv Saran, MBBS, MD, MRCP		
		Modifiable Practices Associated with Patient-Reported Outcomes	Francesca Tentori, MD		
		Panel Discussion	All Faculty		
4:00pm–5:30pm					
Magnolia Ballroom	674	Pulmonary Hypertension and Vascular Disease Update			1.5
		Pulmonary Hypertension	Christopher Spradley, MD		
		Vascular Disease in the Nephrology Patient	Miriam Michael, MD		
6:00pm–7:30pm					
Networking Reception in Exhibit Hall— Visit Posters/Exhibits					
7:30pm–9:30pm					
Delta Ballroom B	804	Bone Fracture in CKD: Clinical Issues and Expert Perspectives <i>Supported by an unrestricted educational grant from Amgen</i>	◆ Chair: Hartmut H. Malluche, MD, FACP		1.5
		Introduction	Hartmut H. Malluche, MD, FACP		
		Fractures in CKD: Epidemiology, Prevention and Treatment	Paul D. Miller, MD		
		Emerging Concepts in Prevention and Treatment	Hartmut H. Malluche, MD, FACP		
		Bone Disease in Kidney Transplant Patients	Margaret Bia, MD		
		Questions and Answers	All Faculty		
7:30pm–9:30pm					
Delta Ballroom C	806	Advances in the Management of Idiopathic Membranous Nephropathy <i>Supported by an unrestricted educational grant from Questcor Pharmaceuticals</i>	◆ Chair: Richard J. Glassock, MD		1.5
		Welcome and Introduction			
		Idiopathic Membranous Nephropathy: All Patients Do Not Require Specific Therapy	Richard J. Glassock, MD		
		Potential New Therapies for the Treatment of Membranous Nephropathies	Fernando C. Fervenza, MD		
		Idiopathic Membranous Nephropathy in the Transplanted Kidney	Sundaram Hariharan, MD		
		Questions and Answers	All Faculty		

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

**SATURDAY
MARCH 28**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom D	282	Tubulo-Interstitial Diseases	◆ Co-Chairs: Li-Li Hsiao, MD, PhD Valerie Luyckx, MD		1.5
		Aristolochic Acid Nephropathy (Chinese Herbs): A Review	Li-Li Hsiao, MD, PhD		
		Lithium Nephropathy	Joel Neugarten, MD		
		Acute Phosphate Nephropathy	Glenn Markowitz, MD		
8:00am–9:30am					
Hermitage A/B	669	Issues and Treatment Options of Sexual Dysfunction in the Nephrology Patient	Doreen N. Perkins, MSN, NP		1.5
9:30am–11:30am					
Exhibit Hall (Brunch served at 10:30am)—Visit Posters/Exhibits					
11:30am–1:00pm					
Hermitage A/B	671	Urine STAT to 24 Hours			1.5
		Understanding the 24-Hour Urine Profile	William Glass, MD, PhD		
		Understanding Urine Microscopy and Cytodiagnostic Urinalysis	David Thomas, MD		
11:30am–1:00pm					
Presidential Ballroom C/D/E	285	KDOQI: A New Era	◆ Co-Chairs: Michael Rocco, MD, FACP Holly Kramer, MD		1.5
		New KDOQI Initiatives: A Natural Progression	Michael Rocco, MD, FACP		
		Premiering KDOQI Clinical Practice Guideline on Nutrition in Children with CKD: Update 2008—A Case-Based Presentation	Donna Secker, PhD, RD Bradley Warady, MD		
		NKF KDOQI Research Grants—Moving Clinical Care Forward	Holly Kramer, MD Research Grantees: Chester Fox, MD Josef Coresh, MD		
1:00pm–1:30pm		Break			
1:30pm–3:00pm					
Hermitage A/B	672	Renal Ultrasoundography to Renal Pathology			1.5
		The Basics of Reading the Renal Ultrasound	David DeWalch, PA-C, MA, MSPA		
		Basic Renal Pathology	Peter Jeurgenson, PA-C		
1:30pm–3:00pm					
Cheekwood G/H	673	Hyperlipidemia: Understanding the Maze of Treating High Cholesterol	John G. McGinnity, MS, PA-C Anne Liles, PharmD		1.5

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
3:30pm–5:00pm					
Presidential Ballroom C/D/E	290	Ongoing Clinical Trials in Nephrology: Updates	◆	Chair: Kirsten Johansen, MD	1.5
		New Trials in Diabetes		Linda Fried, MD, MPH	
		New Trials in Transplantation		Vahakn Shahinian, MD	
		New Trials in CKD		Jerry Yee, MD	

SUNDAY
MARCH 29

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
7:30am–12:30pm					
Lincoln E	212	Renal Pathology Mini Course	■◆	Co-Chairs: Jean Olson, MD Bessie Young, MD, MPH	4.25
8:00am–9:30am					
Washington B	668	Getting Your Money’s Worth Out of Your Advanced Practitioner		Garrett Smith, PA-C Lisa Farris, CRNP	1.5
8:00am–9:30am					
Presidential Ballroom D	292	Kidney Stones	◆	Co-Chairs: John Kevin Tucker, MD Eric Taylor, MD, MSc	1.5
		Assessment of Risk Factors for Stone Disease/Dietary Treatment of Stone Disease		Eric Taylor, MD, MSc	
		Indications for Urologic Intervention		Margaret Pearle, MD, PhD	
		Kidney Stones in Pregnancy		Susan Hou, MD	
8:00am–12:00pm					
Ryman Studio D/E	600	NNCC Exam	■		
9:45am–11:15am					
Presidential Ballroom B	293	Electrolytes	◆	Chair: Harold M. Szerlip, MD, FACP, FASN	1.5
		Hypokalemia		Kamel Kamel, MD, FRCP(C)	
		Disorders of Calcium Sensor		Zalman Agus, MD	
		Hypomagnesemia		Robert Reilly, MD	
		Hypernatremia: Hospital Acquired		Paul Palevsky, MD	
12:30pm		Meeting Adjourns			

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

ADVANCED PRACTITIONER SESSION OBJECTIVES

THURSDAY
MARCH 26

SESSION #	SESSION	OBJECTIVES
260	Pre-emptive Transplantation and the "Transplant First" Initiative	<ol style="list-style-type: none"> 1) Discuss the recommendations of the Transplant First Initiative Consensus Conference. 2) Identify patients in your CKD practice who would benefit from pre-emptive kidney transplantation. 3) Describe the obstacles to pre-emptive transplantation.
660	The Team Approach to the Nephrology Patient: Pre and Post	<ol style="list-style-type: none"> 1) Describe the optimal way to organize a CKD Clinic. 2) Describe the physician perspective on a team approach to rounding in the dialysis.
661	Problems to Solutions in HD/PD	<ol style="list-style-type: none"> 1) Identify two problems that a clinician will commonly see in the hemodialysis unit. 2) Identify 5 common side effects of Hemodialysis and the treatment for each. 3) Describe current initiatives in Hemodialysis and peritoneal dialysis.
662	Snap, Crackle Pop: Ortho in the Dialysis Unit	<ol style="list-style-type: none"> 1) Define basic orthopedic components. 2) Discuss common orthopedic conditions and exam components. 3) Discuss appropriate management of orthopedic conditions.
663	Complete Package of Diabetic Care in the Nephrology Patient	<ol style="list-style-type: none"> 1) Discuss the current trends in the care of the diabetic patient. 2) Describe how to incorporate the current treatment guidelines for the management of hyperglycemia into your clinical practice. 3) Identify 3 pharmacological options for the treatment of patients with DM type2 and the mechanism of action and interaction with other medications.
266	NKF Presidential Address	<ol style="list-style-type: none"> 1) Acquaint audience members with NKF organizational structure and various program offerings. 2) Help audience members understand the goals of the 2007–2010 NKF strategic plan. 3) Identify areas of progress and success in meeting the goals of the NKF strategic plan. 4) Note for audience members areas of continued emphasis to achieve the goals of the NKF strategic plan.
	Shaul Massry Distinguished Lecture	<ol style="list-style-type: none"> 1) Discuss approaches that lead to clinical transplantation tolerance in kidney transplant recipients. 2) Highlight the scientific barriers to achieving clinical transplantation tolerance. 3) Review the non-scientific challenges to achieving clinical transplantation tolerance. 4) Summarize the mechanisms and assay development to measure tolerance. 5) Provide a summary of the advantages of tolerance over immunosuppression.
267	KDIGO Guideline for the Care of the Kidney Transplant Patient	<ol style="list-style-type: none"> 1) Define KDIGO and discuss the process to develop the KDIGO clinical practice guideline. 2) List two guidelines that have been proposed and developed to address the care of the kidney transplant recipient.

THURSDAY
MARCH 26, CONTINUED

SESSION #	SESSION	OBJECTIVES
269	Diabetes Mellitus	<ol style="list-style-type: none"> 1) Discuss two reasons why the pandemic of diabetic nephropathy is declining. 2) Discuss the use of combination drug therapy for diabetic nephropathy and proteinuria. 3) Describe newer treatments for diabetic control.

FRIDAY
MARCH 27

SESSION #	SESSION	OBJECTIVES
271	Polycystic Kidney Disease	<ol style="list-style-type: none"> 1) Identify 3 current clinical designed to decrease the progression of PKD. 2) Discuss current information regarding the primary factors involved in the genesis of PKD. 3) Discuss components of caring for Young Adults with ARPKD and ADPKD.
665	Demystifying the Metabolic Panel/ Acid-Base Review	<ol style="list-style-type: none"> 1) Describe the difference between the Basic Metabolic Panel and the Comprehensive Metabolic Panel and the indication for each. 2) Discuss two components of the metabolic panel and abnormal results. 3) Discuss metabolic acid base disorders. 4) Describe the difference between acute and chronic respiratory disorders.
666	Restless Leg Syndrome and Autoimmune Caused Nephrology Conditions	<ol style="list-style-type: none"> 1) Discuss the basic physiology of sleep. 2) Discuss the consequences of sleep disruptions on chronic disease. 3) Describe restless leg syndrome (RLS). 4) Define autoimmune disease. 5) List and discuss two autoimmune disease in renal disease.
274	Issues in Secondary Hypertension	<ol style="list-style-type: none"> 1) Describe the relationship of obstructive sleep apnea and blood pressure. 2) Discuss the tests involved in the evaluation of hyperaldosteronism. 3) Describe the impact of common medications and illicit drugs on blood pressure.
275	Peritoneal Dialysis Debate	<ol style="list-style-type: none"> 1) Discuss reasons why PD has the better survival rate. 2) Discuss the reasons why HD has the better survival rate. 3) Describe the best time to transition from PD to In-Center or Home HD.
667	Transplant: Making Sense Out of Transplant Medications and Other Follow-up Pearls	<ol style="list-style-type: none"> 1) Describe the three areas of transplant medication: indications, side effects, long-term complications of use. 2) Discuss medication challenges in the renal transplant. 3) Discuss new trends in use of immunosuppressive medication.
670	Nephrology Care: National and International	<ol style="list-style-type: none"> 1) Describe obstacles facing nephrology care in developing countries. 2) Review types of disasters that affect the existing renal patient and result in the creation of new demands for renal care.. 3) Discuss common considerations needed in local, national and international disaster relief.

FRIDAY
MARCH 27, CONTINUED

SESSION #	SESSION	OBJECTIVES
675	Clinical Practices Associated with Improved Outcomes for Hemodialysis Patients in the DOPPS	<ol style="list-style-type: none"> 1) Describe the purpose of DOPPS. 2) Identify factors affecting nutritional status in hemodialysis patients. 3) Identify factors affecting cardiovascular outcomes in hemodialysis patients. 4) Describe modifiable clinical practices associated with patient self-reported outcomes.
674	Pulmonary Hypertension and Vascular Disease Update	<ol style="list-style-type: none"> 1) Discuss the Pathophysiology and clinical presentation of pulmonary artery hypertension (PAT). 2) Discuss the diagnosis and treatment of PAH. 3) Describe the consequences of vascular disease in the renal patient.

SATURDAY
MARCH 28

SESSION #	SESSION	OBJECTIVES
282	Tubulo-Interstitial Diseases	<ol style="list-style-type: none"> 1) Describe the mechanism of Aristolochic Acid Nephropathy. 2) Discuss the cause and treatment of Lithium Nephropathy. 3) Describe acute phosphate nephropathy.
669	Issues and Treatment Options of Sexual Dysfunction in the Nephrology Patient	<ol style="list-style-type: none"> 1) Discuss the diagnosis, evaluation and treatment options in men with organic impotence. 2) Describe the evaluation and treatment options in men with Peyronie's disease. 3) Describe the treatment limitations in men with premature ejaculation.
671	Urine STAT to 24 hours	<ol style="list-style-type: none"> 1) Define the purposes of different types of 24-hour urine panels and their interpretation. 2) Identify factors that affect the accuracy of the results and solutions. 3) Discuss Urine Microscopy and Cytodiagnostic Urinalysis.
285	KDOQI: A New Era	<ol style="list-style-type: none"> 1) Discuss new KDOQI initiatives in areas outside of guideline development. 2) List the changes to the KDOQI Nutritional Guideline for Children with CKD: Update 2008. 3) Describe the new KDOQI research grant program.
672	Renal Ultrasoundography to Renal Pathology	<ol style="list-style-type: none"> 1) Describe the mechanics of ultrasound physics. 2) Describe the physics of the MRI. 3) Describe normal renal pathology.
673	Hyperlipidemia: Understanding the Maze of Treating High Cholesterol	<ol style="list-style-type: none"> 1) Describe the prevalence and rates of control of dyslipidemia in the patient population along with the impact of Dyslipidemia on cardiovascular health and patient outcomes. 2) Discuss controversies regarding the safety of dyslipidemia drug therapies with reference to the current peer-review literature.
290	Ongoing Clinical Trials in Nephrology	<ol style="list-style-type: none"> 1) Describe the objectives and expected contribution of current trials in diabetic nephropathy. 2) Describe the characteristics of ongoing clinical trials in chronic kidney disease(CKD). 3) Describe the characteristics of ongoing clinical trials in dialysis.

SESSION #	SESSION	OBJECTIVES
668	Getting Your Money's Worth Out of Your Advanced Practitioner	<ol style="list-style-type: none"> 1) Discuss reasons for advocating advanced practice in nephrology. 2) Describe benefits of collaboration in the management of patients with early CKD and ESRD.
292	Kidney Stones	<ol style="list-style-type: none"> 1) Describe the important risk factors for nephrolithiasis. 2) Discuss the role of diet and dietary intervention in the management of stone disease. 3) Discuss the treatment options in the management of stone disease.
293	Electrolytes	<ol style="list-style-type: none"> 1) Summarize physiologic principles pertaining to potassium handling by the kidney. 2) Describe clinical pathology of hypercalcemia and hypocalcemia. 3) Discuss the basics of magnesium metabolism and renal handling of magnesium. 4) Describe the incidence and clinical characteristics of hypernatremia in hospitalized patients.

ProRenal QD™ With Omega-3

Finally, a multivitamin for people with kidney disease.

People with Chronic Kidney Disease (CKD) have specific nutritional needs. ProRenal QD™ with Omega-3 is the first multivitamin specially formulated by kidney doctors and kidney nutritionists to meet those needs. Using leading available clinical evidence, including guidelines from the National Kidney Foundation, ProRenal QD™ with Omega-3 provides the right vitamins and minerals in the right amounts (twice the amount of Vitamin D* to promote bone health) and avoids those (such as potassium) that can be unhealthy or harmful. It's also the first such multivitamin to contain Omega-3 fatty acids (fish oil) which may reduce the risk of coronary heart disease.**

Why take a multivitamin overloaded with what you don't need or pay for a vitamin and fish oil separately? ProRenal QD™ fits your precise needs in a daily multivitamin!

Take the vitamin specifically tailored for CKD.

Compare selected ingredients in ProRenal QD™ vs. other multivitamins

Ingredient	Centrum™ Silver	Prenatal Vitamin	Nephrocap™ (dialysis vitamin)	ProRenal QD™ With Omega-3
Vitamin D	500 IU	400 IU	No	800IU
Fish Oil	No	No	No	500mg
Iron	No	Yes	No	Yes
B Complex	Yes	Yes	Yes	Yes
Vitamin C	90mg	100mg	100mg	60mg
Trace Minerals (selenium, zinc, copper)	Yes	Yes	No	Yes
Vitamin A	2500IU	6000IU	No	No
Potassium	80mg	10mg	No	No
Phosphorus	110mg	No	No	No
Prescription	No	No	Yes	No

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
** Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.

To order ProRenal QD with Omega-3, call **1-877-2PRORNL** (1-877-277-6756) or visit **www.myprorenal.com**

Nephroceuticals™ Makers of Smart Nutraceuticals

Discount Code: **CF111**

www.nephroceuticals.com

NEPHROLOGY NURSES & TECHNICIANS PROGRAM

PROGRAM COMMITTEE

Jim Curtis, CHT

Home Dialysis Plus, Ltd., Portland, OR
Program Chair

Lee A. Cauble, BSN, BSB, RN

Desert Dialysis Center, Tucson, AZ
Program Co-Chair

Danilo B. Concepcion, CHT, CCHT

St. Joseph Hospital, Orange, CA

Jackie Crouch

Scott and White Memorial Hospital, Belton, TX

Sheila M. Deziel, RN, BSN, CNN

Hemametrics, Mesa, AZ

Elizabeth Henry, RN, CNN

Scott and White Hospital, Temple, TX

Marianne Neumann, RN, CNN

Albany Dialysis Center, Albany, NY

Heather Paradis, CHT, CCHT

Liberty Dialysis, Nampa, ID

Beverly Sneed, RN, BSN

Abbott Renal Care, Grand Prairie, TX

HOST COMMITTEE

Kay Hall, BSN, RN, CNN

DaVita Inc., Franklin, TN

Kathy Blood, RN, BA

DaVita Inc., Franklin, TN

Anita Tipton, RN, BSN, MSHCA, CNN

Dialysis Clinic Inc, Nashville, TN

PROGRAM GOAL

To improve patient outcomes by enhancing the kidney health care professional's knowledge base and skills which affect the kidney and clinical practice.

CONTINUING EDUCATION INFORMATION

The National Kidney Foundation is an approved provider of continuing nursing education by the New York State Nurses Association, which is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6EXQ7J-PRV-06.

This educational activity has been approved for 30.0 contact hours.

PRE-CONFERENCE COURSES

CKD 101	7.0 credits
Nephrology 201 for Advanced Practitioners	8.0 credits
The Management of the High-Risk Kidney Transplant Recipient: The State of the Art	6.6 credits
Integrated Hemodialysis/ Peritoneal Dialysis	9.5 credits
Dialysis Unit Management	8.0 credits

PRE-CONFERENCE COURSES, EXAMS, & SUNDAY MINI COURSE

CHRONIC KIDNEY DISEASE (CKD) 101

Course Director: Elizabeth Henry, RN, CNN
Wednesday, March 25
7:30am–4:30pm
Session 320 7.0 Credits

TARGET AUDIENCE

This course is designed for nurses and technicians who are new to the field of nephrology or who wish to refresh their knowledge.

COURSE DESCRIPTION

The one-day intensive course discusses the five stages of CKD: presentation, evaluation, complications and treatments.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Describe normal renal anatomy and physiology.
- List the major causes of kidney disease in the adult population.
- Recognize the different stages of kidney disease.
- Describe the steps necessary to prepare the patient for dialysis.
- Outline treatment choices for patients with CKD who require renal replacement therapies.

REQUIRED: Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty Member
7:30am–8:00am Registration and Continental Breakfast	
8:00am–9:15am Review of Normal Renal Anatomy & Physiology	Sheldon C. Chaffer, MD
9:15am–10:00am CKD Stage 1 CKD Stage 2	Sheldon C. Chaffer, MD

10:00am–10:15am

Break

10:15am–11:00am

CKD Stage 3

Sheldon C. Chaffer, MD

11:00am–12:00pm

CKD Stage 4 and
Introduction to Stage 5

Annalisa Perez, MD

12:00pm–1:00pm

Lunch Break

1:00pm–1:30pm

Preparing the Patient
for Dialysis

Annalisa Perez, MD

1:30pm–2:30pm

Treatment Modalities

Annalisa Perez, MD

2:30pm–2:45pm

Break

2:45pm–3:30pm

Vascular Access

Luis Concepcion, MD

3:30pm–4:15pm

Introduction to Transplant

Luis Concepcion, MD

4:15pm–4:30pm

Questions/Answers & Adjourn

NEPHROLOGY 201 FOR ADVANCED PRACTITIONERS

Wednesday, March 25
7:30am–5:30pm
Session 620

See page 66 for course details.

Separate Registration and Fee Required.

THE MANAGEMENT OF HIGH-RISK KIDNEY TRANSPLANT RECIPIENT: THE STATE OF THE ART

Wednesday, March 25
7:30am–5:15pm
Session 220

See page 32 for course details.

Separate Registration and Fee Required.

PRE-CONFERENCE COURSES, EXAMS, & SUNDAY MINI COURSE

INTEGRATED HEMODIALYSIS/PERITONEAL DIALYSIS COURSE

Wednesday, March 25
7:00am–8:00pm
Session 221

See page 33 for course details.

Separate Registration and Fee Required.

DIALYSIS UNIT MANAGEMENT COURSE

Wednesday, March 25
7:30am–5:30pm
Session 223

See page 36 for course details.

Separate Registration and Fee Required.

NNCC CERTIFICATION EXAMS

Sunday, March 29
8:00am–12:00pm
Session 300

Separate Registration and Fee Required.

We are pleased to offer the Nephrology Nursing Certification Commission's (NNCC) certification exams at SCM09. Separate registration fees and registration forms are required to take the certification examinations offered by the Nephrology Nursing Certification Commission (NNCC): Certified Nephrology Nurse (CNN), Certified Dialysis Nurse (CDN), Certified Nephrology Nurse-Nurse Practitioner (CNN-NP), and Certified Clinical Hemodialysis Technician (CCHT).

BONENT EXAMS

Sunday, March 29
8:00am–12:30pm
Session 302

Separate Registration and Fee Required.

The Board of Nephrology Examiners, Nursing and Technology examinations will be held Sunday, March 29th from 8:00am–12:30pm. Please see the NKF Information Booth for detailed room information and instructions.

RENAL PATHOLOGY

Sunday, March 29
7:30am–12:30pm
Session 212

See page 44 for course details.

Separate Registration and Fee Required.

PROGRAM

WEDNESDAY
MARCH 25

TIME/LOCATION	SESSION #	SESSION	NOTES	COURSE DIRECTOR(S)	CREDITS
7:30am–4:30pm					
Governors Ballroom A	320	CKD 101	■	Liz Henry, RN, CNN	7.0
7:30am–5:15pm					
Hermitage C	220	The Management of the High-Risk Kidney Transplant Recipient: The State-of-the-Art	■◆	Milagros D. Samaniego, MD Heidi Schaefer, MD	6.6
7:30am–5:30pm					
Presidential Ballroom A	620	Nephrology 201 for Advanced Practitioners <i>Supported by an unrestricted educational grant from AMAG Pharmaceuticals</i>	■●	Laurie Benton, MPAS, BS, PA-C, RN Kim Zuber, PA-C	7.75
7:00am–8:00pm					
Governors Ballroom B	221	Integrated Hemodialysis/Peritoneal Dialysis Course	■◆	John Burkart, MD	9.5
7:30am–5:30pm					
Hermitage A/B	223	Dialysis Unit Management Course	■◆	Thomas A. Golper, MD	8.0
7:30pm–9:30pm					
Delta Ballroom B	800	Impact of Special Populations and Vitamin D Therapy in Chronic Kidney Disease Outcomes <i>Supported by an unrestricted educational grant from Abbott</i>	◆	Chair: Keith Norris, MD	1.5
		Welcome and Introduction		Keith Norris, MD	
		The Relationship of Special Populations and Cardiovascular Outcomes in CKD Patients		Janice Lea, MD	
		Special Population Differences in CKD and Dialysis Patients: Impact on Survival		Keith Norris, MD	
		Special Population Differences in CKD: The Impact of Vitamin D Therapy		Rajnish Mehrotra, MD, FACP, FASN	
		Discussion with Questions and Answers		All Faculty	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	801	Preventing and Managing Acute Kidney Injury in Patients with Tumor Lysis Syndrome: A Team Approach <i>Supported by an unrestricted educational grant from Sanofi-aventis U.S., Inc.</i>	◆	Chair: A. Ahsan Ejaz, MD, FACP, FASN	1.5
		Welcome and Introduction		A. Ahsan Ejaz, MD, FACP, FASN	
		TLS: An Oncologic and Nephrologic Emergency		Ching-Hon Pui, MD	
		Acute Kidney Injury and TLS		A. Ahsan Ejaz, MD, FACP, FASN	
		Prevention and Treatment of Acute Kidney Injury		Aldo J. Peixoto, MD	
		A Case-Based Interactive Debate—All Faculty Question and Answer Session		All Faculty	
8:00am–9:30am					
Governors Ballroom B	460	Kidney Survivor: Lessons Learned from Experience	●	Cher Thomas, RDH Wendy Rogers, MEd William Dant, MS Aaron Battle, BFA	1.5
8:00am–9:30am					
Washington B	260	Pre-emptive Transplantation and the “Transplant First” Initiative	◆	Co-Chairs: Roy Bloom, MD Anthony Langone, MD	1.5
		The Transplant First Initiative		Robert Gaston, MD	
		Pre-emptive Transplantation: Who, When and How		Panduranga Rao, MD, DNB, MS	
		Pre-emptive Transplantation: A Community Nephrology Perspective		Andrew Howard, MD, FACP	
8:00am–9:30am					
Governors Ballroom D	261	Issues of Dialysis Economics	◆	Co-Chairs: Susan Bray, MD Derrick L. Latos, MD, MACP	1.5
		New Medicare Guidelines for Dialysis Units and Impact		Derrick L. Latos, MD, MACP	
		Medicare Bundling		Rob Blaser	
		Joint Venture for Dialysis Ownership		Chester Amedia Jr, MD, FACP	
9:30am–10:00am					
Break					
10:00am–11:30am					
Presidential Ballroom A	264	Adolescents and CKD: Transition to Adult Nephrology	◆	Co-Chairs: Bradley Warady Kathy Jabs, MD	1.5
		Transition of Adolescents to Adult Care: A “How To” Approach from a Successful Program		Maria Ferris, MD, MPH, PhD	
		What Is the Medical Psychosocial Status of Adolescents with CKD at Time of Transition to Adult Care: Results from the CKiD Study		Bradley Warady, MD	
		The Social Worker Is Crucial to a Successful Transition		Fred Kouri, LMSW	
		Discussion with Audience Participation		All Faculty	

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
10:00am–11:45am					
Jackson D	360	Dealing with Water in Dialysis			1.75
		Understanding Dialysis Water Systems		Jackie Crouch	
		Importance of Ultrapure Water		Richard A. Ward, PhD	
10:00am–11:30am					
Jackson E/F	361	Understanding the Buttonhole Technique		Lynda Ball, RN, MSN, CNN	1.5
12:00pm–2:00pm					
Presidential Ballroom B	362	Council of Nephrology Nurses and Technicians (CNNT) Networking Luncheon—All Are Welcome! <i>Supported by an unrestricted educational grant from Abbott</i>			N/A
		New Technologies for Home Hemodialysis		Jim Curtis, CHT	
2:00pm–2:30pm		Break			
2:30pm–3:30pm					
Presidential Ballroom C/D/E	266	NKF Presidential Address: Transformers: Your NKF and You	◆	Bryan Becker, MD	1.0
		Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!		Mohammed Sayegh, MD	
3:30pm–4:00pm		Break			
4:00pm–5:30pm					
Jackson C/D	363	Developing a Successful Fistula Program		Vo Nguyen, MD	1.5
4:00pm–5:00pm					
Jackson E/F	364	Working with CROWNWeb		Matthew McDonough, MS	1.0
4:00pm–5:30pm					
Magnolia Ballroom	464	The Legal Aspects of Behavior Issues, Patient, Conferences and Agreements	●	Kathy Blood, RN, BA	1.5
6:00pm–7:30pm					
		Opening Ceremonies and Reception in the Exhibit Hall—Visit Posters/Exhibits			

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
7:30pm–9:30pm					
Delta Ballroom B	803	A New Direction in Anemia Management Beyond Erythropoietic Stimulating Agents	◆	Chair: Lynda Szczech, MD, MSCE	1.5
		<i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>			
		Welcome and Introduction		Lynda Szczech, MD, MSCE	
		Overview of Pathophysiology of Iron Deficiency in ESRD Patients		Lynda Szczech, MD, MSCE	
		Strategies for Detecting Iron Deficiency and Iron Excess in ESRD Patients		David B. Van Wyck, MD	
		Strategies for Optimizing Treatment of Iron Deficiency in ESRD Patients		Chaim Charytan, MD	
		Question and Answer Panel Discussion		Chaim Charytan, MD	

FRIDAY
MARCH 27

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	805	Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease	◆	Chair: Vincent W. Dennis, MD	1.5
		<i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>			
		Welcome and Introduction		Vincent W. Dennis, MD	
		Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease		Peter A. McCullough, MD, MPH, FACC	
		Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease		Robert N. Foley, MD	
		Question and Answer Panel Discussion		All Faculty	
7:00am–8:00am					
Continental Breakfast in Exhibit Hall— Visit Posters/Exhibits					
8:00am–9:30am					
Governors Ballroom C	366	Dealing with Disasters from an Interdisciplinary Perspective	●		1.5
		Preparing a Facility for a Disaster		Ed Creamer, BS, JD	
		Nutrition Planning for Dialysis Patients in a Disaster		Paula Frost, RD, CSR, LD	
		Dealing with the Stress after a Disaster		Lisa Hall, MSSW, LCSW	
9:30am–10:00am					
Break					

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
10:00am–11:30am					
Presidential Ballroom C/D/E	275	Debate: Peritoneal Dialysis	◆	Chair: Allan J. Collins, MD, FACP	1.5
		PD Has Better Survival		John Burkart, MD	
		HD Has Better Survival		Bernard Jaar, MD, MPH	
		When Is the Best Time to Transition from PD to In Center/Home HD		John Kevin Tucker, MD	
10:00am–11:30am					
Governors Ballroom B	367	Reduce, Reuse, Recycle		Bertrand Jaber, MD, MS Dwight Morgan	1.5
10:00am–11:30am					
Governors Ballroom C	368	On Course with Cannulation Part 1		Lynda Ball, RN, MSN, CNN	1.5
11:30am–1:00pm					
		Lunch in Exhibit Hall—Visit Posters/Exhibits (Lunch served at 12:00pm)			
1:00pm–2:30pm					
Governors Ballroom C	369	On Course with Cannulation Part 2		Lynda Ball, RN, MSN, CNN	1.5
1:00pm–2:30pm					
Governors Ballroom B	370	Issues in Managing a Dialysis Clinic		Anthony Messana, BSc	1.5
		Effective Facility Management			
		Dealing with the Nursing Shortage			
2:30pm–4:00pm					
Presidential Ballroom A	277	CKD/ESRD and Anticoagulation	■	Co-Chairs: Maria Taylor, PharmD Guillermo Garcia, MD	1.5
		The Risk Benefit Ratio of Anti-Coagulation in ESRD Patients		Donald Brophy, PharmD, MSc	
		Pharmacogenetics Influence of CYP2C9 and VKORC1 on Warfarin Response in Patients with Renal Insufficiency		Nita Limdi, PharmD, PhD	
		HIT		Robert Reilly, MD	
2:30pm–4:00pm					
Magnolia Ballroom	675	Clinical Practices Associated with Improved Outcomes for Hemodialysis Patients in the DOPPS	●	Chair: Bruce Robinson, MD, MS	1.5
		Details of Nutritional Intake and Associated Outcomes in the U.S.		Nancy Ginsberg, MS, RD	
		Cardiovascular Practices and Improved Outcomes		Rajiv Saran, MBBS, MD, MRCP	
		Modifiable Practices Associated with Patient-Reported Outcomes		Francesca Tentori, MD	
		Panel Discussion		All Faculty	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
4:30pm–5:30pm					
Presidential Ballroom C/D/E	279	Challenging Dialysis Patients	■	Chair: Jean Holley, MD	1.5
		Panel Discussion on Challenging Dialysis Patients		Fredric Finkelstein, MD Stephanie Johnstone, LCSW Lee A. Cauble, BSN, . RN Pam Havermann	
6:00pm–7:30pm					
Networking Reception in Exhibit Hall— Visit Posters/Exhibits					
7:30pm–9:30pm					
Delta Ballroom B	804	Bone Fracture in CKD: Clinical Issues and Expert Perspectives	◆	Chair: Hartmut H. Malluche, MD, FACP	1.5
		<i>Supported by an unrestricted educational grant from Amgen</i>			
		Introduction	Hartmut H. Malluche, MD, FACP		
		Fractures in CKD: Epidemiology, Prevention and Treatment	Paul D. Miller, MD		
		Emerging Concepts in Prevention and Treatment	Hartmut H. Malluche, MD, FACP		
		Bone Disease in Kidney Transplant Patients	Margaret Bia, MD		
		Questions and Answers	All Faculty		
7:30pm–9:30pm					
Delta Ballroom C	806	Advances in the Management of Idiopathic Membranous Nephropathy	◆	Chair: Richard J. Glassock, MD	1.5
		<i>Supported by an unrestricted educational grant from Questcor Pharmaceuticals</i>			
		Welcome and Introduction			
		Idiopathic Membranous Nephropathy: All Patients Do Not Require Specific Therapy	Richard J. Glassock, MD		
		Potential New Therapies for the Treatment of Membranous Nephropathies	Fernando C. Fervenza, MD		
		Idiopathic Membranous Nephropathy in the Transplanted Kidney	Sundaram Hariharan, MD		
		Questions and Answers	All Faculty		

**SATURDAY
MARCH 28**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Washington B	371	How Are the New CMS Conditions of Coverage Going?		Glenda Payne, RN, MS, CNN Judith Kari, MSSW, LCISW	1.5
		Facility Surveys		Kay Hall, BSN, RN, CNN	
8:00am–9:30am					
Presidential Ballroom A	281	Vascular Access—Extremes of Age	◆	Co-Chairs: Charmaine Lok, MD William Paulson, MD	1.5
		Debate: All Pediatric HD Patients (>20 kg) Should Have a Fistula (vs a Catheter)		Stuart Goldstein, MD Denis Geary, MB, MRCP, FRCPC	
		Access in the Very Old: Hemocatheter vs AVF/AVG		Ann O'Hare, MD	
8:00am–9:30am					
Governors Ballroom B	283	Pregnancy and Renal Disease	◆	Co-Chairs: Heidi Schaefer, MD Susan Hou, MD	1.5
		Pre-eclampsia with Focus on Novel Findings Re Pathogenesis and Diagnosis		Richard Levine, MD, MPH	
		Hypertension in Pregnancy		Heidi Schaefer, MD	
		CKD, ESRD and Pregnancy: Recommendations, Renal/Patient/Fetal Outcome		Susan Hou, MD	
9:30am–11:30am					
Exhibit Hall Open—Visit Posters/Exhibits (Brunch served at 10:30am)					
11:30am–1:00pm					
Washington B	372	Minimizing Patient Complications During Dialysis			1.5
		Managing the Treatment		Danilo Concepcion, CCHT, CHT	
		Troubleshooting Problems		John Sweeny, BS, CHT	
11:30am–1:00pm					
Presidential Ballroom A	284	Controversies in HD Catheter Related Bacteremia	◆	Co-Chairs: Michele H. Mokrzycki, MD, MS Ann O'Hare, MD	1.5
		Debate: Catheter Related Bacteremia: To Lock or Not to Lock...That Is the Question		Ivan D. Maya, MD vs Michele H. Mokrzycki, MD, MS	
		Debate: Use of Prophylactic Antibiotics in ESRD Patients: Is the Concern for Emerging Resistance Well Founded or an Obstruction to Improving Outcomes?		William Salzer, MD vs Charmaine Lok, MD	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
11:30am–1:00pm					
Presidential Ballroom C/D/E	285	KDOQI: A New Era	◆	Co-Chairs: Michael Rocco, MD, FACP Holly Kramer, MD	1.5
		New KDOQI Initiatives: A Natural Progression		Michael Rocco, MD, FACP	
		Premiering KDOQI Clinical Practice Guideline on Nutrition in Children with CKD: Update 2008—A Case-Based Presentation		Donna Secker, PhD, RD Bradley Warady, MD	
		NKF KDOQI Research Grants—Moving Clinical Care Forward		Holly Kramer, MD and Research Grantees: Chester Fox, MD Josef Coresh, MD	
1:00pm–1:30pm		Break			
1:30pm–3:00pm					
Presidential Ballroom A	289	Home Hemodialysis	◆	Co-Chairs: Christopher Chan, MD Jim Curtis, CHT	1.5
		How to Grow Your Home HD Program		Robert Lockridge, MD	
		Update from the Frequent Hemodialysis Network Randomized Controlled Trial		Michael Rocco, MD, FACP	
		Home/Frequent HD: The Pediatric Perspective		Denis Geary, MB, MRCP, FRCPC	
1:30pm–4:30pm					
Washington B	373	Technician Study Review Course		Heather Paradis, CHT David Fracalossy, CHT, CBNT	3.0
3:00pm–4:30pm					
Lincoln A	374	New Innovations in the Treatment of Renal Failure		Amit Sharma, MD, FACP, FASN	1.5
		Paired Transplants?			
		Bioengineering?			
3:00pm–4:30pm					
Jackson E/F	375	Conditions of Coverage as They Relate to Fluid Management		Diana Hlebovy, RN, BSN, CHN, CNN	1.5
6:00pm–7:00pm					
Governors Ballroom B	101	Health Professionals Networking Reception <i>Supported by an unrestricted educational grant from Watson Nephrology</i>			

SUNDAY
MARCH 29

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
7:30am–12:30pm					
Lincoln E	212	Renal Pathology Mini Course	■● Co-Chairs: Jean Olson, MD Bessie Young, MD, MPH		3.5
8:00am–9:30am					
Presidential Ballroom C	485	Strengthening Adherence in Dialysis Patients	● Bethany Roberts, LICSW Olga Brusilovsky, MS, RD, LD		1.5
8:00am–12:00pm					
Ryman Studio D/E	300	NNCC Exams	■		
8:00am–12:30pm					
Ryman Studio F/G	302	BONENT Exam	■		
9:45am–11:15am					
Presidential Ballroom C	486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	● Kerri Cavanaugh, MD, MHS		1.5
		Nutritional Education and Innovations	Dianne Killebrew, Med, RD, LDN		
11:30am		Meeting Adjourns			

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

NEPHROLOGY NURSES & TECHNICIANS

SESSION OBJECTIVES

THURSDAY
MARCH 26

SESSION #	SESSION	OBJECTIVES
460	Kidney Survivor: Lessons Learned from Experience	<ol style="list-style-type: none"> 1) Explain the early history of dialysis including the “chosen ones”. 2) Explain the benefits of encouraging patients to connect with fellow patients. 3) Explain the benefits that healthcare professionals and patients receive when they encourage and nurture patient involvement. 4) Provide tips on how healthcare professionals can encourage patients. 5) Realize the difference that renal care professionals make in the lives of renal patients.
260	Pre-emptive Transplantation and the “Transplant First” Initiative	<ol style="list-style-type: none"> 1) Summarize the recommendations of the “Transplant First” Initiative Consensus Conference. 2) Identify all patients in your practice who would benefit from pre-emptive kidney transplantation. 3) Recognize the obstacles to pre-emptive transplantation in your practice. 4) Discuss the impact that the implementation of the “Transplant First” Initiative might have in your clinical practice.
261	Issues of Dialysis Economics	<ol style="list-style-type: none"> 1) Review practices and policies of government and private payors. 2) Differentiate between the policies of the Medicare and Medicaid programs. 3) Describe the basic coding and billing issues in dialysis. 4) Review payment issues in dialysis, including recent legislation affecting payment practices.
264	Adolescents and CKD: Transition to Adult Nephrology	<ol style="list-style-type: none"> 1) Identify novel risk factors in the adolescent population for CKD progression. 2) Comprehend the impact of CKD on growth, cognition, behavior and cardiovascular disease. 3) Examine the role of the pediatric nephrologist, adult nephrologist and ancillary staff in the transition of CKD adolescents to adult nephrology. 4) Recognize the key elements of a successful transition program.
360	Dealing with Water in Dialysis	<ol style="list-style-type: none"> 1) Define ultrapure fluids. 2) Discuss the evidence supporting the use of ultrapure fluids. 3) Discuss how ultrapure fluids can be produced. 4) Discuss components of water system.
361	Understanding the Buttonhole Technique	<ol style="list-style-type: none"> 1) List at least two troubleshooting issues that are unique to the buttonhole technique. 2) Describe two differences between cannulating by rotating needle sites and by constant site needling. 3) Explain how patient care staff can reduce the incidence of infection of buttonhole sites.

SESSION #	SESSION	OBJECTIVES
266	NKF Presidential Address: Transformers: Your NKF and You	<ol style="list-style-type: none"> 1) Discuss NKF's organizational structure and goals of the 2007–2010 NKF strategic plan. 2) Review the goals of the 2007–2010 NKF strategic plan. 3) Identify areas of progress and various programs available to assist in successfully meeting these goals. 4) List areas of continued emphasis to achieve the goals of the NKF strategic plan.
	Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!	<ol style="list-style-type: none"> 1) Describe approaches that lead to clinical transplantation tolerance in kidney transplant recipients. 2) Identify the scientific barriers to achieving clinical transplantation tolerance. 3) Review the non-scientific challenges to achieving clinical transplantation tolerance. 4) Summarize the mechanisms and assay development to measure tolerance. 5) List the advantages of tolerance over immunosuppression.
363	Developing a Successful Fistula Program	<ol style="list-style-type: none"> 1) Recognize suitable vessels for mature AV fistula creation 2) Identify problems preventing creation of mature AVF and causing high catheter use 3) Discuss strategies for a successful vascular access program. 4) Recognize how dialysis staff can participate in a vascular access improvement program at a dialysis center level.
364	Working with CROWNWeb	<ol style="list-style-type: none"> 1) Discuss the scope of the first release of CROWNWeb and obtain information on future phases of the CROWNWeb implementation. 2) Outline feedback from the January 2009 CROWNWeb training. 3) Discuss lessons learned from the community and how those lessons may be implemented in future communications and training efforts.
464	The Legal Aspects of Behavior Issues, Patient Conferences and Agreements	<ol style="list-style-type: none"> 1) Recognize a legal document. 2) Explain the difference in laws for hospitals and out-patient settings. 3) Identify both patient and caregiver's rights.

SESSION #	SESSION	OBJECTIVES
366	Dealing with Disasters from an Interdisciplinary Perspective	<ol style="list-style-type: none"> 1) Describe the experiences of ESRD patients and providers with recent disasters. 2) Identify signs and symptoms of trauma experienced by ESRD patients and providers during disasters, and interventions most helpful during the acute trauma phase. 3) Share measures that dialysis and kidney transplant patients can take when planning for disasters to ease stress during and after disasters.
275	Debate: Peritoneal Dialysis	<ol style="list-style-type: none"> 1) Recognize the complexities and problems of comparing mortality in HD and PD. 2) Identify that the risk of death over time is not constant but changing. 3) Recognize that both modalities are still associated with an unacceptably high risk of death.
367	Reduce, Reuse, Recycle	<ol style="list-style-type: none"> 1) Discuss the advantages and disadvantages of dialyzer reuse practices. 2) Compare the advantages and disadvantages of dialyzer single-use practices. 3) Analyze the potential environmental concerns with both dialyzer use practices.
368	On Course with Cannulation Part 1	<ol style="list-style-type: none"> 1) Explain the assessment process for an AV fistula. 2) Describe how stenosis formation occurs with the access, and identify ways that it can be prevented. 3) Demonstrate the correct procedure for the Allen Test.
369	On Course with Cannulation Part 2	<ol style="list-style-type: none"> 1) Discuss the differences between site rotation and the Buttonhole Technique. 2) Identify the assessment criteria in order to cannulate a new AV fistula. 3) Describe the correct needle placement in a reverse flow fistula.
370	Issues in Managing a Dialysis Clinic	<ol style="list-style-type: none"> 1) Explain the revenue and cost structure facility management. 2) Discuss staff recruitment and retention. 3) Identify the impact of regulation on employees and providers.
277	CKD/ESRD and Anticoagulation	<ol style="list-style-type: none"> 1) Recognize the mechanisms by which genetic differences can influence the response to warfarin in CKD patients. 2) Compare the risk/benefit of anticoagulation in ESRD patients. 3) Describe the pathogenesis of heparin induced thrombocytopenia and the reliability of antibody tests in predicting thrombotic events.
675	Clinical Practices Associated with Improved Outcomes for Hemodialysis Patients in the DOPPS	<ol style="list-style-type: none"> 1) Describe the purpose of DOPPS. 2) Identify factors affecting nutritional status in hemodialysis patients. 3) Identify factors affecting cardiovascular outcomes in hemodialysis patients. 4) Describe modifiable clinical practices associated with patient self-reported outcomes.
279	Challenging Dialysis Patients	<ol style="list-style-type: none"> 1) State different approaches in dealing with the difficult dialysis patient. 2) Recognize that in some cases the difficult dialysis patient is dealing with loss of autonomy and control, as well as depression and anger. 3) Summarize how the dialysis team can and must work effectively together to deal with the difficult dialysis patient.

SESSION #	SESSION	OBJECTIVES
371	How are the new CMS Conditions of Coverage Going?	<ol style="list-style-type: none"> 1) Discuss three obstacles for providers in implementing Conditions for Coverage. 2) Identify three strategies for implementing changes required by new Conditions. 3) Describe three benefits of new Conditions for both providers and surveyors.
281	Vascular Access—Extremes of Age	<ol style="list-style-type: none"> 1) List controversies that exist in the Pediatric HD population with respect to vascular access referral. 2) Discuss the present state of vascular access in the Pediatric population. 3) Review the controversies that exist in the Geriatric HD population with respect to vascular access referral. 4) State the controversies that exist about timing of access referral in the Geriatric population. 5) Explain the present state of vascular access in the geriatric population.
283	Pregnancy and Renal Disease	<ol style="list-style-type: none"> 1) Explain the renal physiologic changes in normal pregnancy. 2) Identify the classification system of hypertension in pregnancy and gain knowledge regarding appropriate therapies. 3) Review the pathogenesis and diagnosis of pre-eclampsia with focus on novel findings. 4) List the recommendations regarding pregnancy in CKD/ESRD/Transplant populations. 5) Discuss renal and fetal outcomes associated with pregnancy and kidney disease.
372	Minimizing Patient Complications During Dialysis	<ol style="list-style-type: none"> 1) Discuss common mistakes that can lead to complications. 2) Identify complications not alerted by alarms. 3) List non-clinical incidents that directly effect patients.
284	Controversies in HD Catheter Related Bacteremia	<ol style="list-style-type: none"> 1) Recall the importance of prevention and treatment of catheter-related bacteremia (CRB). 2) Discuss the pathophysiology of CRB and the role of biofilm formation. 3) Review the optimal management of CRB with regard to what to do with the catheter. 4) List the use of both topical and intraluminal antibiotics for the prevention and treatment of CRB. 5) State the risks associated with prophylactic antibiotic use in the hemodialysis setting.
289	Home Hemodialysis	<ol style="list-style-type: none"> 1) State two specific steps that can be taken to help set up a home dialysis program. 2) Identify at least two clinical benefits of more frequent dialysis therapies. 3) Discuss the progress and results of the ongoing randomized NIH clinical trials. 4) Identify how more frequent dialysis impacts pediatric dialysis patients.
373	Technician Study Review Course	<ol style="list-style-type: none"> 1) Discuss the principles of dialysis and how they pertain to the dialysis process. 2) List the components of a water treatment system important monitoring techniques. 3) Describe how dialysis affects patients. 4) Identify three strategies for successful test taking.

SATURDAY
MARCH 28, CONTINUED

SESSION #	SESSION	OBJECTIVES
374	New Innovations in the Treatment of Renal Failure	<ol style="list-style-type: none"> 1) Discuss new concepts in technology. 2) Illustrate the practical implications of the new technology. 3) Describe future applications of developing technology.
375	Conditions of Coverage as They Relate to Fluid Management	<ol style="list-style-type: none"> 1) Discuss the rationale for adding fluid management to the Conditions of Coverage. 2) Review the long-term complications of hemodialysis related to FVE and FVD. 3) State the conditions and interpretive guidelines related to fluid management.

SUNDAY
MARCH 29

SESSION #	SESSION	OBJECTIVES
485	Strengthening Adherence in Dialysis Patients	<ol style="list-style-type: none"> 1) Define issues related to poor adherence in dialysis patients. 2) Identify patient's readiness to learn new behaviors, including the stages of change. 3) Discuss ways to improve and strengthen adherence in dialysis patients.
486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	<ol style="list-style-type: none"> 1) Discuss self-management behaviors (SMB) in CKD/ESRD. 2) Define health literacy and numeracy and its role in CKD. 3) Consider strategies to improve communication to patients with low health literacy/numeracy. 4) Discuss a community based nutrition care process model where nutrition education interventions penetrate the health literacy barrier. 5) Identify tipping point strategies taking food and nutrition messages from once in a while to a lifestyle. 6) Discuss social marketing, food justice and advocacy strategies to drive key messages home to the dinner table.

RENAL AND CLINICAL DIETITIAN PROGRAM

PROGRAM COMMITTEE

Pamela S. Kent, MS, RD, CSR, LD

Genzyme Renal, Vermilion, OH

Program Chair

Marianne Hutton, RD, CSR, CDE

Fresenius Medical Care—North America, Santa Rose, CA

Program Co-Chair

Jerrilynn D. Burrowes, PhD, RD, CDN

C. W. Post Campus of Long Island University, Brookville, NY

Carolyn Cochran, RD, LD, MS, CDE

Dallas Nephrology Associates, Dallas, TX

Ann Cotton, MS, RD

Methodist Hospital, Westfield, IN

Paula Frost, RD, CSR, LD

Lee Street Dialysis, Washington, DC

Aimee Jaremcowicz, RD

DSI—Diversified Specialty Institute, Chicago, IL

Mandy Trolinger, MS, RD

DaVita Littleton Dialysis, Littleton, CO

Mary B. Sundell, RD, LDN, CCRP

Vanderbilt University Medical Center, Nashville, TN

HOST COMMITTEE

Lindy Burns, RD, LDN

DaVita Inc, Cookeville and Gallatin, TN

Cathy Folk, MA, RD, CSR, LDN

DCI Medical Center, Nashville, TN

Jane H. Greene, RD, CSR, LDN

Vanderbilt Medical Center, Nashville, TN

Mary Lollar, RD, LDN

Vanderbilt Dialysis Clinic, Nashville, TN

Sandra Miller, RD, MBA, LDN, CSR

DaVita Dialysis, Nashville, TN

Kathy Reynolds, RD, LDN

DCI Home Training of Middle Tennessee, Nashville, TN

Rita Solomon-Dimmitt, RD, CSR, LDN

Vanderbilt Dialysis Clinic, Nashville, TN


Mary B. Sundell, RD, LDN, CCRP

Vanderbilt University Medical Center, Nashville, TN

Patricia Williams, RD, LDN

DCI Home Training of Middle Tennessee, Nashville, TN

CONTINUING EDUCATION INFORMATION



The National Kidney Foundation is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive up to 31.5 continuing professional education units (CPEUs) for completion of this program/material.

PRE-CONFERENCE COURSES

STRATEGIES I—BUILDING A FOUNDATION

Course Director: Louise Clement, MS, RD, CSR, LD
Wednesday, March 25
8:00am–5:15pm
Session 520, 7.5 CPEUs

TARGET AUDIENCE

This course is designed for dietitians who are new to renal nutrition, as well as for dietitians who work in non-renal settings but wish to strengthen their basic knowledge in this dynamic area.

COURSE DESCRIPTION

Technologies of dialysis, nutrition guidelines, and introductions to dialysis adequacy, anemia management, and bone disease will be presented. Case studies will be presented to illustrate certain principles and will include nutrition diagnostic statements using standardized language, as encouraged by the Standardized Language Task Force of the American Dietetic Association. Participants will gain a solid foundation to practice as an entry-level nutrition specialist in the dialysis setting or in other practice settings with chronic kidney disease, and Stage 5 kidney disease in particular.

COURSE OBJECTIVES

Upon completion of this course, participants will be able to:

- Describe the normal physiology of the kidneys, how it is altered in various types of CKD, and how this affects nutrition therapy.
- Describe the technology of hemodialysis (HD) and peritoneal dialysis (PD). To enhance nutrition intervention in HD and PD by an improved understanding of the methods of each.
- Describe the End Stage Renal Disease (ESRD) program and its place within Centers for Medicare and Medicaid Services (CMS). To describe ESRD Networks and the US Renal Data System (USRDS). To describe Medicare Medical Nutrition Therapy (MNT) reimbursement.
- State the applications of SGA in ESRD and to discuss the components of SGA and how to perform it.
- Recognize major treatment goals and current recommendations for MNT in CKD.
- List laboratory values affected in CKD and in various forms of renal replacement therapy (RRT) and to utilize laboratory data to assess nutrition status in CKD, Stages 3 to 5.

- Identify the impact of diabetes mellitus in CKD, Stages 3 to 5 and to understand the nutrition needs of diabetics with CKD.
- Describe altered bone development in CKD and to understand nutrition intervention in renal osteodystrophy.
- Discuss the development of anemia in CKD and to discuss the evaluation and treatment of anemia in CKD.

REQUIRED: Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:50am–8:00am Welcome and Introductions	Louise Clement, MS, RD, CSR, LD
8:00am–8:30am Physiology of the Kidneys	Janelle Gonyea, RD, LD
8:30am–9:30am Technology of Hemodialysis and Peritoneal Dialysis	Lee A. Cauble, BSN, BSB, RN
9:30am–10:00am Introduction to ESRD Programs	Louise Clement, MS, RD, CSR, LD
10:00am–10:15am BREAK	
10:15am–10:45am MNT for Peritoneal Dialysis	Karen Wiesen, MS, RD, CSR
10:45am–11:45am MNT for Hemodialysis	Marianne Hutton, RD, CSR, CDE
11:45am–12:15pm Subjective Global Assessment	Maureen McCarthy, MPH, RD, CSR, LD
12:15pm–1:00pm LUNCH	
1:00pm–1:45pm Diabetes and the Kidneys	Louise Clement, MS, RD, CSR, LD

PRE-CONFERENCE COURSES

1:45pm–2:30pm	
Understanding Biochemical Markers	Ann Cotton, MS, RD
2:30pm–2:45pm	
Break	
2:45pm–4:15pm	
Basic Principles of Bone Disease in ESRD	Jennifer McGuoirk Filson, MS, RD, CDN
4:15pm–4:55pm	
Basic Principles of Anemia in CKD	Cathy Goeddeke-Merickel, MS, RD, LD
4:55pm–5:15pm	
Evaluations	

STRATEGIES II—TOOLS FOR ADVANCED PRACTICE DIETITIANS IN NEPHROLOGY CARE

Course Director: Jessie Pavlinac, MS, RD, CSR, LD
 Wednesday, March 25
 7:15am–5:00pm
 Session 521, 7.5 credit hours

TARGET AUDIENCE

This course is designed for experienced renal dietitians.

COURSE DESCRIPTION

Participants will benefit from an in-depth review of cutting-edge topics for the dietitian in nephrology care who wants to advance their practice. Experts will examine advanced concepts in physical assessment, nutrition care process and standardized language, and research for the renal dietitian. Nationally recognized leaders in the field of renal nutrition will present topics.

REQUIRED: Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time/Topic	Faculty
7:15am–7:55am	
Registration and Continental Breakfast	
8:00am–8:10am	
Welcome and Introductions	
8:10am–9:10am	
Standards of Professional Performance for Advanced Level Practice for the Dietitian in Nephrology Care	Jessie Pavlinac, MS, RD, CSR, LD
9:10am–9:25am	
Break	
9:25 am–11:30am	
Nutrition Focused Physical Exam for the Nephrology Dietitian	Maureen McCarthy, MPH, RD, CSR, LD
11:30am–12:30pm	
Lunch	
12:30pm–3:00pm	
Advancing Your Practice Using Nutrition Care Process & Standardized Language	Judy Beto, PhD, RD Maureen McCarthy, MPH, RD, CSR, LD
3:00pm–3:15pm	
Break	
3:15pm–4:15pm	
Does Your Practice Reflect the Science and the Regulations?	Karen Wiesen, MS, RD
4:15pm–5:00pm	
Writing for Scientific Publication	Jerrilynn D. Burrowes, PhD, RD, CDN

MOTIVATIONAL INTERVIEWING AND HEALTH COACHING; IMPROVE HEALTH OUTCOMES IN PATIENTS WITH KIDNEY DISEASE

Wednesday, March 25
 8:00am–5:00pm
 Session 421

See page 116 for course details.

Separate Registration and Fee Required.

PROGRAM

WEDNESDAY
MARCH 25

TIME/LOCATION	SESSION #	SESSION	NOTES	COURSE DIRECTOR(S)	CREDITS
8:00am–5:15pm					
Governors Ballroom C	520	Strategies I: Building the Foundation	■	Louise Clement, MS, RD, CSR, LD	7.5
8:00am–5:15pm					
Governors Ballroom D	521	Strategies II: Tools for Advanced Practice Dietitians in Nephrology Care	■	Jessie Pavlinac, MS, RD, CSR, LD	7.5
8:00am–5:00pm					
Jackson C/D	421	Motivational Interviewing and Health Coaching; Improve Health Outcomes in Patients with Kidney Disease	■●	Heather Mercer, PsyD, DrPH	7.0
7:30pm–9:30pm					
Delta Ballroom B	800	Impact of Special Populations and Vitamin D Therapy in Chronic Kidney Disease Outcomes <i>Supported by an unrestricted educational grant from Abbott</i>	◆	Chair: Keith Norris, MD	1.5
		Welcome and Introduction		Keith Norris, MD	
		The Relationship of Special Populations and Cardiovascular Outcomes in CKD Patients		Janice Lea, MD	
		Special Population Differences in CKD and Dialysis Patients: Impact on Survival		Keith Norris, MD	
		Special Population Differences in CKD: The Impact of Vitamin D Therapy		Rajnish Mehrotra, MD, FACP, FASN	
		Discussion with Questions and Answers		All Faculty	

THURSDAY
MARCH 26

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	801	Preventing and Managing Acute Kidney Injury in Patients with Tumor Lysis Syndrome: A Team Approach <i>Supported by an unrestricted educational grant from Sanofi-aventis U.S., Inc.</i>	◆	Chair: A. Ahsan Ejaz, MD, FACP, FASN	1.5
		Welcome and Introduction		A. Ahsan Ejaz, MD, FACP, FASN	
		TLS: An Oncologic and Nephrologic Emergency		Ching-Hon Pui, MD	
		Acute Kidney Injury and TLS		A. Ahsan Ejaz, MD, FACP, FASN	
		Prevention and Treatment of Acute Kidney Injury		Aldo J. Peixoto, MD	
		A Case-Based Interactive Debate—All Faculty Question and Answer Session		All Faculty	

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Governors Ballroom B	460	Kidney Survivor: Lessons Learned from Experience	●	Cher Thomas, AAS Wendy Rogers, MEd Bill Dant, MS Aaron Battle	1.5
8:00am–9:30am					
Presidential Ballroom A	262	Acute Kidney Injury: Identification and Treatment	◆	Co-Chairs: Kathleen Liu, MD Emil Paganini, MD, FACP, FRCP	1.5
		Epidemiology of AKI		Edward Siew, MD	
		New Interventions		Kathleen Liu, MD	
		Role of Biomarkers in AKI		Chirag Parikh, MD	
9:30am–10:00am					
Break					
10:00am–11:30am					
Washington B	560	Obesity Pre-Transplant: Predictor of Post Transplant Outcomes?		Helen L. Carr, RD, CSR, LD, CDE	1.5
10:00am–11:30am					
Lincoln A	561	Getting the Dialysis Patient Through Radiation and Chemo		Teri Borho, RD, CD	1.5
10:00am–11:30am					
Presidential Ballroom A	264	Adolescents and CKD: Transition to Adult Nephrology	◆	Co-Chairs: Bradley Warady Kathy Jabs, MD	1.5
		Transition of Adolescents to Adult Care: A “How To” Approach from a Successful Program		Maria Ferris, MD, MPH, PhD	
		What Is the Medical Psychosocial Status of Adolescents with CKD at Time of Transition to Adult Care: Results from the CKiD Study		Bradley Warady, MD	
		The Social Worker Is Crucial to a Successful Transition		Fred Kouri, LMSW	
		Discussion with Audience Participation		All Faculty	
12:00pm–2:00pm					
Governors Ballroom A	562	Council on Renal Nutrition (CRN) Networking Luncheon: From a Great Past to a Greater Future All Are Welcome! <i>Supported by an unrestricted educational grant from Abbott</i>		Keynote Speaker: Paul Teschan, MD	N/A
2:00pm–2:30pm					
Break					
2:30pm–3:30pm					
Presidential Ballroom C/D/E	266	NKF Presidential Address: Transformers: Your NKF and You	◆	Bryan Becker, MD	1.0
		Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!		Mohammed Sayegh, MD	

◆ Joint with Physicians

◆ Joint with Councils

■ Separate Registration and/or Fee Required

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
3:30pm–4:00pm					
Washington B	563	Joel D. Kopple Award: The Critical Role of Dietary Counseling in the Outcome of ESRD Patients		Raymond Hakim, MD, PhD	0.5
4:00pm–5:30pm					
Washington B	564	The Road-Less-Traveled: Alternate Careers for Renal Dietitians		Chair: Jerrilynn Burrowes, PhD, RD, CDN Linda Moore, RD, LD, CCRP Pam Kent, MS, RD, CSR, LD Maria Karalis, MBA, RD, LDN Mary Sundell, RD, LDN, CCRP Debbie Benner, RD, CSR	1.5
4:00pm–5:30pm					
Presidential Ballroom C/D/E	267	KDIGO Guideline for the Care of the Kidney Transplant Recipient	◆	Co-Chairs: Bertram Kasiske, MD Cathy Garvey, RN, CCTC	1.5
		Overview of KDIGO and the Guideline Process		Bertram Kasiske, MD	
		Examples of Guidelines		Michelle Josephson, MD	
		Examples of Guidelines		Cathy Garvey, RN, CCTC	
		Panel Discussion		All Faculty	
4:00pm–5:30pm					
Governors Ballroom B	269	Diabetes Mellitus	◆	Co-Chairs: William F. Keane, MD Maria Taylor, PharmD	1.5
		Introduction to Diabetic Nephropathy		William F. Keane, MD	
		Pandemic of Diabetic Nephropathy Is Declining		Eli A. Friedman, MD, MACP, FRCP	
		Use of Combination Therapies for Diabetic Nephropathy and Proteinuria		Jamie Dwyer, MD	
		Update on Newer Treatments for Diabetic Control		Craig Williams, PharmD	
6:00pm–7:30pm					
Opening Ceremonies and Reception in the Exhibit Hall—Visit Posters/Exhibits					
7:30pm–9:30pm					
Delta Ballroom B	803	A New Direction in Anemia Management Beyond Erythropoietic Stimulating Agents <i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>	◆	Chair: Lynda Szczech, MD, MSCE	1.5
		Welcome and Introduction		Lynda Szczech, MD, MSCE	
		Overview of Pathophysiology of Iron Deficiency in ESRD Patients		Lynda Szczech, MD, MSCE	
		Strategies for Detecting Iron Deficiency and Iron Excess in ESRD Patients		David B. Van Wyck, MD	
		Strategies for Optimizing Treatment of Iron Deficiency in ESRD Patients		Chaim Charytan, MD	
Question and Answer Panel Discussion				All Faculty	

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	805	Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease <i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>	◆	Chair: Vincent W. Dennis, MD	1.5
		Welcome and Introduction		Vincent W. Dennis, MD	
		Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease		Peter A. McCullough, MD, MPH, FACC	
		Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease		Robert N. Foley, MD	
		Question and Answer Panel Discussion		All Faculty	
7:00am–8:00am					
Continental Breakfast in the Exhibit Hall— Visit Posters/Exhibits					
8:00am–9:30am					
Lincoln A	565	Ready, Set, Go: The How’s and Why’s of Research		Co-Chairs: Jerrilynn Burrowes, PhD, RD, CDN Mary Sundell, RD, LDN, CCRP	1.5
		Why Should the RD Do Research?		Linda Moore, RD, LD, CCRP	
		What Is the Research Process: How to Develop a Problem Statement?		Jerrilynn Burrowes, PhD, RD, CDN	
		A Librarian’s Tips and Tricks for Improved Literature Searching		Jennifer Lyon, MS	
8:00am–9:30am					
Governors Ballroom C	366	Dealing with Disasters from an Interdisciplinary Perspective	●		1.5
		Preparing a Facility for a Disaster		Ed Creamer, BS, JD	
		Nutrition Planning for Dialysis Patients in a Disaster		Paula Frost, RD, CSR, LD	
		Dealing with the Stress after a Disaster		Lisa Hall, MSSW, LCSW	
8:00am–9:30am					
Presidential Ballroom A	272	Hypertension Management Related to CKD Stage	◆	Co-Chairs: Kirsten Johansen, MD Ruth Campbell, MD	1.5
		Impact of CKD Stage 1 and 2 on Hypertension		Ruth Campbell, MD	
		Hypertension in Stage 2–4		Raymond Townsend, MD	
		Hypertension in Stage 5 and ESRD		Rajiv Agarwal, MBBS, MD, FAHA, FASN	
9:30am–10:00am					
Break					

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
10:00am–12:00pm					
Lincoln A	566	Research: Documenting the Process		Co-Chairs: Jerrilynn Burrowes, PhD, RD, CDN Mary Sundell, RD, LDN, CCRP	1.5
		IRB Overview: The Good, The Bad, and The Truth		Jan Zolkower, MSHL, CIP, CCRP	
		Planning and Implementing Data Collection		Paul Harris, PhD	
		Biostatistics 101: Strategy for Clinical Research		Judy Beto, PhD, RD	
10:00am–11:30am					
Washington B	567	Diabetes		Carole A. Conn, PhD, RD, CSSD, FACSM	1.5
10:00am–11:30am					
Presidential Ballroom C/D/E	275	Debate: Peritoneal Dialysis	◆	Chair: Allan J. Collins, MD, FACP	1.5
		PD Has Better Survival		John Burkart, MD	
		HD Has Better Survival		Bernard Jaar, MD, MPH	
		When Is the Best Time to Transition from PD to In Center/Home HD		John Kevin Tucker, MD	
12:00pm–1:15pm					
Lunch in the Exhibit Hall—Visit Posters/Exhibits (Lunch served at 12:00pm)					
12:00pm–2:00pm					
Hermitage D	242	Workshop: Long-Term Complications of Kidney Transplantation	■◆	Co-Chairs: Michael Hofmann, MD Michelle Josephson, MD	2.0
		Infectious Complications in Kidney Transplantation		Nasia Safdar, MD	
		Cardiovascular Disease in Kidney Transplant Patients		Heidi Schaefer, MD	
		Bone Disease in CKD and Kidney Transplantation		Michelle Josephson, MD	
1:15pm–2:15pm					
Washington B	568	Cutting-Edge Research in Nephrology Nutrition		Co-Chairs: Jerrilynn Burrowes, PhD, RD, CDN Mary Sundell, RD, LDN, CCRP	1.0
		Comparison of Predicted Resting Metabolic Rate to Measured Metabolic Rate in Maintenance Dialysis Patients		Jackie Carder, MS, RD, LMNT Kay Taylor, RD,CDE	
		Effect of Aggressive Osteodystrophy Management of Clinical Outcomes in Stage 5 CKD		Laura Byham-Gray, PhD, RD, CNSD	
		Vitamin and Mineral Supplement Use in the HEMO Study		June Leung Fung, RD	
1:15pm–2:15pm					
Lincoln A	569	Legislative Update		Mary Hagar, PhD, RD, FADA Dolph Chianchiano	1.0
2:15pm–2:30pm					
Break					

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
2:30pm–4:00pm					
Washington B	570	GI Panel		Chair: Ann Cotton, MS, RD, CNSD	1.5
		Gastroparesis		Carol Rees Parrish, MS, RD	
		Chronic Pancreatitis		Sarita Bajpai, PhD	
		Ostomy		Kate Willcutts, MS, RD, CNSD	
2:30pm–4:00pm					
Governors Ballroom B	571	Eating Disorders and Renal Nutrition: Anorexia, Bulimia and Dialysis		Therese Shumaker, MS, RD, LD	1.5
2:30pm–4:00pm					
Presidential Ballroom A	278	Geriatric Nephrology	◆	Co-Chairs: Linda Fried, MD, MPH Gregorio Obrador, MD	1.5
		Cognitive Function/Dementia in Dialysis Patients—Prevalence/Screening, Etiology		Manjula Tamura, MD	
		CKD in the Elderly—Physiologic Aging or a Disease?		Linda Fried, MD, MPH	
		Hypertension in the Elderly		Mark Supiano, MD	
4:00pm–4:30pm					
4:30pm–5:30pm					
Presidential Ballroom C/D/E	279	Challenging Dialysis Patients	◆	Chair: Jean Holley, MD	1.0
		Panel Discussion on Challenging Dialysis Patients		Fredric Finkelstein, MD Stephanie Johnstone, LCSW Lee A. Cauble, BSN, RN, CHT Pam Havermann	
4:30pm–5:30pm					
Presidential Ballroom A	280	Wasting Syndrome in CKD	◆	Co-Chairs: Kirsten Johansen, MD Srinivasan Beddhu, MD	1.0
		Is Malnutrition a Misnomer?		Srinivasan Beddhu, MD	
		Anabolic Hormones in Uremic Wasting		Kirsten Johansen, MD	
		Inflammation and Uremic Wasting		Adriana M. Hung, MD, MPH	
4:30pm–6:00pm					
Lincoln A	572	Research: Writing for Dollars		Co-Chairs: Jerrilynn Burrowes PhD, RD, CDN Mary Sundell, RD, LDN, CCRP	1.5
		Writing Effective Research Proposals for Funding? What Are the Reviewers Looking for?		Kathleen Liu, MD	
		Sources of Research Funding for the Dietitian		Johanna Dwyer, DSc, RD	
		How to Write an Abstract/Develop a Poster for Presentation?		Jerrilynn Burrowes, PhD, RD, CDN	
		Oral Abstract Presentation: Nutritional Interventions for Management of Osteodystrophy in HD Patients: A Developing Country Model		Mirey Karavetian, MS	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00pm–7:30pm					
		Networking Reception in Exhibit Hall— Visit Posters/Exhibits			
7:30pm–9:30pm					
Delta Ballroom B	804	Bone Fracture in CKD: Clinical Issues and Expert Perspectives <i>Supported by an unrestricted educational grant from Amgen</i>	♦ Chair: Hartmut H. Malluche, MD, FACP		1.5
		Introduction		Hartmut H. Malluche, MD, FACP	
		Fractures in CKD: Epidemiology, Prevention and Treatment		Paul D. Miller, MD	
		Emerging Concepts in Prevention and Treatment		Hartmut H. Malluche, MD, FACP	
		Bone Disease in Kidney Transplant Patients		Margaret Bia, MD	
		Questions and Answers		All Faculty	
7:30pm–9:30pm					
Delta Ballroom C	806	Advances in the Management of Idiopathic Membranous Nephropathy <i>Supported by an unrestricted educational grant from Questcor Pharmaceuticals</i>	♦ Chair: Richard J. Glasscock, MD		1.5
		Welcome and Introduction			
		Idiopathic Membranous Nephropathy: All Patients Do Not Require Specific Therapy		Richard J. Glasscock, MD	
		Potential New Therapies for the Treatment of Membranous Nephropathies		Fernando C. Fervenza, MD	
		Idiopathic Membranous Nephropathy in the Transplanted Kidney		Sundaram Hariharan, MD	
		Questions and Answers		All Faculty	

SATURDAY
MARCH 28

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom B	573	Micronutrient Homeostasis in Functional Deficit: Physiology, Assessment, Replacement: Part I		Mary Pat Kelly, RD, RN, RNP	1.5
8:00am–9:30am					
Governors Ballroom B	283	Pregnancy and Renal Disease	♦ Co-Chairs: Heidi Schaefer, MD, Susan Hou, MD		1.5
		Hypertension in Pregnancy		Heidi Schaefer, MD	
		Pre-Eclampsia with Focus on Novel Findings Re Pathogenesis and Diagnosis		Richard Levine, MD, MPH	
		CKD, ESRD and Pregnancy: Recommendations, Renal/Patient/Fetal Outcome		Susan Hou, MD	

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
9:30am–11:30am					
		Exhibit Hall—Visit Posters/Exhibits (Brunch served at 10:30am)			
11:30am–1:00pm					
Presidential Ballroom B	574	Inflammation and Biomarker of Nutrition		Adriana M. Hung, MD, MPH	1.5
11:30am–1:00pm					
Presidential Ballroom C/D/E	285	KDOQI: A New Era	◆	Co-Chairs: Michael Rocco, MD Holly Kramer, MD	1.5
		New KDOQI Initiatives: A Natural Progression		Michael Rocco, MD	
		KDOQI Clinical Practice Guideline on Nutrition in Children with CKD: Update 2008—A Case-Based Presentation		Donna Secker, PhD, RD Bradley Warady, MD	
		NKF KDOQI Research Grants—Moving Clinical Care Forward		Holly Kramer, MD Research Grantees: Chester Fox, MD Josef Coresh, MD	
1:00pm–1:30pm		Break			
1:30pm–3:00pm					
Lincoln A	575	The Impact of the Obesity Epidemic: Alternative Approaches to the Treatment of Obesity Through Meditation and Stress Reduction		Luis (Phil) Ramos, MD, MSCI Debra Conneely, MSW, LSW	1.5
1:30pm–3:00pm					
Delta Ballroom C	576	MNT and CKD		Carolyn Cochran, RD, LD, MS, CDE Kathy Schiro Harvey, MS, RD, CSR	1.5
1:30pm–3:00pm					
Jacksoin E/F	481	Communicating with People Who Have Dementia	●	Melissa Fry, CAPSW	1.5
3:00pm–3:30pm		Break			
3:30pm–5:00pm					
Governors Ballroom B	286	Diabetic Nephropathy, Cardiovascular Risk and Metabolic Syndrome	◆	Co-Chairs: Mark Sarnak, MD Manjula Tamura, MD, MPH	1.5
		Is the Metabolic Syndrome an Independent Risk Factor for Kidney Disease or Does This Represent Hypertension/Glycemia?		Manjula Tamura, MD, MPH	
		Cardiac Biomarkers in CKD—Issues with Interpretation and Practical Points (e.g., Troponins, BNP)		Mark Sarnak, MD	
		Update on Glycemic Control and Cardiovascular Outcomes and Implications for Target HbA1C		Stephen N. Davis, MD, FRCP	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

SATURDAY
MARCH 28, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
3:30pm–5:00pm					
Presidential Ballroom B	577	Micronutrient Homeostasis in Functional Deficit: Physiology, Assessment, Replacement: Part II		Mary Pat Kelly, RD, RN, RNP	1.5
3:30pm–5:00pm					
Presidential Ballroom A	578	Grey's Anatomy: The Neighborhood Drama of Renal Physiology		Beth McQuiston, MD, MS, RD, LDN	1.5
6:00pm–7:00pm					
Governors Ballroom B	101	Health Professionals Networking Reception <i>Supported by an unrestricted educational grant from Watson Nephrology</i>	●		

SUNDAY
MARCH 29

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom C	485	Strengthening Adherence in the Dialysis Patient	●	Bethany Roberts, LICSW Olga Brusilovsky, RD, LD	1.5
8:00am–9:30am					
Presidential Ballroom D	292	Kidney Stones		Co-Chairs: John Kevin Tucker, MD Eric Taylor, MD, MSc	1.5
		Assessment of Risk Factors for Stone Disease/Dietary Treatment of Stone Disease		Eric Taylor, MD, MSc	
		Indications for Urologic Intervention		Margaret Pearle, MD, PhD	
		Kidney Stones in Pregnancy		Susan Hou, MD	
9:45am–11:15am					
Presidential Ballroom C	486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	●	Kerri Cavanaugh MD, MHS	1.5
		Nutritional Education and Innovations		Dianne Killebrew, Med, RD, LDN	
9:45am–11:15am					
Presidential Ballroom B	293	Electrolytes	◆	Chair: Harold M. Szerlip, MD, FACP, FASN	1.5
		Hypokalemia		Kamel Kamel, MD FRCP(C)	
		Disorders of Calcium Sensors		Zalman Agus, MD	
		Hypomagnesemia		Robert Reilly, MD	
		Hypernatremia Hospital Acquired		Paul Palevsky, MD	
11:30am		Meeting Adjourns			

RENAL & CLINICAL DIETITIAN SESSION OBJECTIVES

**THURSDAY
MARCH 26**

SESSION #	SESSION	OBJECTIVES
460	Kidney Survivor: Lessons Learned from Experience	<ol style="list-style-type: none"> 1) Explain the early history of dialysis including the criteria for determining who was selected for treatment. 2) Explain the benefits of encouraging patients to connect with fellow patients. 3) Explain the benefits that healthcare professionals and patients receive when they encourage and nurture patient involvement. 4) Provide tips on how healthcare professionals can support and encourage patients. 5) Realize the difference that renal care professionals make in the lives of renal patients.
262	Acute Kidney Injury: Identification and Treatment	<ol style="list-style-type: none"> 1) Discuss the epidemiology of acute kidney injury, including recent temporal trends in the incidence of and outcomes from AKI. 2) Review the potential role of biomarkers for the diagnosis of acute kidney injury. 3) Identify novel biomarkers and review novel interventions for the treatment of acute kidney injury.
560	Obesity Pre-Transplant: Predictor of Post Transplant Outcomes?	<ol style="list-style-type: none"> 1) Discuss obesity as it relates to outcomes in renal transplantation cases. 2) Identify the role of the dietitian in weight management during the pre-transplant evaluation. 3) Describe several case studies involving obesity and renal transplantation.
561	Getting the Dialysis Patient Through Radiation and Chemo	<ol style="list-style-type: none"> 1) Recognize various types of medical therapies for the treatment of cancer. 2) Review several side effects of cancer treatments, and how they can impact nutrient intake and nutritional status. 3) Discuss management strategies for cancer treatment side effects.
264	Adolescents and CKD: Transition to Adult Nephrology	<ol style="list-style-type: none"> 1) Identify novel risk factors in the adolescent population for CKD progression. 2) Comprehend the impact of CKD on growth, cognition, behavior and cardiovascular disease. 3) Examine the role of the pediatric nephrologist, adult nephrologist and ancillary staff in the transition of CKD adolescents to adult nephrology. 4) Recognize the key elements of a successful transition program.
266	NKF Presidential Address: Transformers: Your NKF and You	<ol style="list-style-type: none"> 1) Discuss NKF's organizational structure and goals of the 2007–2010 NKF strategic plan. 2) Review the goals of the 2007–2010 NKF strategic plan. 3) Identify areas of progress and various programs available to assist in successfully meeting these goals. 4) List areas of continued emphasis to achieve the goals of the NKF strategic plan.
	Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!	<ol style="list-style-type: none"> 1) Describe approaches that lead to clinical transplantation tolerance in kidney transplant recipients. 2) Identify the scientific barriers to achieving clinical transplantation tolerance. 3) Review the non-scientific challenges to achieving clinical transplantation tolerance. 4) Summarize the mechanisms and assay development to measure tolerance. 5) List the advantages of tolerance over immunosuppression.

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

THURSDAY
MARCH 26, CONTINUED

SESSION #	SESSION	OBJECTIVES
563	Joel D. Kopple Award: The Critical Role of Dietary Counseling in the Outcome of ESRD Patients	<ol style="list-style-type: none"> 1) Discuss factors that predispose dialysis patients for protein and energy wasting. 2) Identify actionable outcomes that can improve the dialysis patient's nutritional status. 3) Evaluate the role of improvement in serum albumin on patient outcomes. 4) Highlight the important role of dietitians and dietary counseling on dialysis patient outcomes.
564	The Road-Less-Traveled: Alternate Careers for Renal Dietitians	<ol style="list-style-type: none"> 1) Identify ways to increase your visibility to employers. 2) Explore ways to "brand" yourself. 3) Identify ways to improve verbal communication skills. 4) Define the study coordinator role to take research from a grant proposal to an active study. 5) Describe the regulatory process to do research. 6) Recall tools used by the research dietitian. 7) List at least 3 non-typical roles for the nephrology dietitian. 8) Describe attributes that enable a dietitian to be promoted to a non-typical role. 9) Describe how to apply for a non-typical role.
267	KDIGO Guideline for the Care of the Kidney Transplant Recipient	<ol style="list-style-type: none"> 1) Review the KDIGO clinical practice guideline development process. 2) Describe the GRADE system for rating evidence and strength of recommendations. 3) Discuss recommended initial and maintenance immunosuppressive agents for kidney transplant recipients. 4) Recognize the basic infection prophylaxis strategies for kidney transplant recipients.
269	Diabetes Mellitus	<ol style="list-style-type: none"> 1) Recognize the new classes of medications for diabetic control and the targeted groups for their use. 2) Discuss approaches targeting the renin angiotensin system with combination therapy, including the status and limitations of the current data on slowing progression of nephropathy. 3) Review the epidemiology of diabetic nephropathy and projections for ESRD. 4) Differentiate between the targets for prevention of microvascular and macrovascular diabetic complications.

FRIDAY
MARCH 27

SESSION #	SESSION	OBJECTIVES
565	Ready, Set, Go: The How's and Why's of Research	<ol style="list-style-type: none"> 1) Describe criteria that can be used to evaluate a research topic. 2) Identify sources of a research topic. 3) Transform a research topic into a researchable problem statement. 4) Verbalize the steps in the research process. 5) Recognize an acceptable problem statement.

SESSION #	SESSION	OBJECTIVES
366	Dealing with Disasters from an Interdisciplinary Perspective	<ol style="list-style-type: none"> 1) Describe the experiences of ESRD patients and providers with recent disasters. 2) Identify signs and symptoms of trauma experienced by ESRD patients and providers during disasters, and interventions most helpful during the acute trauma phase. 3) Share measures that dialysis and kidney transplant patients can take when planning for disasters to ease stress during and after disasters.
272	Hypertension Management Related to CKD Stage	<ol style="list-style-type: none"> 1) Understand the recommended blood pressure targets for different stages of CKD and the evidence that supports them. 2) Identify the evidence supporting the advantages and disadvantages of using different antihypertensive agents in different stages of CKD. 3) Describe the role of achieved blood pressure and of specific antihypertensive agents in reducing proteinuria.
566	Research: Documenting the Process	<ol style="list-style-type: none"> 1) Define human subject research and IRB. 2) Discuss the need to have IRB approval when conducting research on humans. 3) Discuss tips for determining the type of IRB submission and how to have a positive IRB experience. 4) Review how to ensure adequate data planning prior to initiation of research. 5) Review important data collection concepts. 6) Discuss practical methods for research teams—‘easy ways to do the right thing’.
567	Diabetes	<ol style="list-style-type: none"> 1) Describe the magnitude of the global obesity/diabetes problem. 2) Explain the mechanisms underlying the progression to Type 2 diabetes. 3) Interpret current research documenting methods that delay the diagnosis of diabetes.
275	Debate: Peritoneal Dialysis	<ol style="list-style-type: none"> 1) Recognize the complexities and problems of comparing mortality in HD and PD. 2) Identify that the risk of death over time is not constant but changing. 3) Recognize that both modalities are still associated with an unacceptably high risk of death.
242	Workshop: Long-Term Complications of Kidney Transplantation	<ol style="list-style-type: none"> 1) Recognize risk factors for infections, cardiovascular and bone disease in kidney transplant patients in your practice. 2) Identify the microbial pathogens responsible for acute and chronic infections in kidney transplant recipients. 3) Discuss the management of infectious diseases in kidney transplant recipients with emphasis in newly identified pathogens and prevention. 4) Examine and compare the natural history and management of cardiovascular disease in kidney transplant recipients. 5) Appraise the incidence/prevalence of different forms of bone disease in your kidney transplant patients and summarize their treatment.
568	Cutting-Edge Research in Nephrology Nutrition	<ol style="list-style-type: none"> 1) Identify the different methods for management of bone disease. 2) Describe the long-term effects of mineral and bone disorders in stage 5 CKD. 3) Determine effective strategies in bone disease management. 4) Discuss the relationship between folic acid and its association with plasma homocysteine and cardiovascular and stroke morbidity and mortality. 5) Explain the rationale and methods for the study of folic acid vitamin supplement use and cardiovascular and stroke mortality in hemodialysis patients. 6) Discuss the results and clinical implications of the findings in the study.

SESSION #	SESSION	OBJECTIVES
569	Legislative Update	<ol style="list-style-type: none"> 1) Define how state and federal rules and regulations differ from statutes and are formulated with the intent to ensure safe and quality renal patient care. 2) Describe the ways to make positive and productive impact and contributions to public policy initiatives that impact renal dietitians and patients. 3) Participate in advocacy efforts that promote the recognition of the renal dietitian and quality nutrition care.
570	GI panel	<ol style="list-style-type: none"> 1) Review normal gastric function as well as gastroparesis and the nutritional assessment and therapy for this condition. 2) Define the etiology and signs and symptoms of chronic pancreatitis in patients on renal replacement therapy. 3) Provide nutritional assessments of patients with various gastrointestinal problems. 4) Discuss nutrition support options for patients with chronic pancreatitis on renal replacement therapy (RRT). 5) Describe the nutrition-related issues associated with colostomies. 6) List the nutrition-related issues associated with ileostomies. 7) Explain how multiple factors must be considered to individualize the nutritional goals for patients with ostomies.
571	Eating Disorders and Renal Nutrition: Anorexia, Bulimia, and Dialysis	<ol style="list-style-type: none"> 1) Define electrolyte abnormalities and suggest appropriate repletion and hydration for the dialysis patient with an eating disorder. 2) Discuss the challenges and strategies used to improve energy and protein intake. 3) Discuss the importance of behavioral modification and learn how to utilize behavioral interventions in dialysis patients diagnosed with an eating disorder.
278	Geriatric Nephrology	<ol style="list-style-type: none"> 1) Discuss the epidemiology of aging and loss of kidney function. 2) Recognize the benefits and challenges of treating hypertension in the elderly. 3) Recall the high prevalence of cognitive impairment in CKD and dialysis patients and the implications for care.
279	Challenging Dialysis Patients	<ol style="list-style-type: none"> 1) State different approaches in dealing with the difficult dialysis patient. 2) Recognize that in some cases the difficult dialysis patient is dealing with loss of autonomy and control, as well as depression and anger. 3) Summarize how the dialysis team can and must work effectively together to deal with the difficult dialysis patient.
280	Wasting Syndrome in CKD	<ol style="list-style-type: none"> 1) Review the literature on the role of anabolic and catabolic processes in causing wasting syndrome in uremic patients. 2) State the effects of anabolic hormones on muscle mass in dialysis patients. 3) Discuss the literature on inflammation and anti-inflammatory therapy for wasting syndrome in uremia.
572	Research: Writing for Dollars	<ol style="list-style-type: none"> 1) Describe the purpose of an abstract and poster presentation. 2) List the steps to develop an abstract for presentation. 3) List the steps to develop a poster for presentation.

SESSION #	SESSION	OBJECTIVES
573	Micronutrient Homeostasis in Functional Deficit: Physiology, Assessment, Replacement: Part I	<ol style="list-style-type: none"> 1) State three (3) major etiologies of irritated, painful oral mucosa. 2) Cite roles that inadequate iron, niacin, V-B6, V-B12, folate play in oral pathology. 3) Itemize treatment therapies for oral Candida. 4) Describe environmental exposures that might complicate oral health.
283	Pregnancy and Renal Disease	<ol style="list-style-type: none"> 1) Explain the renal physiologic changes in normal pregnancy. 2) Identify the classification system of hypertension in pregnancy and gain knowledge regarding appropriate therapies. 3) Review the pathogenesis and diagnosis of pre-eclampsia with focus on novel findings. 4) List the recommendations regarding pregnancy in CKD/ESRD/Transplant populations. 5) Discuss renal and fetal outcomes associated with pregnancy and kidney disease.
574	Inflammation and Biomarker of Nutrition	<ol style="list-style-type: none"> 1) State the definition and epidemiology of Protein Energy Wasting (PEW). 2) Describe the pathophysiology of PEW and the role that inflammation plays in PEW vs. poor nutritional intake. 3) Review potential treatments for PEW.
285	KDOQI: A New Era	<ol style="list-style-type: none"> 1) Review the new KDOQI initiatives in areas outside of guideline development. 2) List the changes to the KDOQI Nutritional Guideline for Children with CKD: Update 2008. 3) State aspects of the new KDOQI research grant program.
286	Diabetic Nephropathy, Cardiovascular Risk and Metabolic Syndrome	<ol style="list-style-type: none"> 1) Review the new data from studies of glucose control and cardiovascular outcomes and the implications for care and target HbA1c. 2) Identify the use and interpretation of cardiac biomarkers in the setting of CKD. 3) State the prevalence of the metabolic syndrome, its association with cardiovascular disease and the potential mediators of the risk of CVD.
575	The Impact of the Obesity Epidemic in CKD: Alternative Approaches to the Treatment of Obesity through Meditation & Stress Reduction	<ol style="list-style-type: none"> 1) Describe relaxation techniques to help patients reduce stress and lose weight. 2) Teach patients to reduce the stress they feel by gentle stretches, proper breathing, meditation postures, and guided meditation. 3) Recognize the importance of the body/mind connection in working with patients to lose weight. 4) Identify how to assist patients reconnect body with mind through meditation.
576	MNT and CKD	<ol style="list-style-type: none"> 1) Describe nutrition risks associated with CKD. 2) Identify appropriate interventions to prevent and/or treat nutrition risks. 3) Discuss appropriate treatments for additional CKD complications..
481	Communicating with People Who Have Dementia	<ol style="list-style-type: none"> 1) Identify different types of dementia. 2) Define validation. 3) Identify benefits of validation. 4) Identify validation goals. 5) Describe the four phases of resolution. 6) Describe validation techniques to use in the dialysis setting.

SATURDAY
MARCH 28, CONTINUED

SESSION #	SESSION	OBJECTIVES
577	Micronutrient Homeostasis in Functional Deficit: Physiology, Assessment, Replacement: Part II	<ol style="list-style-type: none"> 1) Identify newly defined roles of V-B12, V-D, and electrolyte balance in fall prevention. 2) Discuss the role diuretics, ACE inhibitors place in electrolyte imbalance. 3) Recall the need for V-C, Zinc, Cu in wound healing and balance their role in renal failure.
578	Grey's Anatomy: The Neighborhood Drama of Renal Physiology	<ol style="list-style-type: none"> 1) Describe renal physiology. 2) Apply the principles of acid base balance, acute renal failure and chronic renal failure. 3) Use the principles of hormone and electrolyte imbalances with chronic renal failure.

SUNDAY
MARCH 29

SESSION #	SESSION	OBJECTIVES
485	Strengthening Adherence in Dialysis Patients	<ol style="list-style-type: none"> 1) Define issues related to poor adherence in dialysis patients. 2) Identify patient's readiness to learn new behaviors, including the stages of change. 3) Discuss ways to improve and strengthen adherence in dialysis patients.
292	Kidney Stones	<ol style="list-style-type: none"> 1) List the important risk factors for nephrolithiasis. 2) Identify the role of diet and dietary intervention in the management of stone disease. 3) Describe the role of urologic intervention in the management of stone disease. 4) Recall the unique diagnostic and management strategies for kidney stones in a pregnant woman.
486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	<ol style="list-style-type: none"> 1) Discuss self-management behaviors (SMB) in CKD/ESRD. 2) Define health literacy and numeracy. 3) Discuss role of health literacy/numeracy in chronic kidney disease. 4) Consider strategies to improve communication to patients with low health literacy/numeracy. 5) Discuss a community based nutrition care process model where nutrition education interventions penetrate the health literacy barrier. 6) Discuss tipping point strategies taking food and nutrition messages from once in a while to a lifestyle. 7) Discuss social marketing, food justice and advocacy strategies to drive key messages home to the dinner table.
293	Electrolytes	<ol style="list-style-type: none"> 1) Discuss the causes and treatment of hypernatremia in hospitalized patients. 2) List the mechanisms and appropriate treatment of hypomagnesemia. 3) Review the pathophysiology of hypokalemia. 4) Identify the disorders associated with defects in the calcium sensor.

NEPHROLOGY SOCIAL WORKER PROGRAM

PROGRAM COMMITTEE

Andrea DeKam, LMSW

University of Michigan Dialysis, Livonia, MI
Program Chair

Rebecca Hays, MSW, APSW

University of Wisconsin Hospital and Clinics, Madison, WI
Program Co-Chair

Sandra Coorough, ACSW, LCSW

Phoenix Children's Hospital Kids Kidney Center, Phoenix, AZ
Continuing Education Coordinator

Jessica Farrell, MSW, LCSW-P

Duke University Medical Center, Durham, NC

Diane Perry, LISW

DaVita Richfield Dialysis, Richfield, MN

Kristin Stockard, LICSW

Children's Hospital and Region Medical Center, Seattle, WA

Lara Tushla, LCSW, MSW

Rush Presbyterian Hospital, Chicago, IL

Jane Kwatcher, MSW, LCSW

DaVita Pomona Dialysis, Pomona, CA

HOST COMMITTEE

Lindsay Gregory, CMSW

DaVita Inc. Dialysis, Nashville, TN

Melissa Herb, CMSW

DaVita Inc, Nashville, TN

Lynn Lewis, MSW

Dialysis Clinic, Inc, Madison, TN

Lisa Varner, LCSW

DaVita Memphis Central, Memphis, TN

Fairfax R. Wynne, CNSW

DaVita East, Memphis, TN

CONTINUING EDUCATION INFORMATION

A minimum of 34.0 continuing education clock hours for social workers (for the entire program) have been applied for through the following agencies:

- The National Kidney Foundation Council of Nephrology Social Workers, provider #1014, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) **www.aswb.org**, phone: 1.800.225.6880, through the Approved Continuing Education (ACE) program. The National Kidney Foundation Council of Nephrology Social Workers maintains responsibility for the program.
- Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling, provider #50-1414, expires March 31, 2009.
- The National Kidney Foundation Council of Nephrology Social Workers, approval number PCE 2410, is approved as a Continuing Education Provider by the California Board of Behavioral Sciences. This course meets the qualifications for continuing education credit for LCSWs as required by the California Board of Behavioral Sciences.

It is the conference registrants responsibility to make sure their home state (if not noted above) accepts the ASWB ACE provider as sufficient for CEUs, or if they need to do anything additional to independently receive state CEUs.

PROGRAM GOALS

- Participants will gain the knowledge and skills for outcome-oriented clinical nephrology social work practice.
- Participants will gain knowledge of biopsychosocial variables affecting chronic kidney disease patients and their families.
- Participants will learn skills to ameliorate and address biopsychosocial variables affecting kidney disease patients and their families.
- Participants will gain knowledge and skills to address issues of diversity among chronic kidney disease patients and health care professionals.

PRE-CONFERENCE COURSES

NEPHROLOGY SOCIAL WORK: AN OUTCOMES-DRIVEN PRACTICE MODEL

Course Co-Directors: Mary Beth Callahan, ACP, ACSW, Stephanie Johnstone, LCSW and Megan Prescott, MSW
Wednesday, March 25
8:45am–5:00pm
Session 420, 7.0 credit hours

TARGET AUDIENCE

Nephrology Social Workers

COURSE DESCRIPTION

This full-day course will focus on a contemporary model of Nephrology Social Work practice that targets specific variables such as adherence behavior, depression, social support, satisfaction with care, conflict resolution, team training, quality of life measurement and modality selection to enhance overall outcome goals. The course will also focus on restructuring social work services within your organization and applying case management and time-saving strategies to make the delivery of those services possible.

REQUIRED: Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time	Topic
8:45am–9:00am	Welcome and Introductions
9:00am–9:30am	Introduction to Outcomes-Driven Nephrology Social Work
9:30am–10:30am	Phases of Adjustment to CKD: Designing Interventions to Enhance Outcomes
10:30am–10:45am	Break
10:45am–11:30am	Phases of Adjustment to CKD (Continued)
11:30am–12:00pm	Improving Adherence Behavior
12:00pm–12:30pm	Lunch

12:30pm–1:30pm	Improving Transplant Outcomes
1:30pm–1:40pm	Stretch Break
1:40pm–2:25pm	Prevention and Management of Depression
2:25pm–2:45pm	Improving Rehabilitation Outcomes
2:45pm–3:00pm	Break
3:00pm–3:15pm	Patient, Staff and Team Satisfaction
3:15pm–4:15pm	Understanding and Managing the Challenging Patient
4:15pm–4:45pm	Evolving into an Outcomes-Driven Model of Practice
4:45pm–5:00pm	Questions and Evaluations

MOTIVATIONAL INTERVIEWING AND HEALTH COACHING; IMPROVE HEALTH OUTCOMES IN PATIENTS WITH KIDNEY DISEASE

Course Director: Heather Mercer, PsyD, DrPH
Wednesday, March 25
8:00am–5:00pm
Session 421, 7.0 credit hours

TARGET AUDIENCE

Social Workers, physicians, psychologists, dietitians, allied health professions, and any other health care professionals who are interested in health coaching and enhancing the behavioral change process for their clients.

COURSE DESCRIPTION

Motivational Interviewing (MI) was developed by William Miller, PhD and Stephen Rollnick, PhD. In this course, we will review the foundation of MI and learn basic MI coaching skills, and allow plenty of time for practice and skill acquisition. This health-coaching approach is a directive, client-centered approach that elicits behavioral changes by helping individuals explore and resolve ambivalence. MI is a helpful tool to utilize with less ready, less motivated individuals.

PRE-CONFERENCE COURSES

REQUIRED: Additional registration fee of \$125 for meeting registrants; \$175 when registering for the course only. Includes syllabus, breakfast, boxed lunch and CME/CE credits.

COURSE AGENDA

Time	Topic
8:00am–8:30am	Welcome and Introductions
8:30am–9:00am	Theories of Motivation and Health Behavior Change
9:00am–9:30am	Evidence Base for MI
9:30am–10:30am	Spirit and Principles of MI
10:30am–10:45am	Break
10:45am–12:00pm	MI Basic Skills and Tools
12:00pm–1:00pm	Lunch
1:00pm–3:00pm	Practice! Practice! Practice! Videos, Group Activities, Role Play and Real Play
3:00pm–3:15pm	Break
3:15pm–4:00pm	Pulling It All Together
4:00pm–4:30pm	How to Integrate into Practice
4:30pm–5:00pm	Summary and Closing Remarks

PROGRAM

WEDNESDAY MARCH 25

TIME/LOCATION	SESSION #	SESSION	NOTES	COURSE DIRECTOR(S)	CREDITS
8:45am–5:00pm					
Jackson E/F	420	Nephrology Social Work: An Outcomes-Driven Practice Model	■	Mary Beth Callahan, LCSW, ACSW Stephanie Johnstone, LCSW Megan Prescott, LCSW	7.0
8:00am–5:00pm					
Jackson C/D	421	Motivational Interviewing and Health Coaching: Improve Health Outcomes in Patients with Kidney Disease	■●	Heather Mercer, PsyD, DrPH	7.0

THURSDAY MARCH 26

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Governors Ballroom B	460	Kidney Survivor: Lessons Learned from Experience	●	Cher Thomas, AAS Wendy Rogers, MEd Bill Dant, MS Aaron Battle	1.5
9:30am–10:00am		Break			
10:00am–11:30am					
Presidential Ballroom A/B	264	Adolescents and CKD: Transition to Adult Nephrology	◆	Co-Chairs: Brad Warady, MD Kathy Jabs, MD	1.5
		Transition of Adolescents to Adult Care: A “How To” Approach from a Successful Program		Maria Ferris, MD, MPH, PhD	
		What Is the Medical Psychosocial Status of Adolescents with CKD at Time of Transition to Adult Care: Results from the CKiD Study		Bradley Warady, MD	
		The Social Worker Is Crucial to a Successful Transition		Fred Kouri, LMSW	
		Discussion with Audience Participation		All Faculty	
10:00am–11:30am					
Magnolia Ballroom	461	Relaxation Therapy in the Nephrology Setting: Implications for Practice		Gary Petingola, BA, BSW, RSW	1.5

THURSDAY
MARCH 26, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
12:00pm–2:00pm					
Delta Ballroom C	462	Council of Nephrology Social Workers Networking Luncheon—All Are Welcome! <i>Supported by an unrestricted educational grant from Abbott</i>			N/A
2:30pm–3:30pm					
Presidential Ballroom C/D/E	266	NKF Presidential Address: Transformers: Your NKF and You	◆	Bryan Becker, MD	1.0
		Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!		Mohammed Sayegh, MD	
4:00pm–5:30pm					
Jackson A	463	Ethics—All Day, Every Day		John Gowan, LMSW	1.5
4:00pm–5:30pm					
Magnolia Ballroom	464	The Legal Aspects of Behavior Issues, Patient Conferences, and Agreements	●	Kathy Blood, RN, BA	1.5
6:00pm–7:30pm					
		Opening Ceremonies and Reception in the Exhibit Hall—Visit Posters/Exhibits			
7:30pm–9:30pm					
Delta Ballroom B	803	A New Direction in Anemia Management Beyond Erythropoietic Stimulating Agents <i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>	◆	Chair: Lynda Szczech, MD, MSCE	1.5
		Welcome and Introduction		Lynda Szczech, MD, MSCE	
		Overview of Pathophysiology of Iron Deficiency in ESRD Patients		Lynda Szczech, MD, MSCE	
		Strategies for Detecting Iron Deficiency and Iron Excess in ESRD Patients		David B. Van Wyck, MD	
		Strategies for Optimizing Treatment of Iron Deficiency in ESRD Patients		Chaim Charytan, MD	
		Question and Answer Panel Discussion		All Faculty	

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
6:00am–7:45am					
Delta Ballroom B	805	Exploring Recent Evidence Related to Cardiovascular Calcification and Chronic Kidney Disease	◆	Chair: Vincent W. Dennis, MD	1.5
		<i>Supported by an unrestricted educational grant from Fresenius Medical Care—North America</i>			
		Welcome and Introduction	Vincent W. Dennis, MD		
		Recent Evidence into the Pathophysiology of Cardiovascular Calcification in Chronic Kidney Disease	Peter A. McCullough, MD, MPH, FACC		
		Recent Evidence on the Impact of Phosphorus Binders and Vitamin D Analogues on Survival in Patients with Chronic Kidney Disease	Robert N. Foley, MD		
		Question and Answer Panel Discussion	All Faculty		
7:00am–8:00am					
		Continental Breakfast in Exhibit Hall—Visit Posters/Exhibits			
8:00am–9:30am					
Governors Ballroom C	366	Dealing with Disasters from an Interdisciplinary Perspective	●		1.5
		Preparing a Facility for a Disaster	Ed Creamer, BS, JD		
		Nutrition Planning for Dialysis Patients in a Disaster	Paula Frost, RD, CSR, LD		
		Dealing with the Stress after a Disaster	Lisa Hall, MSSW, LCSW		
8:00am–9:30am					
Governors Ballroom A	465	Working with the Adolescent Patient		Marrie Ketchum, LICSW	1.5
8:00am–9:30am					
Governors Ballroom B	466	Let’s Talk About Sex...or Should We? CKD and Sexuality		Julie Burnett, BA, BSW, MSW, RSW Amy Canter, MSW, RSW	1.5
9:30am–10:00am		Break			
10:00am–11:00am					
Governors Ballroom A	467	Renal Replacement Therapy and Barriers to Choice—The Patient’s Perspective		Caroline Jennette, MSW CNSW Research Grant Winner	1.0
10:00am–11:00am					
Governors Ballroom D	468	Support Groups: Getting Participation		Sharrie Cranford, LGSW	1.0
11:00am–12:00pm					
Governors Ballroom A	469	Advocacy: Not Just Howling at the Moon		Wendy Funk Schrag, LMSW, ACSW	1.0

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
11:00am–12:00pm					
Governors Ballroom D	470	Kidney Transplant Patient Employment Potential: Re-Evaluation of an Important Outcome Measure by Use of New Methodologies		Mary Beth Callahan, LCSW, ACSW CNSW Research Grant Winner	1.0
12:00pm–1:00pm					
Lunch in the Exhibit Hall—Visit Posters/Exhibits					
1:00pm–2:00pm					
Governors Ballroom A	471	Effective Strategies for Preventing Patient/Provider Conflict		Deborah Collinsworth, LMSW	1.0
1:00pm–2:00pm					
Governors Ballroom D	472	Pediatric Toolkit: Child Abuse		Sandra Coorough, ACSW, LCSW Kristin Stockard, MSW, LICSW	1.0
2:00pm–2:30pm					
Break					
2:30pm–4:00pm					
Governors Ballroom A	473	Dialysis: Transplant Social Work Teamwork		Rebecca Hays, MSW, APSW Julie Vonderhoff, MSSW, LCSW	1.5
2:30pm–4:00pm					
Governors Ballroom B	571	Eating Disorders and Renal Nutrition: Anorexia, Bulimia, and Dialysis	●	Therese Shumaker MS, RD, LD	1.5
4:30pm–5:30pm					
Presidential Ballroom C/D/E	279	Challenging Dialysis Patients Panel Discussion on Challenging Dialysis Patients	◆	Chair: Jean Holley, MD Fred Finkelstein, MD Stephanie Johnstone, LCSW Lee A. Cauble, BSN, BSB, RN Pam Havermann	1.0
4:30pm–5:30pm					
Governors Ballroom A	475	A Nationwide Survey of Kidney Transplant Social Workers' Job Roles, Responsibilities, and Occupational Well-Being		Joe Merighi, MSW Teri Browne, PhD, LSW CNSW Research Grant Winners	1.0
4:30pm–5:30pm					
Governors Ballroom D	476	Views on Organ Donation Among Native American Nations		Satara Armstrong, PhD	1.0
6:00pm–7:30pm					
Networking Reception in Exhibit Hall— Visit Posters/Exhibits					

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required

FRIDAY
MARCH 27, CONTINUED

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
7:30pm–9:30pm					
Delta Ballroom B	804	Bone Fractures in CKD: Clinical Issues and Expert Perspectives	◆	Chair: Hartmut H. Malluche, MD, FACP	1.5
		<i>Supported by an unrestricted educational grant from Amgen</i>			
		Introduction		Hartmut H. Malluche, MD, FACP	
		Fractures in CKD: Epidemiology, Prevention and Treatment		Paul D. Miller, MD	
		Emerging Concepts in Prevention and Treatment		Hartmut H. Malluche, MD, FACP	
		Bone Disease in Kidney Transplant Patients		Margaret Bia, MD	
		Questions and Answers		All Faculty	

SATURDAY
MARCH 28

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–10:00am					
Hermitage D	477	Nephrology Social Work 101		Megan Prescott, LCSW Stephanie Stewart, LICSW, MBA	2.0
8:00am–10:00am					
Lincoln A	478	Ethical Issues in Pediatric Organ Donation after Cardiac Death		Charlotte Harrison, JD, MPH, MTS	2.0
10:30am–11:30am					
		Brunch Served in the Exhibit Hall— Visit Posters/Exhibits			
11:30am–1:00pm					
Jackson E/F	479	Preventing Suicide: Clinical Practices and Structured Programs		Jane Kwatcher, LCSW Matt Stricherz, EdD	1.5
11:30am–1:00pm					
Hermitage D	480	Psychosocial Implications of Conditions of Coverage for the Pediatric Patient Population		Debbie Brady, LCSW, ACSW Sandra Coorough, ACSW, LCSW Camille Yuscak, LCSW-R, ACSW	1.5
1:00pm–1:30pm					
		Break			

**SATURDAY
MARCH 28, CONTINUED**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
1:30pm–3:00pm					
Jackson E/F	481	Communicating with People Who Have Dementia		Melissa Fry, CAPSW	1.5
1:30pm–3:00pm					
Hermitage D	482	Adherence Issues in Organ Transplantation: Risk Factors and Interventions		Mary Amanda Dew, PhD	1.5
3:00pm–3:30pm					
3:30pm–5:00pm					
Hermitage D	483	Assessing Decisional Capacity in Transplantation		Rebecca Brashler, LCSW	1.5
3:30pm–5:00pm					
Hermitage A/B	474	Unraveling the Mystery of Assessing Physical and Mental Functioning		Beth Witten, ACSW, LSCSW Dori Schatell, MS	1.5
5:00pm–6:00pm					
Hermitage A/B	484	CNSW Town Hall		CNSW Executive Board	N/A
6:00pm–7:00pm					
Governors Ballroom B	101	Health Professionals Networking Reception <i>Supported by an unrestricted educational grant from Watson Nephrology</i>	●		

**SUNDAY
MARCH 29**

TIME/LOCATION	SESSION #	SESSION	NOTES	FACULTY	CREDITS
8:00am–9:30am					
Presidential Ballroom C	485	Strengthening Adherence in Dialysis Patients	●	Bethany Roberts, LICSW Olga Brusilovsky, RD, LD	1.5
8:00am–9:30am					
Presidential Ballroom B	291	End of Life Care for the ESRD Patient	◆	Chair Jean Holley, MD	1.5
		The Choice of Hospice Care		Camille Yuscak, LCSW-R, ACSW	
		The Choice of No Dialysis for the Elderly Patient		Jean Holley, MD	
		Pain Control in the ESRD Patient		Steven Weisbord, MD, MSc	
9:45am–11:15am					
Presidential Ballroom C	486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	●	Kerri Cavanaugh MD, MHS	1.5
		Nutritional Education and Innovations		Dianne Killebrew, MEd, RD, LDN	
11:15am					
Meeting Adjourns					

◆ Joint with Physicians

● Joint with Councils

■ Separate Registration and/or Fee Required



**The Council of Nephrology Social Workers (CNSW)
and Healthcare Providers Service Organization (HPSO)
have partnered to save you money!**



CE courses at SCM09 provide valuable knowledge about the latest topics and trends in Social Work, and can earn you a 10% non-cumulative discount for up to 3 years on a full-time, individual professional liability insurance policy through HPSO. Here's how:

- All sessions on the Social Work Program at this meeting have been approved for this discount.
- Complete at least 6 hours in the Social Work program.
- Stop by Booth # 1622 for the form you'll need to complete and return to HPSO in order to receive the discount.
- You must provide a certificate of attendance showing course name, number of hours and course date.

**For more information, contact HPSO at 800.982.9491
Or visit their Web site at www.hpso.com/cnsw**

This program is underwritten by American Casualty Company of Reading, Pennsylvania, a CNA company and is offered through the Healthcare Providers Service Organization Purchasing Group. All products and services may not be available in all states and may be subject to change without notice. This information is for illustrative purposes only and is not a contract. It is intended to provide a general overview of the products and services offered. Only the policy can provide the actual terms, coverages, amounts, conditions and exclusions. CNA is a service mark and trade name registered with the U.S. Patent and Trademark Office. Healthcare Providers Service Organization is a registered trade name of Affinity Insurance Services, Inc.; in CA (License #0795465), MN & OK, AIS Affinity Insurance Agency, Inc.; and in NY, AIS Affinity Insurance Agency.

© 2009 Affinity Insurance Services, Inc.

CNSW-A209B

KEEP™

NATIONAL KIDNEY FOUNDATION KIDNEY EARLY EVALUATION PROGRAM (KEEP)

KEEP IS THE LARGEST KIDNEY HEALTH DETECTION PROGRAM IN THE U.S.,
WITH MORE THAN 125,000 PARTICIPANTS TO DATE



**Learn more about KEEP
while you are at the conference.**

- Visit us at the NKF booth #1623 for the latest information.
- Joins us for a free CME Breakfast Symposium Thursday, March 26, 2009 6:00AM – 7:45AM: **Kidney and Vascular Risk Factor Control in KEEP**
- View the latest KEEP information being presented during the poster session. Look for poster numbers 42, 54, 58, 60, 173.

The NATIONAL KIDNEY FOUNDATION gratefully acknowledges the support of our KEEP sponsors:



ADDITIONAL SUPPORT PROVIDED BY Lifescan, Inc. and Suplena

©2009 National Kidney Foundation, Inc. All rights reserved. 02.35.627A_JBAJ

SPONSORED BY



WWW.KEEPONLINE.ORG

NEPHROLOGY SOCIAL WORKER SESSION OBJECTIVES

THURSDAY
MARCH 26

SESSION #	SESSION	OBJECTIVES
460	Kidney Survivor: Lessons Learned from Experience	<ol style="list-style-type: none"> 1) Explain the early history of dialysis including the “chosen ones”. 2) Explain the benefits of encouraging patients to connect with fellow patients. 3) Explain the benefits that healthcare professionals and patients receive when they encourage and nurture patient involvement. 4) Provide tips on how healthcare professionals can encourage patients. 5) Realize the difference that renal care professionals make in the lives of renal patients.
264	Adolescents and CKD: Transition to Adult Nephrology	<ol style="list-style-type: none"> 1) Identify novel risk factors in the adolescent population for CKD progression. 2) Understand the impact of CKD on growth, cognition, behavior and cardiovascular disease. 3) Examine the role of the pediatric nephrologist, adult nephrologist and ancillary staff in the transition of CKD adolescents to adult nephrology. 4) Describe the key elements of a successful transition program.
461	Relaxation Therapy in the Nephrology Setting: Implications for Practice	<ol style="list-style-type: none"> 1) Appreciate the needs and strengths of patients and caregivers affected by CKD and their suitability for relaxation therapy. 2) Describe the benefits of relaxation therapy and its implications to nephrology social work practice in addressing anxiety, depression, reduced quality of life and chronic pain. 3) Identify current skills and examine the training and educational requirements necessary to provide relaxation therapy as a clinical social work intervention. 4) Collaborate with nephrology colleagues across disciplines to ensure the inclusion of relaxation therapy as part of comprehensive care.
266	NKF Presidential Address: Transformers: Your NKF and You	<ol style="list-style-type: none"> 1) Identify with NKF organizational structure and various program offerings. 2) Understand the goals of the 2007-2010 NKF strategic plan. 3) Identify areas of progress and success in meeting the goals of the NKF strategic plan. 4) Note areas of continued emphasis to achieve the goals of the NKF strategic plan.
	Shaul Massry Distinguished Lecture: Achieving Clinical Transplantation Tolerance: Myth No More, But!	<ol style="list-style-type: none"> 1) Discuss approaches that lead to clinical transplantation tolerance in kidney transplant recipients. 2) Highlight the scientific barriers to achieving clinical transplantation tolerance. 3) Review the non-scientific challenges to achieving clinical transplantation tolerance. 4) Summarize the mechanisms and assay development to measure tolerance. 5) Provide a summary of the advantages of tolerance over immunosuppression.

THURSDAY
MARCH 26, CONTINUED

SESSION #	SESSION	OBJECTIVES
463	Ethics: All Day, Every Day	<ol style="list-style-type: none"> 1) Introduce and discuss ethical considerations facing renal healthcare professionals. 2) Explore ways to address the issues in the renal setting with the interdisciplinary. 3) Introduce skills for success with difficult ethical situations.
464	The Legal Aspects of Behavior Issues, Patient Conferences, and Agreements	<ol style="list-style-type: none"> 1) Recognize a legal document. 2) Understand the difference in laws for hospitals and out-patient settings. 3) Become familiar with both patient and caregiver's rights.

FRIDAY
MARCH 27

SESSION #	SESSION	OBJECTIVES
366	Dealing with Disasters from an Interdisciplinary Perspective	<ol style="list-style-type: none"> 1) Describe the experiences of ESRD patients and providers with recent disasters. 2) Identify signs and symptoms of trauma experienced by ESRD patients and providers during disasters, and interventions most helpful during the acute trauma phase. 3) Share measures that dialysis and kidney transplant patients can take when planning for disasters to ease stress during and after disasters.
465	Working with the Adolescent Patient	<ol style="list-style-type: none"> 1) Develop assessment strategies specific to adolescent patients. 2) Develop appropriate intervention plans with consideration to adolescent development and specific health care needs. 3) Identify appropriate resource tools to engage teens in their health care plan.
466	Let's Talk About Sex...or Should We? CKD and Sexuality	<ol style="list-style-type: none"> 1) Classify the effects CKD and treatment has on sexual function. 2) Identify what, if anything, nephrology teams are doing to address the issue at this point. 3) Understand how other professionals are addressing the topic of sexual function with their patients. 4) Recognize diversities and special considerations affecting sexuality. 5) Consider implications for future research and support/education for professionals addressing this topic with their patients.
467	Renal Replacement Therapy and Barriers to Choice—The Patient's Perspective	<ol style="list-style-type: none"> 1) Understand the patient's perception of their disease at onset and how these perceptions may influence their choice of RRT. 2) Identify perceived barriers and facilitators to alternative forms of RRT. 3) Discuss patient generated ideas for RRT education.
468	Support Groups: Getting Participation	<ol style="list-style-type: none"> 1) Describe the Support Group model and potential for effectiveness and keeping the patient involved. 2) Recognize your patient population. 3) Understand the setbacks of the Support Group titled model.
469	Advocacy: Not Just Howling at the Moon	<ol style="list-style-type: none"> 1) List three federal committees that oversee Medicare legislation. 2) Describe the most effective and influential advocacy tactics and resources available through the NKF public policy office and website. 3) List specific advocacy activities at the local, state and federal levels.

SESSION #	SESSION	OBJECTIVES
470	Kidney Transplant Patient Employment Potential: Re-Evaluation of an Important Outcome Measure by Use of New Methodologies	<ol style="list-style-type: none"> 1) Understand research design. 2) Understand research results. 3) Understand research conclusions and implications for social work practice in study setting that could be duplicated.
471	Effective Strategies for Preventing Patient/Provider Conflict	<ol style="list-style-type: none"> 1) Explain the dynamics of patient/provider conflict in the dialysis setting. 2) Examine factors that contribute to unnecessary conflict. 3) Consider effective strategies for preventing conflict between patients and staff.
472	Pediatric Toolkit: Child Abuse	<ol style="list-style-type: none"> 1) Understand how pediatric kidney disease can impact a child's risk factors for child maltreatment as well as the visible warning signs. 2) Examine the role of non-adherence in medical neglect cases. 3) Learn about resources for evaluation, intervention, and prevention of child abuse and neglect.
473	Dialysis: Transplant Social Work Teamwork	<ol style="list-style-type: none"> 1) Provide tools to improve collaboration between dialysis and transplant teams, as outlined in Conditions for Coverage and Conditions of Participation. 2) Demonstrate ways that these tools work in practice with patients who get 'stalled' on the way to transplant candidacy. 3) Outline collaborative intervention, using the differences in the dialysis and transplant social work roles, to address psychosocial barriers to transplant.
571	Eating Disorders and Renal Nutrition: Anorexia, Bulimia, and Dialysis	<ol style="list-style-type: none"> 1) Understand electrolyte abnormalities and suggest appropriate repletion and hydration for the dialysis patient with an eating disorder. 2) Discuss the challenges and strategies used to improve energy and protein intake. 3) Discuss the importance of behavioral modification and learn how to utilize behavioral interventions in dialysis patients diagnosed with an eating disorder.
279	Challenging Dialysis Patients	<ol style="list-style-type: none"> 1) Understand different approaches to dealing with the difficult dialysis patient. 2) Understand that in some cases the difficult dialysis patient is dealing with loss of autonomy and control, as well as depression and anger. 3) Discuss how the dialysis team can and must work effectively together to deal with the difficult dialysis patient.
475	A Nationwide Survey of Kidney Transplant Social Workers' Job Roles, Responsibilities, and Occupational Well-Being	<ol style="list-style-type: none"> 1) Summarize research that has examined the occupational and psychological factors that affect renal social workers' professional practice. 2) Review the study aims and survey methodology. 3) Discuss key findings with regard to kidney transplant social workers' overall job satisfaction, workload demands, emotional exhaustion, and management of workplace emotions.
476	Views on Organ Donation Among Native American Nations	<ol style="list-style-type: none"> 1) Understand the purpose of the presented research project. 2) Differentiate between reservation and non-reservation dwelling Native Americans. 3) Examine the results of the study.

SESSION #	SESSION	OBJECTIVES
477	Nephrology Social Work 101	<ol style="list-style-type: none"> 1) Understand the range of tasks and responsibilities. 2) Discuss the psychosocial impact of ESRD and dialysis (and the need to ensure adequate clinical focus). 3) Understand the social worker role on the Interdisciplinary team. 4) Understand the importance of communication with the dialysis team. 5) Identify tools to assist with a psychosocial assessment, depression and anxiety screening during a transplant evaluation. 6) Discuss the role of the transplant social worker with the long term patient population.
478	Ethical Issues in Pediatric Organ Donation After Cardiac Death	<ol style="list-style-type: none"> 1) Describe organ donation after cardiac death (DCD) in its social and clinical context. 2) Discuss the major ethical issues in DCD, especially for children as donors. 3) Identify important factors in the development of a DCD policy at Children's Hospital Boston. 4) Consider the ethics involved in current controversies. 5) Discuss case examples and raise questions about the subject.
479	Preventing Suicide: Clinical Practices and Structured Programs	<ol style="list-style-type: none"> 1) Define the problem of suicidal threat by dialysis patients. 2) Identify the components of a suicidal risk assessment. 3) Demonstrate competence in intervening with suicidal patients.
480	Psychosocial Implications of Conditions of Coverage for the Pediatric Patient Population	<ol style="list-style-type: none"> 1) Explore ways to further develop the psychosocial component of nephrology social work for pediatric patients/families within the context of the Conditions of Coverage. 2) Discuss the toolkit approach to deal with psychosocial issues within the continuum of chronic kidney disease care. 3) Develop programs using the guidelines from the Conditions of Coverage to promote teamwork and provide continuity of care for pediatric patients.
481	Communicating with People Who Have Dementia	<ol style="list-style-type: none"> 1) Identify different types of dementia. 2) Define Validation and its benefits. 3) Identify Validation Goals. 4) Describe the four phases of resolution. 5) Indicate techniques to use in dialysis setting.
482	Adherence Issues in Organ Transplantation: Risk Factors and Interventions	<ol style="list-style-type: none"> 1) Understand the prevalence of nonadherence to each component of the medical regimen after transplantation. 2) Understand the full range of risk factors that have been found to be associated with nonadherence. 3) Be aware of evidence concerning interventions that have been tested to date and intervention strategies that would be useful to consider in future clinical and research work.

SATURDAY
MARCH 28, CONTINUED


SESSION #	SESSION	OBJECTIVES
483	Assessing Decisional Capacity in Transplantation	<ol style="list-style-type: none"> 1) Identify two tools to use when assessing a patient's decisional capacity during the transplantation process. 2) Describe the elements needed for thorough documentation of the results of a capacity assessment for the medical record. 3) Discuss the conflicts that arise when patients with decisional capacity refuse medical recommendations and the cases when limiting autonomy may feel appropriate.
474	Unraveling the Mystery of Assessing Physical and Mental Functioning	<ol style="list-style-type: none"> 1) Explain why it is important to measure health-related quality of life (HRQOL). 2) Describe the KDQOL-36 survey for measuring HRQOL. 3) Review two examples of approaches for using HRQOL scores for care planning.

SUNDAY
MARCH 29



SESSION #	SESSION	OBJECTIVES
485	Strengthening Adherence in Dialysis Patients	<ol style="list-style-type: none"> 1) Define issues related to poor adherence in dialysis patients. 2) Identify patient's readiness to learn new behaviors, including the stages of change. 3) Discuss ways to improve and strengthen adherence in dialysis patients.
291	End of Life Care for the ESRD Patient	<ol style="list-style-type: none"> 1) Recognize that not starting dialysis is an option that should be presented to the elderly patient with co-morbidity. 2) Understand that dialysis patients have many physical complaints and that the dialysis team can address these and ameliorate some of these. 3) Understand the role of Hospice in managing the end of the life of the dialysis patient.
486	Literacy & Numeracy: Potential Barriers to Self-Management in Chronic Kidney Disease	<ol style="list-style-type: none"> 1) Discuss self-management behaviors (SMB) in CKD/ESRD. 2) Define health literacy and numeracy and its role in CKD. 3) Consider strategies to improve communication to patients with low health literacy/numeracy. 4) Discuss a community based nutrition care process model where nutrition education interventions penetrate the health literacy barrier. 5) Identify tipping point strategies taking food and nutrition messages from once in a while to a lifestyle. 6) Discuss social marketing, food justice and advocacy strategies to drive key messages home to the dinner table.

EXHIBIT HALL MAP

NATIONAL KIDNEY FOUNDATION SPRING
MARCH 26-28, 2010
GAYLORD OPRYLAND RESORT & CASINO
RYMAN B1-B6 EXHIBITION
NASHVILLE, TENNESSEE



ING CLINICAL MEETING 2009 CONVENTION CENTER HALLS SSEE



TECHNICAL INFORMATION

DRAINAGE GRADES:
 A-B5
 CIRCULAR DRAIN MOSTLY LOCATED IN RYMAN
 RECTANGULAR DRAIN MOSTLY LOCATED IN RYMAN C1-C2
 (NOTE: ALL DRAINS ARE LOCATED NEAR A WATER OUTLET)
PIPES:
 6" DIAMETER DRAIN PIPE
 (NOTE: PIPES LOCATED ON THE COLUMNS DO NOT EXCEED 1" DIAMETER)
ELECTRICAL OUTLET INFORMATION:
 E INDICATES ELECTRICAL DROPS
 (NOTE: ELECTRICAL & PHONE LINES ARE LOCATED ON ALL COLUMNS)
 OUTPUTS: 4-110V 20AMP
 1-110V 20AMP
 1-120/208V 20AMP 3 WIRE 3 PHASE
 1-120/208V 20AMP 3 WIRE 3 PHASE
 1-120/208V 20AMP 3 WIRE 3 PHASE
 1-120/208V 20AMP 3 WIRE 3 PHASE
 (NOTE: 277-480V AVAILABLE UPON REQUEST)
CEILING HEIGHT (AVERAGE CLEARANCE):
 RYMAN A EXHIBIT HALL- 12'
 RYMAN B1-B6 EXHIBIT HALL- 16'
 RYMAN C1-C2 EXHIBIT HALL- 19'
AIRLINE DROPS:
 FLOOR LOAD: 500LBS PER SQUARE FT.
 COLUMNS: VARY IN SIZE. ALL COLUMN DIMENSIONS ARE LOCATED NEXT TO THE PROPER COLUMN.
F.E. FIRE EXTINGUISHERS:
 SHADED AREA INDICATES POWER & CROSSOVER AREA BETWEEN C1-B6 HALLS
 (NOTE: CEILING HEIGHT IN THIS AREA IS 12')

BOOTH COUNT

Inventory as of 02/24/2009

Dimension	Size	Qty	SqFt
10'x10'	100	72	7,200
10'x20'	200	6	1,200
10'x40'	400	1	400
20'x20'	400	7	2,800
20'x22'	441	1	441
20'x30'	600	2	1,200
30'x30'	900	1	900
30'x40'	1,200	1	1,200
30'x50'	1,500	1	1,500
40'x40'	1,600	2	3,200
40'x50'	2,000	1	2,000
Totals:		95	22,041

144 POSTERS

SCM09 EXHIBITORS

Exhibiting Company	Booth				
Abbott Nutrition	1412	Global Health Products, Inc.	1028	Nephrology News and Issues	1417
Abbott Renal Care	1404	Health Informatics International, Inc.	1512	Nephrology Times	916
Alcavis HDC	1607	Hema Assistance Products, Inc.	815	NephroPath	1322
AMAG Pharmaceuticals, Inc.	1623	HemoCue, Inc., A Quest Diagnostics Company	1418	Nephro-Tech, Inc.	1415
American Academy of Nurse Practitioners	931	Innovations for Dialysis	817	Nova Biomedical	1419
American Academy of Physician Assistants	1617	Integrated Nephrology Network	1229	Novartis Pharmaceuticals Corporation	1313
American Association of Kidney Patients	925	International Institute for the Advancement of Medicine	1718	Nutrepletion Resources	1326
American Regent, Inc.	1523	Kibow Biotech, Inc.	1328	Ortho Biotech Products, L.P.	1507
American Renal Associates, Inc.	914	Kidney Community Emergency Response Coalition	1618	Pentec Health	1529
American Society of Nephrology	1609	Litholink Corporation	1117	ProPath	1531
Amgen	1105	Llorens Pharmaceutical International Division, Inc.	915	Quantitative Medical Systems (QMS)	919
AngioDynamics	922	Medcomp	1317	RenaLab Inc.	1330
Apheresis Technologies, Inc.	813	Medical Nutrition USA, Inc.	1615	Renal Advantage Inc.	1231
Associates of Cape Cod, Inc.	930	Merck & Co., Inc.	1319	Renal & Urology News	1527
Athena Diagnostics, Inc.	1712	National Association of Nephrology Technicians/Technologists (NANT)		Renal Business Today/Virgo Publishing Medical Group	1514
Baxter Healthcare	1215	National Kidney and Urologic Disease Information Clearinghouse (NKUDIC)	928	Renal Physicians Association	1611
The Binding Site, Inc.	1022	National Kidney Foundation	1629	Roche Transplant	1704
Courier Med	1414	AJKD		Satellite Laboratory Services, LLC	1513
Covidien	819	KDIGO		Scantibodies Clinical Laboratory	918
DaVita	1416	KDOQI		Shire Pharmaceuticals	1422
DCRX Infusion, Inc.	1026	KEEP		Sigma-Tau Pharmaceuticals, Inc.	1516
Dialysis and Transplantation	1227	KLS		Spectra Laboratories	805
Dialysis Patients Citizens	927	NKF cyberNephrology Experience	711	Spire Biomedical, Inc.	1223
Dialysis Recruiting Specialists/The Fortus Group	1519	NKF Professional Councils	1622	Sysmex America, Inc.	924
DVA Laboratory Services, Inc.	1619	National Kidney Foundation Serving East Tennessee	1710	Transonic Systems Inc.	1030
Elsevier, Inc.	1613	National Kidney Foundation of Middle Tennessee	1708	Watson Nephrology	1413
FMQAI	917	Nephroceuticals	1714	Wyeth Pharmaceuticals	1605
Fresenius Medical Care — Renal Pharmaceuticals	1011				
Fresenius Medical Care — Renal Products	1005				
Fresenius Medical Services	905				
Genzyme Corporation	1122				

2009 EXHIBITORS

ABBOTT NUTRITION

Booth 1412

Abbott Nutrition is THE world leader in adult nutrition. Nepro with Carb Steady is therapeutic nutrition for people on dialysis and is clinically shown to help manage blood glucose response. Suplena with Carb Steady is therapeutic nutrition for people with CKD stages 3 & 4.

ABBOTT RENAL CARE

Booth 1404

Abbott is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products to medical devices and pharmaceutical therapies. Our comprehensive product line encircles life itself—addressing important health needs for all ages.

ALCAVIS HDC

Booth 1607

Alcavis HDC is dedicated to supporting the renal community through education and aid with innovative and progressive antiseptics, disinfectants and medical devices. Our core products are electrolytically produced sodium hypochlorite based solutions available in several concentrations for applications that include skin and wound care and connectivity. Alcavis HDC also distributes peracetic acid for dialyzer reprocessing and the MAKY and ARM II reuse machines.

AMAG PHARMACEUTICALS, INC

Booth 1623

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Feraheme™ (ferumoxytol injection) is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. Visit us at www.amagpharma.com.

AMERICAN ACADEMY OF NURSE PRACTITIONERS

Booth 931

AANP is the oldest, largest and only full-service professional membership organization for NPs of all specialties. AANP provides national representation for over 125,000 NPs through its various membership categories. Stop by our booth and learn about nurse practitioners and the wide array of membership benefits AANP offers.

AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS

Booth 1617

The American Academy of Physician Assistants is the only national organization to represent all physician assistants (PAs) in all medical specialties.

AMERICAN ASSOCIATION OF KIDNEY PATIENTS

Booth 925

The American Association of Kidney Patients (AAKP) is the national, patient organization, which, for over 35 years, has been dedicated to improving the lives of kidney patients and their families by helping them cope with the emotional, physical and social impact of kidney disease.

AMERICAN REGENT, INC.

Booth 1523

American Regent, "Your IV Iron Company," is the manufacturer and distributor of Venofer® (iron sucrose injection, USP), the #1 prescribed IV Iron in the U.S. Venofer® is available in 100mg/5mL and 200mg/10mL single dose vials (preservative free). Venofer® is covered nationally by CMS/Medicare and has been assigned a permanent national HCPCS Code "J1756" for CKD services provided on or after January 1, 2003. Please visit us at our booth for more information.

AMERICAN RENAL ASSOCIATES, INC.

Booth 914

American Renal Associates (ARA) develops dialysis facilities in partnership with nephrologists. ARA has become the sixth largest provider of kidney dialysis services with more than 78 facilities in 16 states and the District of Columbia.

AMERICAN SOCIETY OF NEPHROLOGY

Booth 1609

The American Society of Nephrology (ASN) is organized and operated exclusively for scientific and educational purposes, including enhancing the field of nephrology by advancing the scientific knowledge and clinical practice of that discipline through stimulation of basic and clinical investigation, providing access to new knowledge through the publication of journals and the holding of scientific meetings. Contact ASN with comments by phone at 1-202-659-0599 or by email at email@asn-online.org.

AMGEN

Booth 1105

Amgen (NASDAQ:AMGN), a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.

ANGIODYNAMICS

Booth 922

AngioDynamics (www.angiodynamics.com) is a provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse lines include radiofrequency ablation systems, vascular access products, angiographic products, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization and venous products.

APHERESIS TECHNOLOGIES, INC.

Booth 813

Apheresis Technologies, Inc., is dedicated to the field of therapeutic plasmapheresis, providing the ASAH Plasmaflo™ plasma separator, related tubing sets and our new dual-track plasma pump. Future products will also be in the field of therapeutic plasmapheresis.

ASSOCIATES OF CAPE COD, INC.

Booth 930

Associates of Cape Cod (ACC) is a global biopharmaceutical company specializing in endotoxin and glucan detection. We're the first company licensed by the FDA to manufacture LAL for use as a quality control test for endotoxin in the pharmaceutical and medical device markets. ACC also operates a Contract Testing Service.

ATHENA DIAGNOSTICS, INC.

Booth 1712

Athena Diagnostics, leader for twenty years in neurological genetic testing, now offers molecular assays for common renal disorders to provide the most comprehensive line of renal genetic testing commercially available.

BAXTER HEALTHCARE

Booth 1215

Baxter Healthcare Corporation is a global diversified healthcare company, bringing together Science, Systems, Solutions, and Support to offer a full portfolio of PD, HD, and Renal Critical Care products. For over 50 years, Baxter has conducted extensive research and development, and is committed to bringing to market product innovations that help to advance the treatment of renal disease including the first and only peritoneal dialysis solutions with non-glucose osmotic agents.

THE BINDING SITE, INC.

Booth 1022

Freelite serum free light chain assays are more sensitive than current methodologies for detecting multiple myeloma and AL Amyloidosis patients, many of whom first present with renal failure. They replace the need for urine assays.

COURIERMED INC.

Booth 1414

Couriermed Inc. is a nationwide specialized durable medical equipment company, providing medical supplies to patients at their home. Some of our specialty supplies include CD-1000 Catheter Access Protector, Less-N-Pain affordable topical anesthetic, SureSeal pressure bandage, diabetic supplies and free diabetic monitors.

COVIDIEN

Booth 819

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines including our complete line of Dialysis Products. Please stop by our booth to see what's new.

DAVITA

Booth 1416

DaVita, a FORTUNE 500® company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with CKD and ESRD. We manage more than 1,300 outpatient facilities and acute units in more than 700 hospitals located in 43 states and Washington D.C., serving approximately 107,000 patients.

DCRX INFUSION, INC.

Booth 1026

DCRX Infusion, Inc. is one of the nation's largest providers of Intradialytic Parenteral Nutrition and Intraperitoneal Parenteral Nutrition. Commitment to the highest quality control standards and customer service has made DCRX Infusion, Inc. a leader in the infusion therapy industry.

DIALYSIS AND TRANSPLANTATION

Booth 1227

Available from John Wiley & Sons, *Dialysis & Transplantation (D&T)* publishes original research pertaining to all aspects of renal replacement therapy and renal transplant, with a focus on clinical application. *D&T* has the largest multidisciplinary audience among nephrology journals in the United States and is read in more than 120 foreign countries. Visit www.Eneph.com for submission guidelines/free access to online issues.

DIALYSIS PATIENT CITIZENS

Booth 927

DPC is a nonprofit patient organization dedicated to improving dialysis patients' quality of life by developing awareness of dialysis issues, advocating for dialysis patients, improving the partnership between patients and caregivers, and promoting favorable public policy. We are a nationwide, nonprofit, patient-led dialysis organization with membership open only to dialysis and pre-dialysis patients and their families. Our policies and our mission are guided solely by our membership.

DIALYSIS RECRUITING SPECIALISTS/ THE FORTUS GROUP

Booth 1519

The first full service executive search firm specializing in Dialysis and Transplantation, providing recruitment and placement of dialysis professionals world wide, including permanent, travel. As specialists in the nephrology and transplantation industries, we have grown to assist our clients in oncology, academia, and locum tenens.

DVA LABORATORY SERVICES, INC.

Booth 1619

DVA Laboratory Services offers state-of-the-art ESRD laboratory testing. We recognize the need for precise patient data, and address it with a comprehensive range of laboratory services including: dialysis specific testing, client support staff, rapid turnaround times, peritoneal dialysis testing, water analysis and a leading-edge order entry and reporting system—LabScope Online®. Now you can access LabScope from anywhere, anytime, using LSO On The Go from any computer with Internet access.

ELSEVIER, INC.

Booth 1613

ELSEVIER is proud to publish the *American Journal of Kidney Disease*, the official journal of the National Kidney Foundation. Please stop by our booth to view the latest issue of the journal and browse our other books and journals in the field of nephrology.

FMQAI

Booth 917

In February 2009, the Centers for Medicare and Medicaid (CMS) phased in the first release of CROWNWeb, a web-based program that enables dialysis facilities to securely submit patients' demographic and clinical data electronically. Future releases will continue to expand the number of participating facilities, so be sure to visit the CROWNWeb booth and stay up to date with the latest developments.

FRESENIUS MEDICAL CARE – RENAL PHARMACEUTICALS

Booth 1011

Fresenius Medical Care Renal Pharmaceuticals division, offering PhosLo® and Venofer® for the ESRD patient, is dedicated to delivering outstanding pharmaceutical products and therapies to the nephrology community and the patients that it treats.

FRESENIUS MEDICAL CARE – RENAL PRODUCTS

Booth 1005

The Fresenius Medical Care Renal Products division is a leading provider of dialysis products and services. Product offerings include Optiflux® dialyzers, 2008 series hemodialysis machines, stay safe™, and the Liberty® cyclor. Kidney Options®, AREP and success@home™ provide extraordinary resources to the renal community. To learn more, visit us at www.fmcna.com or contact us at 1-800-662-1237.

FRESENIUS MEDICAL SERVICES

Booth 905

The mission of Fresenius Medical Services (FMS), a division of Fresenius Medical Care of North America, is "Through UltraCare®, improving the Quality of Life of Every Patient, Every Treatment." FMS considers its relationships with nephrology professionals to be critical in fulfilling that mission in providing exceptional patient care. Come visit us to hear more about the services we provide like UltraCare at home, Fresenius Medical Care Rx, CV Matching, UltraCare-Dialysis.com website and more.

GENZYME CORPORATION

Booth 1122

Genzyme, a global health care company, delivers innovative biotechnology products and services in therapeutics, surgery and diagnostic areas. Genzyme is the manufacturer of Renvela® (sevelamer carbonate), Renagel® (sevelamer hydrochloride), and Hectorol® (doxercalciferol). Genzyme is a leader in health care awareness and education for renal care specialists and patients worldwide. For more information, visit www.genzyme.com or call 1-800-847-0069.

GLOBAL HEALTH PRODUCTS, INC.

Booth 1028

Global Health is a company committed to the manufacturing and distribution of innovative nutritional supplements. Global Health is dedicated to working closely with healthcare professionals to solve problems and improve overall patient health.

HEALTH INFORMATICS INTERNATIONAL, INC.

Booth 1512

Health Informatics International (HII) is the renal industry leader in electronic medical records and billing software. HII's TIME™ System is the backbone of its outsourced billing solutions. Please visit us at www.hiiweb.com.

HEMA ASSISTANCE PRODUCTS, INC.

Booth 815

The HemaStrap™, by Hema Assistance Products, is a lightweight fabric strap that is comfortable, easy to use and does not interfere with dialysis or infusion treatment. It is designed to secure and stabilize dialysis/infusion tubing during patient treatment to minimize tugging and painful infiltration.

HEMOCUE, INC., A QUEST DIAGNOSTICS COMPANY

Booth 1418

The HemoCue Albumin 201 System is CLIA waived and provides quantitative results in about 90 seconds when testing for low levels of albumin in urine. The system consists of a small, specially designed analyzer and individually packaged microcuvettes containing a freeze-dried reagent.

INNOVATIONS FOR DIALYSIS

Booth 817

Clear Band: ClearBand provides reliable hemostasis and eliminates manual pressure following needle or sheath removal. ClearBand is a soft plastic that comfortably fits the arm without cutting into it. Locking ridges face away from the skin to prevent binding or pinching. **Hemo:** Hemo is a topical hemostasis pad with calcium ions to speed up the clotting process for reliable hemostasis at any access site.

INTEGRATED NEPHROLOGY NETWORK

Booth 1229

Integrated Nephrology Network (INN) is the largest national physician services network dedicated exclusively to nephrology. It helps nephrology practices and dialysis providers control costs, streamline their business, and enhance quality care.

INTERNATIONAL INSTITUTE FOR THE ADVANCEMENT OF MEDICINE

Booth 1718

The International Institute for the Advancement of Medicine (IIAM) provides non-transplantable, normal and diseased, human organs, and anatomical specimens consented for medical research and education.

KIBOW BIOTECH, INC.

Booth 1328

After a decade of scientific R&D, Kibow Biotech has developed a specifically formulated and clinically validated probiotic dietary supplement product (Kibow Biotics®) that could help maintain a healthy kidney function.

KIDNEY COMMUNITY EMERGENCY RESPONSE COALITION

Booth 1618

Comprised of partners from the entire kidney community, Kidney Community Emergency Response (KCER) Coalition develops, disseminates, implements, maintains, continuously improves a coordinated preparedness/response framework for dialysis and transplant patients, serves as providers in the event of any emergency/disaster, and provides organization/guidance to emergency management stakeholders.

LITHOLINK CORPORATION

Booth 1117

Litholink is a diagnostic testing laboratory that uses standard of care testing as a basis for comprehensive programs for chronic disease management. Founded by one of the nation's leading academic and clinical nephrologists, Fred Coe MD of the University of Chicago Medical School, Litholink is able to use sophisticated computer algorithms to provide patient specific treatment recommendations on test reports as well as other programmatic support to physicians and their patients. The diseases which Litholink currently manages are recurrent kidney stone disease and chronic kidney disease.

LLORENS PHARMACEUTICAL INT'L DIVISION, INC.

Booth 915

During the past 22 years, Llorens Pharmaceutical has experienced significant growth, introducing a diversity of new products in the United States and Puerto Rico. Llorens Pharmaceutical is continually working to improve the health and well-being of patients, with products such as Proteinex, Proteinex-18 and Nephronex.

MEDCOMP

Booth 1317

Medcomp is the market leader for dialysis access catheters. The Tesio Catheter and Split Cath long-term products have set the standard for patient care. Medcomp offers a full line of CVCs and accessories, designed to save peripheral veins and future access sites.

MEDICAL NUTRITION USA, INC.

Booth 1615

Medical Nutrition USA, Inc. develops and distributes products for nutritionally at-risk individuals under medical supervision. Our low-volume Pro-Stat® products are ideal for ESRD patients, as they provide 15 grams of protein and up to 101 calories per ounce. Fiber-Stat, our liquid fiber supplement, delivers 15 grams of soluble fiber per ounce.

MERCK & CO., INC.

Booth 1319

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. For more information, visit: www.merck.com.

NATIONAL ASSOCIATION OF NEPHROLOGY TECHNICIANS/TECHNOLOGISTS (NANT)

Booth 929

NANT promotes education and advances the professional role of the multidisciplinary team in delivering the highest quality of care to the CKD patient. It provides educational opportunities, encourages the development of nephrology professionals in leadership roles and achieves recognition of technology practitioners in the total care of the CKD patient.

NATIONAL KIDNEY AND UROLOGIC DISEASE INFORMATION CLEARINGHOUSE (NKUDIC)

Booth 928

The National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) is an information and referral service of the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), one of the National Institutes of Health. The clearinghouse responds to inquiries, develops and distributes publications, and provides referrals to kidney and urologic organizations.

NATIONAL KIDNEY FOUNDATION

Booth 1629

AJKD—American Journal of Kidney Diseases

American Journal of Kidney Diseases (AJKD), the official journal of the National Kidney Foundation, is recognized worldwide as a leading journal in clinical nephrology. Please visit the NKF booth to browse *AJKD* and the two other NKF journals: *Advances in Chronic Kidney Disease* and *Journal of Renal Nutrition*.

KDIGO®—Kidney Disease: Improving Global Outcomes

Visit the booth to learn about KDIGO's global initiatives, including clinical practice guidelines for *Hepatitis C*, *Care of the Transplant Recipient*, *Mineral and Bone Disorders*, *Acute Kidney Injury*, and *Glomerulonephritis*. Receive a demonstration of KDIGO's online tool for accessing and comparing the latest nephrology guideline

recommendations from around the world. KDIGO was established in 2003 as an independently incorporated non-profit foundation governed by an international Board with the stated mission "to improve care and outcomes of kidney patients worldwide through coordination of initiatives to develop and implement clinical practice guidelines." www.kdigo.org

KDOQI™—Kidney Disease Outcomes Quality Initiative

Stop by the NKF booth to learn about the newest KDOQI initiatives for improving patient outcomes. KDOQI will be premiering *Nutrition in Children with CKD: Update 2008*, and "KDOQI 2009 and Beyond" will be presented Saturday morning; mark your schedules to attend this exciting presentation. Visit us at www.kidney.org/Professionals/kdoqi/

KEEP®—Kidney Early Evaluation Program

Over 125,000 people across the country have participated in the NKF's Kidney Early Evaluation Program (KEEP). Visit the booth to learn more about this free, community-based health screening for people at increased risk for chronic kidney disease (CKD) and to learn more about the KEEP longitudinal component and other KEEP program updates.

KLS®—Kidney Learning System

The National Kidney Foundation's KIDNEY LEARNING SYSTEM (KLS®) is a comprehensive curriculum for chronic kidney disease (CKD). It provides educational opportunities, programs and practical tools for physicians and other health care professionals, CKD patients and their families and those at increased risk for CKD. All KLS materials are based on scientific findings and published guidelines. All educational activities in the KLS curriculum are developed, peer-reviewed and pilot-tested with the help of clinical experts supported by the professional KLS staff of the National Kidney Foundation. KLS offers a full line of free CME/CE activities as well as clinical tools and interactive online clinician support resources, such as a GFR calculator and stage-specific clinical action plans. Visit our Web site at www.kidney.org/KLS for a comprehensive listing of educational resources.

In addition, the KLS curriculum expands according to identified needs relative to CKD—new science, educational gaps, and evolving and changing directions and health care trends. In light of the potential for growth, there may be opportunities for KLS to offer customized solutions depending upon unique unmet educational needs.

NKF CYBERNEPHROLOGY EXPERIENCE

Booth 711

Come, relax and learn with some of the many resources available at cyberNephrology. This year, you can enjoy two cyberNephrology locations: Booth 711 in the expo hall and a special area near conference registration.

NKF PROFESSIONAL COUNCILS

Booth 1622

The **National Kidney Foundation Council of Nephrology Nurses and Technicians (CNNT)**, a strong volunteer professional membership organization, promotes and participates in the establishment of public services directed toward prevention, detection and care of persons with kidney and/or related diseases. Members collaborate in the development of health policies that impact professional practices and the delivery of patient care. The Council advocates and contributes to the professional development of members through education, networking and the dissemination of information related to professional practice and quality of patient care.

The **National Kidney Foundation Council of Nephrology Social Workers (CNSW)**, a volunteer professional organization with over 1,000 social work members, upholds and supports the profession of nephrology social work through advocacy and the creation of patient and professional education materials. Members provide assistance, education and support to patients and their families in dealing with the psychosocial stresses and lifestyle readjustments encountered by patients in all stages of CKD and facilitate a treatment program that will maximize rehabilitation potential. The Council supports the federal regulations governing ESRD reimbursement in regard to standards for social work practice and in the definition of a qualified social worker.

The **National Kidney Foundation Council on Renal Nutrition (CRN)**, a 1500-member volunteer professional organization, is dedicated to promoting quality nutritional care and education to kidney patients. Members impact regulatory and legislative issues and actively promote the professional education of the renal dietitian. The Council stimulates, supports and disseminates nutrition-related research, as well as develops patient and professional public education materials encouraging quality nutrition care for CKD patients.

The **National Kidney Foundation Council of Advanced Practitioners (CAP)**, comprised of Nurse Practitioners, Physician Assistants and Clinical Nurse Specialists, continues to grow as NKF's newest volunteer professional organization. The Council provides a diversified, advanced educational curriculum for the nephrology advanced practitioner and supports the growth of advanced practitioners coming to nephrology, as well as those already in practice. Members educate the public about this growing sector of the nephrology team and advocate for health policies and legislation that support sound practice and good outcomes for kidney health professionals and patients. The Council aims to elevate the voices of PAs, NPs and CNSs in nephrology to better serve their patients, enhance their practices and educate themselves on innovations in research and patient care.

NATIONAL KIDNEY FOUNDATION SERVING EAST TENNESSEE

Booth 1710

The National Kidney Foundation Serving East Tennessee, Inc., a major voluntary health organization, seeks to prevent kidney diseases, improve the well-being of individuals and families affected by these diseases, and increase the availability of all organs for transplantation. We serve thirty-four counties and for more than 35 years, East Tennesseans have turned to us for assistance.

NATIONAL KIDNEY FOUNDATION OF MIDDLE TENNESSEE

Booth 1708

The National Kidney Foundation of Middle Tennessee (NKFMT) was chartered in 1972. We handle around 32% of the 7,376 Tennesseans who suffer from chronic kidney failure. We are also proud to be working with Q-Source on a chronic kidney disease task force opportunity with the state of Tennessee.

NEPHROCEUTICALS

Booth 1714

Nephroceuticals™ was formed with the core mission of creating nutritional supplements aimed at promoting health in people with chronic kidney disease (CKD)—an epidemic thought to affect 25 million people within the United States alone. People with CKD have specific nutritional needs that are not being addressed by currently available nutritional supplements. Nephroceuticals™ employs a tailored approach to the formulation of its nutraceutical products based on the best available clinical evidence and guidelines.

NEPHROLOGY NEWS AND ISSUES

Booth 1417

NEPHROLOGY NEWS & ISSUES® covers the political, social, and economic issues in dialysis and transplant care. Stop by our booth for the latest issue, our 2009 Renal Care Calendar and Meetings Guide, and our just-released '09 Buyer's Guide. Stay up to date on renal news at www.nephronline.com, and sign up for our e-newsletters.

NEPHROLOGY TIMES

Booth 916

Nephrology Times (www.nephrologytimes.com) provides timely, authoritative, and engaging coverage of the news that affects the range of professionals treating patients with kidney problems. The publication puts the latest clinical advances from the peer-reviewed literature and professional meetings into context with commentary and analysis from experts in the field, as well as reports on emerging trends and breaking political and economic developments—all in a lively and convenient newspaper format. Please come by our booth to get your copy of our latest issue.

NEPHROPATH

Booth 1322

Under the direction of Patrick D. Walker, MD, NephroPath offers more than 30 years of experience interpreting renal biopsies. Because we understand the critical effect time to diagnosis can have on the outcome of many renal diseases, we offer complete results (Light, Immunofluorescence, and Electron Microscopy) on the same day we receive a biopsy.

NEPHRO-TECH

Booth 1415

Nephro-Tech, Inc. provides high quality pharmaceuticals at affordable prices. Introducing Vital-D Rx™; treat vitamin D (25-OH D3) deficiency daily. Nephron FA® is an iron, vitamin, stool softener combination. Great for PD patients! NephPlex® Rx is one of the most cost-effective, renal multivitamins on the market that contains zinc. The MagneBind® products are magnesium/calcium combination phosphate binders reduce calcium intake without compromising binding ability. Calphron is 667 mg calcium acetate and costs \$15.00/200 through Nephro-Tech, Inc. RenaPlex® is a direct sell multivitamin costing \$9.00/100 plus \$4.95 shipping. Call 1-800-879-4755 for more information.

NOVA BIOMEDICAL

Booth 1419

Nova Biomedical offers fast, whole blood analyzers for the laboratory and point-of-care. Our StatSensor™ Creatinine Point-of-Care Monitor measures creatinine and calculates eGFR by MDRD or Cockcroft-Gault equations from a small, 1.2 microliter fingerstick blood sample with fast, 30-second results. StatSensor is an excellent tool to rapidly assess kidney function.

NOVARTIS PHARMACEUTICALS CORPORATION

Booth 1313

For over 25 years, Novartis Pharmaceuticals Corporation has been a leading contributor to the advancement of transplant science and medicine. Our focus remains on developing meaningful therapeutic advances that improve the quality of life of transplant recipients and enhancing the long-term success of transplantation. Please visit our exhibit where specialists from Novartis will be available to discuss our products, answer questions and supply scientific information.

NUTREPLETION RESOURCES

Booth 1326

NutrePletion Resources is a Joint Commission accredited pharmacy, which provides therapy for dialysis patients who require specialized nutritional support, including Intradialytic Parenteral Nutrition (IDPN) and Intraperitoneal Nutrition (IPN).

ORTHO BIOTECH PRODUCTS, L.P.

Booth 1507

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit www.orthobiotech.com.

PENTEC HEALTH

Booth 1529

Pentec Health — a niche specialty pharmacy company that is a provider of IDPN/IPN therapies to the CKD-5 dialysis population. Website at www.pentechealth.com/ www.pentechinfusions.com.

PROPATH

Booth 1531

ProPath is one of the largest physician owned pathology group practices serving nephrologists, transplant surgeons and others by providing renal biopsy interpretations. We provide comprehensive diagnostic tissue interpretation and consultation of renal biopsies including light microscopy, immunohistochemistry, and electron microscopy. Call 1-800-258-1253, or visit www.propath.com for more information.

QUANTITATIVE MEDICAL SYSTEMS

Booth 919

Quantitative Medical Systems, Inc. (QMS) is the leader in providing comprehensive information management software to the field of renal dialysis. QCS, our EMR application, allows data to be captured and managed easily for improved quality patient care. QMS Focus, which is fully integrated with QCS, remains the industry standard in dialysis billing software by providing the tools needed to obtain maximum reimbursements.

RENALAB

Booth 1330

RenalLab has been serving the dialysis community for 15 years and has designed systems to provide the most reliable result information in the most expedient manner. Test orders and results can be accessed via web based portals. Stop by Booth 1330 to talk with RenalLab's courteous and friendly representatives.

RENAL ADVANTAGE INC

Booth 1231

Renal Advantage Inc. (RAI), is the third largest for profit provider of dialysis services in the country, providing dialysis services to approximately 10,500 patients in 136 dialysis centers in 18 states. RAI also delivers laboratory services through RenalLab, a state-of-the-art independent clinical laboratory located in Jackson, Mississippi. RAI is committed to establishing a cooperative relationship with its clinics and providing a high level of service to their physicians, employees, and patients.

RENAL & UROLOGY NEWS

Booth 1527

Renal & Urology News is a monthly tabloid with a circulation of 16,000 Nephrologists, dialysis nurses and urologists. The publication's primary editorial mission is to report on new scientific developments of interest to these three specialist groups. News coverage focuses on medical conferences but also includes reporting on recently published papers in peer-reviewed journals. Various features and departments compliment the news coverage.

RENAL BUSINESS TODAY/VIRGO PUBLISHING MEDICAL GROUP

Booth 1514

Renal Business Today delivers top-quality editorial for practice-management professionals. The Web site, www.renalbusiness.com, offers daily industry news updates, editor Keith Chartier's RenalBiz Blog, a free eNewsletter, online exclusives and much more.

RENAL PHYSICIANS ASSOCIATION

Booth 1611

The Renal Physicians Association is a national organization with the expertise and successful track record of proactively defending the discipline of the nephrology practice. Membership is comprised of healthcare providers in the subspecialty of internal medicine known as nephrology. Stop by to check out RPA's latest programs and publications or visit us at www.renalmnd.org.

ROCHE TRANSPLANT

Booth 1704

Roche is the U.S. prescription drug unit of the Roche Group, a leading, global innovator of pharmaceuticals and diagnostics. We invite you to our exhibit to learn more about CellCept, Valcyte, and our ongoing commitment to transplantation. www.rocheusa.com or www.roche.us.

SATELLITE LABORATORY SERVICES, LLC

Booth 1513

Satellite Laboratory Services, LLC is a full service renal laboratory serving the independent dialysis community. We provide a complete testing menu using sophisticated instrumentation and innovative technologies, including LabCheck for simple order entry, comprehensive patient management and extensive reporting capabilities. Satellite is a single source for all your ESRD laboratory needs.

SCANTIBODIES CLINICAL LABORATORY

Booth 918

Scantibodies Clinical Laboratory invites you to stop by booth 918 and see how you might join in the PASS Study Initiative to compare PTH assays' accuracy and stability. Nearly 500 doctors and dialysis facilities are taking part in this analysis and the results of the first two years will be available soon.

SHIRE PHARMACEUTICALS

Booth 1422

Shire is a leading global specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire centers its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. For further information on Shire, please visit: www.shire.com.

SIGMA-TAU PHARMACEUTICALS, INC.

Booth 1516

Sigma-Tau Pharmaceuticals is the manufacturer and distributor of Carnitor® (levocarnitine) injection. Carnitor injection is covered nationally by CMS/Medicare. The Carnitor Injection Reimbursement Assistance Program provides in-depth support services regarding reimbursement policy, documentation requirements and claims troubleshooting. Contact the Reimbursement Hotline at 1-800-490-3262 for assistance. Please visit www.carnitor.com for more information.

SPECTRA LABORATORIES

Booth 805

Spectra Laboratories is the leading provider of renal-specific laboratory services. We utilize state-of-the-art analytical equipment, automated specimen processing, and reporting applications to provide rapid and reliable test results. Our on-site training and education by a team of renal clinicians, comprehensive managed care program, and coordination of STAT testing services help customers deliver optimal patient care.

SPIRE BIOMEDICAL, INC.

Booth 1223

Introducing the Gold Series Family of End-Point Bonded Heparin Coated Hemodialysis Catheters. This unique coating reduces thrombus accumulation by 94% and 96% in animal and in-vitro studies, respectively. The coating, located on both internal and external surfaces, effectively mitigates thrombosis (at the catheter tip) and fibrin sheath propagation (on the catheter shaft). Please stop by Booth 1223 to learn how to reduce catheter-related bacteremia in your patient population.

SYSMEX AMERICA, INC.

Booth 924

Sysmex is a leader in laboratory solutions, including clinical diagnostics, automation and information systems. Serving laboratories for 40 years in more than 150 countries, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.

TRANSONIC SYSTEMS INC.

Booth 1030

Based on Transonic Systems gold standard flow/dilution measurement technology, the HD03 hemodialysis monitoring system provides noninvasive, accurate, immediate results of delivered blood flow, recirculation, access flow and cardiac output during dialysis treatment. The HD03 allows for early detection and correction of stenosis and a reduction in thrombosis, preserving dialysis access sites.

WATSON NEPHROLOGY

Booth 1413


Watson Nephrology proudly offers the injectable iron therapies Ferrlecit® (sodium ferric gluconate complex in sucrose injection) and INFeD® (iron dextran injection, USP), as well as the NephroVite® line of renal vitamins. Together with the nephrology community, we seek to improve and extend the lives of patients with kidney disease through continued development of appropriate pharmaceutical therapies, clinical research, education, and community advocacy.

WYETH PHARMACEUTICALS

Booth 1605

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

GAYLORD OPRYLAND FLOOR PLAN



FACULTY

KENNETH ABREO, MD

Louisiana State University Health
Sciences Center
Shreveport, LA

ANIL K. AGARWAL, MD, FACP, FASN

The Ohio State University
Dublin, OH

ANUPAM AGARWAL, MD

University of Alabama at Birmingham
Birmingham, AL

RAJIV AGARWAL, MBBS, MD, FAHA, FASN

Indiana University School of Medicine
Indianapolis, IN

ZALMAN S. AGUS, MD

University of Pennsylvania School
of Medicine
Philadelphia, PA

ENVER AKALIN, MD

Albert Einstein College of Medicine
Bronx, NY

ALEJANDRO ALVAREZ, MD

Washington University School
of Medicine
Saint Louis, MO

CHESTER AMEDIA, MD, FACP

Boardman, OH

SATARA ARMSTRONG, PHD

East Central University
Ada, OK

STEPHEN R. ASH, MD, FACP

Clarian Arnett Health
Lafayette, IN

ARIF ASIF, MD

University of Miami School of Medicine
Miami, FL

SARITA BAJPAI, PHD

Clarian Health Partners
Indianapolis, IN

GEORGE BAKRIS, MD, FAHA, FASN

University of Chicago
Chicago, IL

LYNDA K. BALL, RN, MSN, CNN

Northwest Renal Network
Seattle, WA

AARON L. BATTLE

IPRO/ESRD Network of New York
Weehawken, NJ

CAROLYN BAUER, MD

Montefiore Medical Center
Bronx, NY

BRYAN BECKER, MD

University of Wisconsin
Madison, WI

SRINIVASAN BEDDHU, MD

University of Utah
Salt Lake City, UT

DEBBIE BENNER, RD, CSR

DaVita Inc.
Yorba Linda, CA

LAURIE BENTON, MPAS, BS, PA-C, RN

Scott & White Memorial Hospital
Temple, TX

ANATOLE BESARAB, MD

Henry Ford Hospital
Detroit, MI

JUDITH BETO, PHD RD

Loyola University Medical Center
River Forest, IL

MARGARET BIA, MD

Yale University School of Medicine
New Haven, CT

ROB BLASER

Renal Physicians Association
Rockville, MD

KATHY BLOOD, RN, BA

DaVita Dialysis
Franklin, TN

ROY BLOOM, MD

University of Pennsylvania
Philadelphia, PA

W. KLINE BOLTON, MD

University of Virginia Hospital
Charlottesville, VA

TERI J. BORHO, RD, CD

Clarian Health, Indiana University
Hospital
Indianapolis, IN

DEBBIE BRADY, LCSW, ACSW

Arkansas Children's Hospital
Little Rock, AR

REBECCA BRASHLER, MSW, LCSW

Rehabilitation Institute of Chicago
Chicago, IL

EMMANUEL L. BRAVO, MD

Cleveland Clinic
Cleveland, OH

ROBERT BRAY, PHD

Emory University Hospital
Atlanta, GA

SUSAN BRAY, MD

Drexel University College of Medicine
Philadelphia, PA

ROBERT BRENNER, MD

AMAG Pharmaceuticals
Lexington, MA

FACULTY

**DONALD BROPHY, PHARM.D, MSC,
FCCP, FASN, BCPS**

Virginia Commonwealth University
School of Pharmacy
Richmond, VA

TERI BROWNE, PH.D, LSW

University of South Carolina
Columbia, SC

OLGA BRUSILOVSKY, RD, LD

Minneapolis Veterans Affairs
Medical Center
Eden Prairie, MN

JOHN M. BURKART, MD

Wake Forest University
Winston-Salem, NC

**JULIE BURNETT, BA, BSW, MSW,
RSW**

Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

JOHN BURNETT, MD

Mayo Clinic
Rochester, MN

**JERRILYNN D. BURROWES, PH.D, RD,
CDN**

C. W. Post Campus of Long Island
University
Brookville, NY

**LAURA BYHAM-GRAY, PH.D, RD,
CNSD**

University of Medicine and Dentistry of
New Jersey
Allentown, NJ

**MARY BETH CALLAHAN, LCSW,
ACSW**

Dallas Transplant Institute
Dallas, TX

AMY CANTER, MSW, RSW

Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

JACKIE CARDER, MS, RD, LMNT

Dialysis Center of Lincoln

Lincoln, NE

HELEN L. CARR, RD, CSR, LD, CDE

University of Texas
Texas Transplant Center
Galveston, TX

LEE A. CAUBLE, BSN, BSB, RN

Desert Dialysis Center
Tucson, AZ

KERRI L. CAVANAUGH, MD, MHS

Vanderbilt University Medical Center
Nashville, TN

SHELDON C. CHAFFER, MD

Scott & White Memorial Hospital
Temple, TX

CHRISTOPHER CHAN, MD, FRCPC

The Toronto General Hospital,
University Health
Toronto, Ontario, Canada

ARLENE CHAPMAN, MD

Emory University School of Medicine
Atlanta, GA

CHAIM CHARYTAN, MD

New York Hospital Medical Center
of Queens
Flushing, NY

DOLPH CHIANCHIANO, JD, MPA

National Kidney Foundation
New York, NY

MICHAEL J. CHOI, MD

Johns Hopkins University School
of Medicine
Baltimore, MD

LOUISE CLEMENT, MS, RD, CSR, LD

South Plains Kidney Disease Center
Lubbock, TX

**CAROLYN COCHRAN, RD, LD, MS,
CDE**

Dallas Nephrology Associates
Dallas, TX

MARSHIA COE, RN, BSN

Wake Forest Outpatient Dialysis
Winston-Salem, NC

ALLAN J. COLLINS, MD, FACP

National Kidney Foundation
Minneapolis, MN

DEBORAH COLLINSWORTH, LMSW

Dialysis Clinic, Inc.
Jackson, TN

RAYMOND L. COMENZO, MD

Tufts Medical Center
Boston, MA

DANILO B. CONCEPCION, CCHT, CHT

St. Joseph Hospital Renal Center
Orange, CA

LUIS CONCEPCION, MD

Scott and White Hospital
Temple, TX

**CAROLE A CONN, PH.D, RD, CSSD,
FACSM**

The University of New Mexico
Albuquerque, NM

DEBRA A. CONNEELY, MSW, LSW

DSI Scottsdale
Chicago, IL

SANDRA COOROUGH, ACSW, LCSW

Phoenix Children's Hospital
Kid's Kidney Center
Scottsdale, AZ

ANN COTTON, MS, RD, CNSD

Clarian Transplant Methodist Campus
Westfield, IN

SHARRIE CRANFORD, LGSW

University of South Alabama
Mobile, AL

EDWARD CREAMER, BS, JD

DCI Corporate, Risk Management
Department

JACKIE CROUCH

Scott and White Memorial Hospital
Temple, TX

JIM R. CURTIS, CCHT

Home Dialysis Plus, Ltd.
Portland, OR

WILLIAM DANT, BS, MS

Orem, UT

STEPHEN N. DAVIS, MD, FRCP

Vanderbilt University
Nashville, TN

KATHERINE DELL, MD

University Hospitals
Cleveland, OH

LAURA DEMBER, MD

Boston University School of Medicine
Boston, MA

VINCENT W. DENNIS, MD

Ambulatory Services of America
Chagrin Falls, OH

MARY AMANDA DEW, PHD

University of Pittsburgh School
of Medicine
Pittsburgh, PA

DAVID DEWALCH, PA-C, MA, MSPA

Tyler Radiology Association
Tyler, TX

MARY ANNE DOOLEY, MD, MPH

University of North Carolina
Chapel Hill, NC

JAMIE DWYER, MD

Vanderbilt University Medical Center
Nashville, TN

JOHANNA DWYER, DSC, RD

Tufts University
Boston, MA

ANDREA EASOM, APN, BC, CNN-NP

University of Arkansas
Little Rock, AR

A. AHSAN EJAZ, MD, FACP, FASN

University of Florida
Gainesville, FL

STEPHEN Z. FADEM, MD

Kidney Associates
Houston, TX

ROSE FARATRO, RN

Toronto General Hospital / University
Health Network
Toronto, Ontario, Canada

LISA FARRIS, CRNP

University of Alabama, Kirklin Clinic
Birmingham, AL

HARVEY FELDMAN, MD

NOVA South Eastern University
Fort Lauderdale, FL

CARLOS FERRARIO, MD, FACC, FACA

Wake Forest University Health Center
Winston-Salem, NC

MARIA FERRIS, MD, MPH, PHD

University of North Carolina
Kidney Center
Chapel Hill, NC

**FERNANDO FERVENZA, MD, PHD,
FASN**

Mayo Clinic
Rochester, MN

FREDRIC FINKELSTEIN, MD

Metabolism Associates
New Haven, CT

ROBERT N. FOLEY, MD

The Health Sciences Center
Newfoundland, Canada

CHARLES J. FOULKS, MD

University of Oklahoma
Tulsa, OK

DAVID FRACALOSSY, CHT, CBNT

Liberty Dialysis
Little Falls, NJ

STANLEY FRANKLIN, MD

University of California
Los Angeles, CA

BARRY FREEDMAN, MD

Wake Forest University School
of Medicine
Winston Salem, NC

LINDA FRIED, MD, MPH

University of Pittsburgh
Pittsburgh, PA

ELI A. FRIEDMAN, MD, MACP, FRCP

Downstate Medical Center
Brooklyn, NY

PAULA FROST, RD, CSR, LD

DaVita
Washington, DC

MELISSA FRY, MSW, CAPSW

Mile Bluff Medical Center
Mauston, WI

CATHY GARVEY, RN, BA, CCTC

University of Minnesota Medical Center-
Fairview
St. Paul, MN

ROBERT S. GASTON, MD

University of Alabama at Birmingham
Birmingham, AL

FACULTY

DENIS GEARY, MB, MRCP, FRCPC

The Hospital for Sick Children
Toronto, Ontario, Canada

HOWARD GEBEL, PHD

Emory University Hospital
Atlanta, GA

GREG GERMINO, MD

Johns Hopkins University School
of Medicine
Baltimore, MD

NANCY GINSBERG, MS, RD

Renal Research Institute
Hartsdale, NY

JEFF GIULLIAN, MD

South Denver Nephrology Associates
Denver, CO

WILLIAM GLASS, MD, PHD

Bostwick Laboratories, Inc
Glen Allen, VA

RICHARD J. GLASSOCK, MD, MACP

The David Geffen School of Medicine
at UCLA
Laguna Niguel, CA

CATHERINE GOEDDEKE-MERICKEL, MS, RD, LD

Lincoln, NE

DAVID GOLDFARB, MD, FACP, FASN

NYU School of Medicine
New York, NY

STUART GOLDSTEIN, MD

Baylor College of Medicine
Houston, TX

THOMAS A. GOLPER, MD

Vanderbilt University Medical Center
Nashville, TN

JANELLE GONYEA, RD, LD, BS

Mayo Clinic
Rochester, MN

CRAIG GORDON, MD, MS

Boston Medical Center
Boston, MA

JOHN Q. GOWAN, LMSW

ESRD Network of Texas, Inc
Dallas, TX

ROGER GREENWOOD, MD

East and North Herts NHS Trust,
Stevenage, BC, UK

KAREN A. GRIFFIN, MD

Loyola University Medical Center and
Edward Hines Jr. VA
Maywood, IL

ORLANDO M. GUTIÉRREZ, MD

University of Miami
Miller School of Medicine
Miami, FL

MARY HAGAR, PHD, RD, FADA

American Dietetic Association
Washington, DC

RAYMOND HAKIM, MD, PHD

Fresenius Medical Care North America
Brentwood, TN

LISA M. HALL, MSSW, LCSW

FMQAI: The Florida ESRD Network
Tampa, FL

YOSHIO N. HALL, MD

VA Puget Sound HCS University
of Washington
Seattle, WA

KAY HALL, BSN, RN, CNN

DaVita Inc.
Franklin, TN

RICHARD HAMBURGER, MD, FACP, FASN

Indiana University
Indianapolis, IN

SUNDARAM HARIHARAN, MD

Medical College of Wisconsin
Milwaukee, WI

PAUL HARRIS, PHD

Vanderbilt University
Nashville, TN

CHARLOTTE HARRISON, JD, MPH, MTS

Children's Hospital Boston
Boston, MA

KATHY SCHIRO HARVEY, RD, CSR

Puget Sound Kidney Centers
Mountlake Terrace, WA

PAM HAVERMANN

Dialysis Clinic, Inc.
Nashville, TN

REBECCA HAYS, MSW, APSW

University of Wisconsin Hospital
and Clinics
Madison, WI

ELIZABETH HENRY, RN, CNN

Scott and White Hospital
Temple, TX

GARY S. HILL, MD

Service de Néphrologie
Paris, FRANCE

DIANA HLEBOVY, RN, BSN, CHN, CNN

HemaMetrics
Elyria, OH

MICHAEL HOFMANN, MD

University of Wisconsin Hospital
Fitchburg, WI

JEFFREY HOGGARD, MD, FACP, FASN

Eastern Nephrology Associates
Greenville, NC

NORMAN HOLLENBERG, MD Brigham and Womens's Hospital Boston, MA	BERNARD JAAR, MD, MPH Johns Hopkins University Baltimore, MD	MARIA KARALIS, MBA, RD, LDN Abbott Renal Care Vernon Hills, IL
JEAN L. HOLLEY, MD University of Illinois Urbana, IL	BERTRAND L. JABER, MD, MS Caritas St. Elizabeth's Medical Center Boston, MA	MIREY KARAVETIAN, MS Rafic Hariri University Hospital Beirut, AL, Lebanon
PETER HOSSEINPOUR, PHARM D St. Joseph Hospital San Clemente, CA	KATHY JABS, MD Vanderbilt University School of Medicine Nashville, TN	JUDITH KARI, LCISW Center for Medicare & Medicaid Services Baltimore, MD
SUSAN HOU, MD Loyola University Medical Center Maywood, IL	CAROLINE JENNETTE, MSW University of North Carolina Kidney Center Chapel Hill, NC	BERTRAM KASISKE, MD Hennepin County Medical Center Minneapolis, MN
ANDREW HOWARD, MD, FACP Metropolitan Nephrology Associates Alexandria, VA	PETER JEURGENSON, PA-C Metabolism Assoicates New Haven, CT	WILLIAM F. KEANE, MD Seno Medical Instruments San Antonio, TX
LI-LI HSIAO, MD, PHD Brigham and Women's Hospital Boston, MA	KIRSTEN JOHANSEN, MD University of California at San Francisco San Francisco, CA	MARY PAT KELLY, RD, RN, RNP VA Palo Alto Health Care System Menlo Park, CA
ADRIANA M. HUNG, MD, MPH Vanderbilt University Medical Center Nashville, TN	RICHARD J. JOHNSON, MD, FACP University of Colorado Denver, CO	PAMELA KENT, MS, RD, CSR, LD Genzyme Renal Vermilion, OH
LAWRENCE G. HUNSICKER, MD U. Iowa College of Medicine Iowa City, IA	STEPHANIE JOHNSTONE, LCSW Fresenius Medical Care-North America San Diego, CA	MARRIE KETCHUM, LICSW Seattle Children's Hospital and Regional Medical Center Seattle, WA
MARRIANNE HUTTON, RD, CSR, CDE Fresenius Medical Services North America Santa Rosa, CA	MICHELLE JOSEPHSON, MD University of Chicago Chicago, IL	DIANNE KILLEBREW, MED, RD, LDN Vanderbilt University Medical Center Nashville, TN
T. ALP IKIZLER, MD Vanderbilt University Medical Center Nashville, TN	KAMEL KAMEL, MD, FRCP(C) University of Toronto St. Michael's Hospital Toronto, Ontario, Canada	CHRISTINA KLEIN, MD University of Wisconsin Madison, WI
AJAY ISRANI, MD, MS Hennepin Faculty Associates Minneapolis, MN	NORMAN M. KAPLAN, MD University of Texas Southwestern Medical Center Dallas, TX	MYRA A. KLEINPETER, MD, MPH Tulane University School of Medicine New Orleans, LA
JOSEPH L. IZZO, JR., MD SUNY at Buffalo Buffalo, NY		ALAN KLIGER, MD Metabolism Assoicates New Haven, CT

FACULTY

NELSON KOPYT, DO

Nephrology Hypertension Associates
of Lehigh Valley
Allentown, PA

FRED M. KOURI, LMSW

The Children's Mercy Hospitals
and Clinics
Kansas City, MO

HOLLY KRAMER, MD, MPH

Loyola University Medical Center
Maywood, IL

RONALD KRAMER, MD

Colorado Neurological Institute (CNI)
Denver, CO

ZIPPORAH KRISHNASAMI, MD

University of Alabama at Birmingham
Birmingham, AL

DANA KUMJIAN, MD

Medical Associates of Savannah
Savannah, GA

JANE KWATCHER, MSW, LCSW

DaVita Pomona Dialysis
Pomona, CA

ANTHONY LANGONE, MD

Vanderbilt University Medical Center
Nashville, TN

DERRICK L. LATOS, MD, MACP

Nephrology Associates, Inc.
Wheeling, WV

JANICE P. LEA, MD

Emory University
Atlanta, GA

STANLEY LEE, MD

Nephrology Associates/Vanderbilt
Medical Center
Nashville, TN

ALAN LEICHTMAN, MD

University of Michigan
Ann Arbor, MI

JUNE LEUNG FUNG, RD

Tufts-New England Medical Center
Boston, MA

RICHARD LEVINE, MD, MPH

National Institutes of Health
Washington, DC

ANNE LILES, PHARM.D

Auburn University Harrison School
of Pharmacy
Auburn, AL

NITA A. LIMDI, PHARM.D, PH.D, MSPH

University of Alabama at Birmingham
Birmingham, AL

KATHLEEN D. LIU, MD, PH.D

University of California, San Francisco
San Francisco, CA

ROBERT S. LOCKRIDGE, MD

Lynchburg Nephrology Physicians
Lynchburg, VA

CHARMAINE LOK, MD, FRCP(C), MSC

Toronto General Hospital
Toronto, Ontario, Canada

VALERIE LUYCKX, MD

University of Alberta
Edmonton, AB, Canada

JENNIFER LYON, MS, MLIS

Eskind Biomedical Library
Vanderbilt University Medical Center
Nashville, TN

HARTMUT H. MALLUCHE, MD, FACP

University of Kentucky Chandler
Medical Center
Lexington, KY

BARBARA WEIS MALONE, RN, FNP, CFNP

University of Colorado Health
Sciences Center
Golden, CO

GLENN MARKOWITZ, MD

Columbia University Medical Center
New York, NY

TEJ MATTOO, MD, FRCP

Wayne State University School
of Medicine
Detroit, MI

IVAN D. MAYA, MD

University of Alabama
Birmingham, AL

MAUREEN MCCARTHY, RD, MPH, CSR, LD

Oregon Health & Science University
Portland, OR

PETER A. MCCULLOUGH, MD, MPH, FACC, FACP

William Beaumont Hospital
Royal Oak, MI

MATTHEW J. MCDONOUGH, MS

FMQAI – The Florida ESRD Network
Tampa, FL

JOHN MCGINNITY, PA-C, MS

Wayne State University
Detroit, MI

JENNIFER MCGUOIRK, RD, LDN, BS

Abbott Laboratories
Aston, PA

BETH MCQUISTON, MD, MS, RD, LDN

Rush University Medical Center
Park Ridge, IL

ROXANA MEHRAN, MD, FACC

Columbia University Medical Center
New York, NY

RAJNISH MEHROTRA, MD, FASN, MBBS

Harbor-UCLA Medical Center
Torrance, CA

HEATHER MERCER, PSYD, DRPH

DaVita Village Health
San Bernardino, CA

JOE MERIGHI, MSW, PHD

Boston University School of Social Work
Boston, MA

ANTHONY MESSANA, BSC

St. Joseph Hospital Renal Center
Orange, CA

MIRIAM MICHAEL, MD

Howard University Hospital
Washington, DC

PAUL D. MILLER, MD

Colorado Center for Bone Research
Lakewood, CO

SHARON M. MOE, MD

Indiana University
Indianapolis, IN

MICHELE H. MOKRZYCKI, MD, MS

Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY

DONALD A. MOLONY, MD

University of Texas Health Science
Center at Houston
Houston, TX

LINDA MOORE, RD, LD, CCRP

The Methodist Hospital Physician
Organization
Houston, TX

DWIGHT MORGAN

MCM Environmental Technologies, Inc.
Hackensack, NJ

ANDREW S. NARVA, MD, FACP

National Institutes of Health
Bethesda, MD

ANNE T. NEFF, MD

Vanderbilt University Medical Center
Nashville, TN

JOEL NEUGARTEN, MD

Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY

MARK NEUMANN

Nephrology News & Issues
Scottsdale, AZ

VO NGUYEN, MD

Memorial Nephrology Associates
Olympia, WA

VANDANA NIYYAR, MD

Emory University School of Medicine
Atlanta, GA

KEITH NORRIS, MD

Charles Drew University of Medicine
and Science
Lynwood, CA

NAIMA OGLETREE, MSN, APRN, BC

Henry Ford Health System
Detroit, MI

ANN O'HARE, MD

University of Washington
Seattle, WA

JEAN OLSON, MD

University of California At San Francisco
Cottage Grove, MN

CHARLES O'NEIL, MD

Emory University School of Medicine
Atlanta, GA

SUZANNE OPARIL, MD

University of Alabama at Birmingham
Birmingham, AL

JEFFREY PACKER, DO, FACOI, FASN

University of Arizona College
of Medicine
Phoenix, AZ

EMIL PAGANINI, MD, FACP, FRCP

The Cleveland Clinic Foundation
Cleveland, OH

PAUL M. PALEVSKY, MD

VA Pittsburgh Healthcare System
Pittsburgh, PA

HEATHER PARADIS, CHT

Liberty Dialysis
Nampa, ID

CHIRAG PARIKH, MD, PHD

Yale University and VAMC
West Haven, CT

CAROL REES PARRISH, MS, RD

University of Virginia Health System
Charlottesville, VA

WILLIAM D. PAULSON, MD

Charlie Norwood VAMC and Medical
College of Georgia
Augusta, GA

JESSIE PAVILINAC, MS, RD, CSR, LD

Oregon Health & Science University
Portland, OR

GLENDA PAYNE, RN, MS, CNN

CMS
Dallas, TX

MARGARET PEARLE, MD, PHD

The University of Texas Southwestern
Medical Center
Dallas, TX

ALDO J. PEIXOTO, MD

Yale University School of Medicine
New Haven, CT

FACULTY

MARC PENN, MD, PHD

Cleveland Clinic
Cleveland, OH

BRIAN J.G. PEREIRA, MD

AMAG Pharmaceutical, Inc.
Lexington, MA

ANNALISA PEREZ, MD, MPH

Scott and White Hospital
Temple, TX

DOREEN N. PERKINS, MSN, NP

Health Services Foundation
Birmingham, AL

CRAIG PETERS, MD, FACS, FAAP

University of Virginia
Charlottesville, VA

GARY PETINGOLA, BA, BSW, RSW

Sudbury Regional Hospital
Sudbury, Ontario, Canada

BETH PIRAINO, MD

University of Pittsburgh
Pittsburgh, PA

MARC A. POHL, MD

The Cleveland Clinic Foundation
Cleveland, OH

POLLY PORTER, PA-C, MPAS, ATC

INOVA Mt. Vernon Hospital
Alexandria, VA

MEGAN R. PRESCOTT, LCSW

University of Colorado Hospital
Parker, CO

CHING-HON PUI, MD

St. Jude Children's Research Hospital
Memphis, TN

SUSAN QUAGGIN, MD

Mount Sinai Hospital
Toronto, Ontario, Canada

LUIS (PHIL) RAMOS, MD, MSCI

Vanderbilt University Medical Center
Nashville, TN

PANDURANGA RAO, MD, DNB, MS

University of Michigan
Ann Arbor, MI

LLOYD E. RATNER, MD

Columbia University
New York, NY

ROBERT REILLY, MD

UT Southwestern Medical Center
Dallas, TX

BETHANY ROBERTS, LICSW

Minneapolis VA Medical Center
Minneapolis, MN

BRUCE ROBINSON, MD

Arbor Research Collaborative for Health
Ann Arbor, MI

MICHAEL ROCCO, MD, FACP

Wake Forest University School of
Medicine
Winston Salem, NC

WENDY RODGERS, MA

Torrance, CA

RUDY RODRIGUEZ, MD

VA Pudget Sounds Medical Center
Seattle, WA

CAROL A. ROE, RN, JD

Centers for Dialysis Care
Shaker Heights, OH

DAVID ROTH, MD

University of Miami School of Medicine
Miami, FL

BHARAT SACHDEVA, MD

Louisiana State University Health
Science Center
Shreveport, LA

NASIA SAFDAR, MD

University of Wisconsin School
of Medicine
Madison, WI

JEFF SALAND, MD

The Mount Sinai School of Medicine
New York, NY

LOAY SALMAN, MD

University of Miami School of Medicine
Miami, FL

WILLIAM SALZER, MD

University of Missouri-Columbia School
of Medicine
Columbia, MO

ANTHONY SAMAHA, MD

Kidney and Hypertension Center
Cincinnati, OH

MILAGROS D. SAMANIEGO, MD

University of Michigan Medical School
Ann Arbor, MI

PAUL W. SANDERS, MD

University of Alabama at Birmingham
Birmingham, AL

RAJIV SARAN, MBBS, MD, MRCP, MS

University of Michigan
Ann Arbor, MI

MARK SARNAK, MD

Tufts-New England Medical Center
Boston, MA

MOHAMMED SAYEGH, MD

Harvard Medical School
Boston, MA

HEIDI M. SCHAEFER, MD

Vanderbilt University Medical Center
Nashville, TN

DORI SCHATELL, MS

Medical Education Institute
Madison, WI

BRIGETTE SCHILLER, MD

Satellite Healthcare
Redwood City, CA

DONALD SCHON, MD

Arizona Kidney Disease &
Hypertension Center
Paradise Valley, AZ

**WENDY FUNK SCHRAG, LMSW,
ACSW**

Fresenius Medical Care North America
Newton, KS

ROBERT W. SCHRIER, MD

University of Colorado
Denver, CO

DONNA SECKER, PHD, RD, FDC

The Hospital for Sick Children
Toronto, Ontario, Canada

ADRIAN SEQUEIRA, MD

Louisiana State University Health
Science Center
Shreveport, LA

AMIT SHARMA, MD, FACP, FASN

Boise Kidney and Hypertension Institute
Meridian, ID

THERESE SHUMAKER, MS, RD, LD

Mayo Clinic
Rochester, MN

DOMENIC SICA, MD

Virginia Commonwealth University
Richmond, VA

EDWARD SIEW, MD

Vanderbilt University
Nashville, TN

GARRETT SMITH, PA-C

Nephrology Consultants, LLC
Huntsville, AL

KIM SOLEZ, MD, FRCP(C)

University of Alberta
Edmonton, AB, Canada

SANDEEP SOMAN, MD

Henry Ford Hospital
Detroit, MI

DAVID M. SPIEGEL, MD

University of Colorado
Health Sciences Center
Denver, CO

CHRISTOPHER SPRADLEY, MD

Scott & White Clinic
Salado, TX

WILLIAM STEIN, PA-C, MPAS, BS, AS

BMI Nephrology, Inc.
High Point, NC

STEPHANIE STEWART, LICSW

Mayo Clinic
Rochester, MN

JOHN C. STIVELMAN, MD

University of Washington, Northwest
Kidney Centers
Seattle, WA

KRISTIN STOCKARD, LICSW

Seattle's Children's Hospital
Seattle, WA

MATT STRICHERZ, EDD

University of South Dakota
Vermillion, SD

MARY B. SUNDELL, RD, LDN, CCRP

Vanderbilt University Medical Center
Nashville, TN

MARK A. SUPIANO, MD

University of Utah and
Salt Lake City VA Medical Center
Salt Lake City, UT

JOHN SWEENEY, BS, CHT

Baxter Healthcare Corporation
Largo, FL

LYNDA SZCZECZ, MD, MSCE

Duke University Medical Center
Durham, NC

PAUL SZCZYBOR, PA-C

Franklin Square Hospital Center
Catonsville, MD

**HAROLD M. SZERLIP, MD, FACP,
FASN**

Medical College of Georgia
Augusta, GA

MANJULA TAMURA, MD, MPH

Stanford University School of Medicine
San Francisco, CA

ERIC TAYLOR, MD, MSC

Brigham and Women's Hospital
Boston, MA

KAY TAYLOR, RD, CDE

Dialysis Center of Lincoln
Columbus, NE

MARIA TAYLOR, PHARM D

University of Alabama
Birmingham, AL

ISAAC TEITELBAUM, MD

University of Colorado School
of Medicine
Aurora, CO

FRANCESCA TENTORI, MD

Arbor Research Collaborative for Health
Ann Arbor, MI

PAUL TESCHAN, MD

Vanderbilt University School of Medicine
Nashville, TN

FACULTY

STEPHEN C. TEXTOR, MD Mayo Clinic Foundation Rochester, MN	JOE VERBALIS, MD Georgetown University Medical Center Washington, DC	JAY B. WISH, MD University Hospitals Case Medical Center Cleveland, OH
JEANNE THACKER, RN, MSN, CNS-C, FNP-C Renal Associates Lakehills, TX	JULIE VONDERHOFF, MSSW, LCSW Howard Young Medical Center Woodruff, WI	BETH WITTEN, ACSW, LSCSW Medical Education Institute, Inc. Overland Park, KS
CHER THOMAS, RD Renal Support Network Galveston, TX	BRADLEY A. WARADY, MD The Children's Mercy Hospital and Clinics Kansas City, MO	LESLIE WONG, MD Northwest Kidney Centers Seattle, WA
DAVID THOMAS, MD Nephrocor Uniondale, NY	RICHARD A. WARD, PHD University of Louisville Louisville, KY	JACK WORK, MD Emory University, Dialysis Access Center Atlanta, GA
KATHRYN TINCKAM, MD MMSC FRCPC University Health Network Toronto, Ontario, Canada	LAWRENCE WEISBERG, MD UMDNJ/Robert Wood Johnson Medical School, The Cooper Health System Camden, NJ	STEVEN WU, MD Massachusetts General Hospital Boston, MA
ASHITA TOLWANI, MD University of Alabama at Birmingham Birmingham, AL	STEVEN D. WEISBORD, MD, MSC VA Pittsburgh Healthcare System Pittsburgh, PA	JERRY YEE, MD Henry Ford Health System Detroit, MI
JOSE TORREALBA, MD University of Wisconsin-Madison Madison, WI	ADAM WHALEY-CONNELL, DO, MSPD, FAHA University of Missouri-Columbia School of Medicine Columbia, MO	ALEXANDER S. YEVZLIN, MD University of Wisconsin Madison, WI
RAYMOND TOWNSEND, MD, FAHA, FCHBPR University of Pennsylvania Philadelphia, PA	JOHN JASON WHITE, MD Medical College of Georgia Augusta, GA	BESSIE YOUNG, MD, MPH VA Puget Sound Health Care System Seattle, WA
JOHN KEVIN TUCKER, MD Brigham and Women's Hospital Boston, MA	KAREN WIESEN, RD, LD, MS Washington University School of Medicine St. Louis, MO	CAMILLE M. YUSCAK, LCSW-R, ACSW Dialysis Clinic, Inc. Hawthorne, NY
MARK UNRUH, MD, MSC University of Pittsburgh Pittsburgh, PA	KATE WILLCUTTS, MS, RD, CNSD University of Virginia Crozet, VA	JAN ZOLKOWER, MSHL, CIP, CCRP Vanderbilt University Nashville, TN
DAVID B. VAN WYCK, MD DaVita, Inc Tucson, AZ	CRAIG WILLIAMS, PHARM D Oregon Health and Science University Medical Center Portland, OR	KIM ZUBER, PA-C Metropolitan Nephrology Alexandria, VA

NOTES

NOTES

Just in Time for the Rough Economy
Valuable New Member Benefits in 2009!

JOIN NKF TODAY

More than half of the attendees at the National Kidney Foundation Spring Clinical Meetings are members. Join them and the thousands of other health care professionals in the U.S. and around the world and take advantage of the resources and savings NKF membership offers.

There's an NKF professional membership just right for you!


— NEW IN 2009 —

- **Physicians** – In addition to monthly issues of the *American Journal of Kidney Diseases*, membership now includes a subscription to *Advances in Chronic Kidney Disease*! (a \$450 saving)
- **Council of Nephrology Social Workers** – Professional liability insurance and the opportunity to obtain a Nephrology Social Worker credentialed (NSW-C) certification through NKF.
- **Council of Nephrology Nurses and Technicians** – *Advances in Chronic Kidney Disease* is now bimonthly – that's 50% more issues per year.
- **Council of Renal Nutrition** – The 4th Edition of the popular and valuable *Pocket Guide to Nutritional Assessment of the Patient with Chronic Kidney Disease* arrives this spring, and all members receive a complimentary copy!
- **Council of Advanced Practitioners** – New members receive a complimentary copy of the brand new 5th Edition of NKF's respected *Primer on Kidney Disease*, a valuable resource examining all aspects of kidney and related diseases (non-members pay \$80!)

Join NKF here at the 2009 Spring Clinical Meetings and get an NKF Notebook - FREE!



**Enroll at Registration or
go to www.kidney.org**





AMGEN NEPHROLOGY.

WHERE THE MIND OF A SCIENTIST MEETS THE HEART OF AN EXPLORER.

At Amgen Nephrology, we believe making a difference requires taking a different approach. Your patients deserve it. The fight against kidney disease demands it. So we see ourselves as bio-explorers—continually searching to understand the underlying mechanisms of kidney disease and the challenges your patients face. This discovery-based approach has enabled us to create a wide range of treatments. But we're still focused on the next giant leap.

Explore booth #1105 to learn more

AMGEN®

Nephrology

A HISTORY OF DISCOVERY. A FUTURE OF POSSIBILITIES.